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ABSTRACT
EPIGENETIC MODIFICATION OF VITAMIN D-INDUCED GENE
EXPRESSION IN HUMAN COLORECTAL AND BREAST CANCER CELL
LINES
MAY 2018
SHARMIN HOSSAIN, B.S., UNIVERSITY OF DHAKA
M.S., UNIVERSITY OF DHAKA
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Richard J. Wood
Epigenetics is the study of the regulation of genes that is not dependent on
nucleotide sequence. This may include heritable changes in gene activity and expression
but also those that are not heritable. In recent years, epigenetic researchers have made great
strides in understanding the molecular mechanisms behind cellular functions in response
to diet, exercise, and other lifestyle modifications, like methylation, histone modification
etc. It is now known that the epigenome is critical to healthy human development in
addition to genetics, and dietary factors can modulate epigenetic alterations in cells.
The classic view of cancer etiology is that genetic alterations damage DNA
structure and induce mutated proteins (oncogenes) that lead to disease progression. More
recently, the role of epigenetic alterations during development and chronic disease
development has gained increasing attention. This caused a paradigm shift in our
understanding of possible mechanisms leading to disease susceptibility. Epidemiological
studies have revealed an inverse correlation between the intake of cruciferous vegetables
and the risk of certain types of cancer [1]. There has also been evidence, from various
epidemiological studies, of higher intake or blood levels of vitamin D and its association
with a reduced risk of colorectal and breast cancer [2]. Thus, there is evidence that both
higher intake of cruciferous vegetable and better vitamin D status are associated with a
reduced risk of cancer. The primary focus of my dissertation is the manipulation of histone
modification via dietary agents like vitamin D and sulforaphane in human colorectal and
breast cancer cell lines with a review of current literature focusing on vitamin D and breast
cancer.
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CHAPTER 1
INTRODUCTION

1.1 Overview
Although there is some evidence that vitamin D may have a protective role in
preventing colorectal cancer, existing literature marginally supports the preventive
potential of vitamin D in other malignancies, like breast cancer, with the exception of
possible benefits of vitamin D supported by genetic data in bladder and prostate cancer [3].
Epidemiological studies have shown that a high level of consumption of cruciferous
vegetables such as broccoli, Brussel sprouts etc. is associated with a reduced risk of certain
human cancers [4] and is attributable to certain bioactive phytochemicals, such as,
isothiocyanates (ITCs) found at relatively high levels in these vegetables. Sulforaphane
(SFN), derived from glucosinolates in cruciferous vegetables, is an ITC found to be more
potent than other major glucosinolates and ITCs with proposed anticancer effects [5].

1.2 Statement of Problem

The question if vitamin D has a role in cancer incidence, progression, and mortality
has been studied in detail for over two decades. Specific focus has been on colorectal,
breast, and prostate cancers since these three malignancies account for approximately 35%
of total cancer cases and 20% of cancer deaths in the United States. While vitamin D status
has been reported to have an inverse association with colorectal cancer (CRC) incidence
and mortality; findings in breast cancer (BC) patients suggested a lower risk for progression
and mortality with higher serum 25- hydroxyvitamin D3 [25(OH)D3], a biomarker of

1

vitamin D status [3]. 25(OH) D3 is a pro-hormone form of vitamin D produced in the liver
and is considered the most reliable indicator of vitamin D status. 25(OH) D3 is then
converted to 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], the hormonally active form of
vitamin D, in the kidneys. There are several enzymes involved in this process and will be
discussed in greater detail to elucidate D action in the subsequent chapters.
Although, observational studies show positive outcomes between vitamin D and
BC, randomized clinical trials have generally failed to support these associations, to date.
The current literature provides conflicting findings regarding the vitamin D action in
cancer. Due to these inconsistencies, it is difficult to ascertain if vitamin D (the active form)
is related to a direct reduction in cancer risk, or to what extent higher concentrations of
vitamin D status biomarker, serum 25(OH) D3 serve as a surrogate for an overall healthier
lifestyle and lower cancer risk in population studies [6].
The important role of active vitamin D compounds in various cancer cell types,
including malignant breast cells, by inducing cellular differentiation, inhibition of cell
growth and cell death via apoptosis is well-established [7-10]. While, dietary intake of
vitamin D has been inconsistently linked to breast cancer risk, studies considering the
association of breast cancer risk and sun exposure as a proxy of endogenous vitamin D
synthesis, have observed inverse associations[11, 12].
Isothiocyanates (ITCs) are naturally occurring secondary metabolites of cruciferous
vegetables. Glucosinolates in cruciferous vegetables are converted to ITCs upon hydrolysis
by the enzyme myrosinase [13]. These ITCs, predominantly sulforaphane, have been
reported to possess chemopreventive and chemotherapeutic effects both in vitro and in vivo
[14]. Rigorous SFN research is now focused on its anti-carcinogenic roles considering the

2

growing body of evidence, although it was first identified as a potent inducer of phase 2
detoxification enzyme[15, 16].
Epigenetic changes, which can be triggered by various dietary components can
cause heritable changes in the DNA structure and chromatin complex without disrupting
the actual coding sequence of the DNA. In other words, epigenetics focuses on modifying
the DNA (gene expression) via external agents, such as vitamins, minerals, phytochemicals
etc. that do not change the primary DNA sequence. Histone protein modification in the
chromatin structure and DNA methylation are two key epigenetic mechanisms studied in
cancer. Epigenetic effects of SFN has been linked predominantly to post-translational
histone modification processes. Histone deacetylase (HDAC) inhibition by SFN in human
colon and prostate cancer cells in vitro were supported by in vivo experiments in humans,
and was similar in preclinical models of gastrointestinal and prostate cancer [17]. HDACs
remove acetyl groups from DNA and affect transcription which can result in silencing
numerous important tumor suppressor genes. SFN has several known biochemical
properties, including activation of antioxidant enzymes via Nrf2 transcription factor
activation, altering phase I and II detoxification enzymes, and inhibition of HDAC activity
[16, 18-21]. By inhibiting the HDAC action, sulforaphane can reverse epigenetically
silenced genes in cancer cells, resulting in cell cycle arrest and/or apoptosis [18, 22].
Despite numerous studies demonstrating the anti-cancer effects of various ITCs,
the exact mechanism of SFN action is still unclear and requires further attention. There is
also not enough information on how sulforaphane works particularly in colorectal and
breast cancers on a molecular level.
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CHAPTER 2
LITERATURE REVIEW

Vitamin D deficiency is considered a pandemic because of its widespread presence
in all age groups and in nearly all geographical regions [3]. It is a culmination of lifestyle
changes in the modern societies that involve a decrease in time spent outdoors, widespread
use of sunscreens, and air pollution which contribute to insufficient exposure to sunlight,
and thus reduced skin synthesis of vitamin D. Other factors that notably increase the risk
of vitamin D deficiency are: aging of populations and the resulting decline of vitamin D
synthesis in the skin, low intake of vitamin D with the diet, and the obesity epidemic. In
the absence of sufficient sun exposure to maintain adequate vitamin D status, an alternative
way to get adequate vitamin D is through certain foods or vitamin D supplements.
Historically speaking, vitamin D recommendation for adults of 5 μg/d (200 IU/d)
vitamin D was considered adequate to prevent osteomalacia (adult vitamin D deficiency)
in the absence of sunlight. But more was needed to help prevent osteoporosis and secondary
hyperparathyroidism. Later on, other health benefits of vitamin D supplementation were
suggested to accrue based on observations from epidemiological studies, such as:
prevention of some cancers and reduced risks of multiple sclerosis and hypertension [23].
In 2011, the US Institute of Medicine (IOM) established a Dietary Reference Intake (DRI)
for vitamin D across all age groups, considering newer research findings since 1997, the
previous estimate of vitamin D needs of the population. Based on this review of the
evidence, the IOM has tripled the recommended daily intakes of vitamin D to 15 µg (600
IU) per day for people aged 1-70 years, and increased to 20 µg (800 IU) per day for those
older than 70 years [24]. The recommendation for dietary Vitamin D is based on how much
6

is needed to achieve a serum 25(OH)D of 20 ng/ml (50 nmol/L) in 97.5% of the population.
A serum 25(OH)D concentration of 20 ng/mL to 50 ng/mL (50nM- 125nM) is considered
adequate for healthy people. A level less than 20 ng/mL indicates vitamin D deficiency.
However, some researchers recommend maintaining serum 25(OH)D3 levels of 30 ng/mL
(75 nmol/L) may be needed to prevent chronic diseases like cancer, but this has not been
sanctioned by the IOM due to lack of sufficient evidence. In the 2000–2004 NHANES
cycle, 78% of Americans had a serum 25(OH)D3 less than 30ng/ml [25].

2.1 Synthesis and Metabolism of Vitamin D
The metabolism of vitamin D is complex and involves several different enzymes
and organs. In humans with adequate sun exposure, vitamin D3 (cholecalciferol) is formed
from cutaneous 7-dehydrocholesterol (7-DHC) synthesized in the basal layer of the
epidermis. Initially, the β-ring of 7-DHC undergoes photolysis upon the exposure of skin
to UV-B radiation, leading to the formation of pre-vitamin D3 that non-enzymatically is
converted to vitamin D and then transferred into the blood[26]. Subsequent activation of
vitamin D3 involves sequential 25- and 1-α-hydroxylations of vitamin D3 in the liver and
kidney, respectively. In the liver, vitamin D3 is hydroxylated by 25-hydroxylase to 25hydroxyvitamin D3 also known as 25-hydroxycholecalciferol or abbreviated as 25(OH)D3
[27]. 25(OH)D3 is then hydroxylated a second time in the kidneys by mitochondrial 1αhydroxylase (CYP27B1) producing 1,25(OH)2D3 (calcitriol), the hormonal

form of

vitamin D, that can activate the vitamin D receptor [27]. Several tissues and organs, such
as the intestines and skin, can also activate vitamin D through these two-sequential
enzymatic hydroxylations [28], but liver and kidney are the primary sites of regulation. The
activity of 25(OH)D3 and 1,25(OH)2D3 is counteracted by the enzyme 24-hydroxylase
7

(CYP24A1), which transforms them to the inactive vitamin D metabolites
24,25(OH)2D3 and 1,24,25(OH)3D3, respectively, prior to further oxidation and cleavage
of the side chain resulting in complete inactivation and eventual elimination from the
body[29]. Both 24,25(OH)2D3 and 1,24,25(OH)3D3 possess significantly lower affinity for
the vitamin D receptor (VDR) than 1,25(OH)2D3 [30]. This property is important when
considering molecular functions of vitamin D.

2.2 Dietary sources of Vitamin D
A well-balanced diet with a high vitamin D content can help maintain adequate
vitamin D in our system in the absence of cutaneous sunlight exposure. However, only a
relatively few foods naturally provide substantial amounts of vitamin D. There are a couple
of dietary products that are rich in vitamin D, e.g.: fish oils, sea fish etc. Fortified products
are an important dietary source of vitamin D in the US. One cup of milk contains
approximately 50 IU of vitamin D, and the average American consumes about 1¼ c of
milk/day, with adults consuming less[31]. It is assumed that a well-balanced diet should
provide all the essential nutrients, minerals and vitamins. However, there are groups of
people who are particularly vulnerable to deficiency of vitamin D, e.g. children,
adolescents, pregnant and nursing women and the elderly. Vitamin D supplements should
be used when sun exposure and the diet are unable to fulfill vitamin D needs.
Currently, the recommended dietary allowance (RDA) for vitamin D3 is 600 IU/day
(age 1 yr. to 69 yr.) and the upper limit tolerance is 4000 IU/day [32]. Due to the high
prevalence of vitamin D deficiency and the risk of the related deficiency diseases,
fortification of certain products, especially milk, orange juice, margarine, butter etc. are
becoming increasingly common. Vitamin D is relatively stable and does not decompose in
8

heat or during long-term storage. However, it may be destroyed by ultraviolet radiation.
Under aerobic conditions in aqueous medium it may undergo autoxidation and lose its
functional properties.
While national surveys in both the United States and Canada show the average total
intake of vitamin D among North Americans to be below the median requirement, they
also show that average blood levels of 25(OH)D3 are above 20 ng/mL, which is equivalent
to 50 nmol/L, what the IOM found necessary for good bone health for all individuals [24].
The IOM interpreted the seemingly inconsistent observations of low dietary vitamin D
intake but adequate vitamin D status to suggest that sun exposure currently contributes
meaningful amounts of sunlight for vitamin D synthesis in North Americans and that most
of the population is meeting its needs for vitamin D. Table 2.1 lists the average daily
recommended amounts from the Food and Nutrition Board (a national group of experts)
for different ages.
Table 2.1: Recommended Dietary Allowances (RDAs) for Vitamin D [2]
Age

Male
400IU (10 mcg)

Female
400IU (10 mcg)

0–12
months*
1–70 years
600IU (15 mcg) 600IU (15 mcg)
>70 years
800IU (20 mcg) 800IU (20 mcg)
* Adequate Intake (AI). 1 mcg vitamin D= 40 IU
Since most Americans will only receive a small amount of vitamin D from dietary
sources, the more logical source for vitamin D is through sun exposure. Spending
approximately thirty minutes outside at noon will produce approximately 10,000 IU of
vitamin D [33].
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2.3 What is Sulforaphane (SFN)?
Sulforaphane belongs to a broad class of phytochemicals called isothiocyanates
(ITCs). ITCs are a chemical class of compounds that are not naturally present in cruciferous
vegetables, such as broccoli, Brussel sprouts, cabbage, radish, kale, cauliflower etc.
However, it can be generated from hydrolysis of secondary metabolites, known as
glucosinolates, by action of the enzyme myrosinase, released from plant cells during the
process of crushing or mastication (chewing) [34]. ITCs may also be produced in the
intestines where the resident microflora can promote hydrolysis of glucosinolates to
isothiocyanates. Sulforaphane is especially high in broccoli and broccoli sprouts [14]. It is
well known as a potent inducer of phase-2 detoxification enzymes [35] which inhibits
tumorigenesis in animal models. Indeed, sulforaphane has been implicated in a variety of
anticarcinogenic mechanisms including effects on cell cycle checkpoint controls and cell
survival and apoptosis in various cancer cells [36-43]. The protective effects of
sulforaphane in humans, however, may be influenced by individual genetic variation
(polymorphisms) in the metabolism and elimination of isothiocyanates from the body [21].

2.4 Bioavailability of SFN
It is important to understand the bioavailability and function of nutrient and nonnutrient compounds found in various foods with health-promoting properties. Human
intestinal perfusion studies showed that 74 ± 29% of sulforaphane from broccoli extracts
can be absorbed in the jejunum [44]. Pharmacokinetic studies in both rats and humans also
support the notion that sulforaphane can be distributed in the body and reach micromolar
concentrations in the blood. For example, in rats, following a 50 μmol gavage, detectable
sulforaphane was evident in the plasma after 1 h and peaked at ∼20 μmol/L at 4 h, with a
10

half-life of ∼2.2 h [45]. We know that different nutrients (macro and micro) have varying
degrees of absorbability that can affect their bio efficacy. Broccoli sprouts contain up to 50
times higher concentrations of the sulforaphane precursor glucoraphanin than mature
broccoli. Thus, in humans, most studies have used broccoli sprouts as a particularly rich
dietary source of glucoraphanin/sulforaphane. In human subjects, given single doses of
200 μmol ITC preparation from broccoli sprouts, ITC plasma concentrations peaked
between 0.943 and 2.27 μmol/L 1 h after feeding (half-life =1.77 ± 0.13 h) [46]. However,
it is important to note that the glucosinolate dose per unit body weight given to rats in the
Hu et al. study cited above were much higher (4-fold less ITC with markedly lower body
weight in the rat) than given to human subjects. The primary aim of this literature review
is to present our current understanding of the role of vitamin D and SFN and breast and
colon cancer - what is known and established, what is still missing and where does that
lead us.

2.5 Vitamin D & CRC Epidemiological Studies
Dietary intake, dietary supplementation, latitude and sun exposure, all predictors of
serum of 25(OH)D3 levels, have been associated with differences in cancer incidence and
mortality. This association is particularly strong for CRC [47].

2.5.1 Vitamin D & CRC Meta-Analyses and Systematic Reviews

To date, meta-analyses of the association between serum 25(OH)D3 and CRC have
consistently demonstrated a statistically significant inverse relationship for incidence, but
not recurrence, though data for the latter outcome are comparatively sparse [48, 49]. Since
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the results of these meta-analyses were reported in 2008 and 2015 respectively, a third
study of adenoma recurrence was published, which again showed no statistically
significant association between 25(OH)D3 and odds of adenoma recurrence [50].
Underlying mechanisms for the observed differences in the association for 25(OH)D3 by
incident vs. recurrent adenomas are currently only speculative. Differences in methylation
patterns during adenoma growth and development [51] and variation in expression of key
vitamin D pathway enzymes during different stages of development [52, 53] could be two
potential mechanisms through which differential effects of vitamin D are seen on CRC
incidence vs. recurrence. It is also possible that individuals included in recurrent lesions
studies have different risk factor profiles and the carcinogenic pathway is not affected by
vitamin D the same way as individuals without recurring lesions. Taken together, these
observational studies indicate that vitamin D may have a role in reducing the risk of
incident colorectal adenomas, but after removal of these lesions, there is no evidence that
it will prevent the formation of another.
Several meta-analyses of serum 25(OH)D3 concentrations and CRC incidence have
been conducted, and all have shown a statistically significant inverse association. The
results are summarized in Table 2.2.
Table 2.2: Vitamin D and CRC Meta Analyses and Systematic Review Summary
Serum 25 (OH)D3
55ng/mL
50ng/mL
Every 25ng/mL
increase
<44nM or >72nM
High vs. Low
High vs. Low

Outcome
measure

Statistic

Effect size

RRpooled
OR
OR

0.62
0.4
0.92

38% decrease
60% decrease
8% decrease

[54]
[55]
[56]

RR
OR
RR

0.66
0.68
0.67
vs. 66

34% decrease
32% decrease
33% decrease
vs. 34% decrease

[3]
[57]
[6]

Citations
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High vs. Low
High vs. Low
Every 20ng/mL
increase
High vs. Low
Every 10ng/mL
increase
High vs. Low
≥33 ng/mL,

ORpooled
RR
OR

0.66
0.96
0.82

34% decrease
4% decrease
18% decrease

[58]
[59]
[48]

RRpooled
RR

0.67
0.85

33% decrease
15% decrease

[60]
[61]

OR
ORpooled

0.70
0.49

30% decrease
50% decrease

[49]
[62]

2.5.2 Vitamin D & CRC Randomized Clinical Trials

Randomized clinical trials provide the best evidence if an exposure (e.g. vitamin
D) reduces the risk of any cancer, and to date, only four have been published on vitamin D
with data specific to CRC [63-66]. The Women's Health Initiative (WHI) randomized
women to 400 IU vitamin D and 1000 mg of calcium vs. placebo. No differences in risk
for CRC by treatment group were observed, although some limitations of the trial were
noted, including the relatively healthy study population, the timing of the intervention, and
the comparatively short follow-up time [65]. In addition, it has been suggested that the dose
of vitamin D used in WHI was too low to elicit protective effects [64]. Another clinical
trial conducted in the United Kingdom, randomized men and women to receive 100,000
IU of vitamin D every four months for five years [66]. No reduction in risk of either CRC
incidence or mortality was observed. Results from the ongoing Vitamin D and Omega-3
Trial (VITAL) trial [67], will likely provide more definitive evidence regarding the efficacy
of vitamin D in CRC prevention. In this study, participants are supplemented with 2000
IU/d of vitamin D with and without an omega-3 fatty acid supplement to ascertain whether
the intervention can prevent the development of cancer or cardiovascular disease.
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Four large-scale clinical trials on vitamin D supplementation are currently
underway and summarized in Table 2.3.
Table 2.3: Ongoing Large-Scale Randomized Trials of Vitamin D Supplementation
Worldwide[67]

Trial, Location

Treatment
Duration

Vitamin D
intervention

Primary
endpoints

VITAL, USA
D-Health, Australia1

5y
5y

2000IU/d
60,000 IU/month
(bolus)
1600 IU/d or
3200IU/d
100,000 IU/month
(bolus)

Cancer, CVD
Total mortality,
Cancer
Cancer CVD

FIND, Finland2

5y

VIDAL, UK3

5y

Total mortality,
Cancer

1Neale

R. [11.09.14]; D-Health Trial Australian New Zealand Clinical Trials Registry
identifier: ACTRN12613000743763. Available
at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364534&isClinical
Trial=False
2

Toumainen T-P. [11.09.14];Finnish Vitamin D Trial
(FIND) ClinicalTrials.gov identifier: NCT01463813. Available
at: http://www.clinicaltrials.gov/ct2/show/NCT01463813?intr=vitamin+D&outc=cancer
&rank=10
3 Peto J. [11.09.14];Vitamin D and Longevity (VIDAL) Trial: Randomized Feasibility
Study. ISRCTN46328341. Available at: http://www.controlledtrials.com/ISRCTN46328341
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2.5.3 Vitamin D & CRC Case-Control Studies

Numerous case-control studies analyzed the effect of vitamin D and the risk of
CRC. Some of them are nested within large prospective cohorts. While some studies
focused only on serum 25(OH)D3, others were interested in vitamin D intake,
supplementation and in some cases, sun exposure, to reach their conclusions. Majority of
these studies confirm that vitamin D as measured by serum 25(OH)D3 has a protective role
against CRC. A summary of relevant vitamin D case-control studies is provided in Table
2.4.
Table 2.4: Vitamin D and CRC Case-Control Studies Summary

Serum 25 (OH)D3/
Vitamin D intake

Outcome
measure

Statistic

101.5 nM 25(OH)D3

OR

0.51

Effect size
Citations
49% decrease

21.9 vs. 23.9 ng/mL
Of 25(OH)D3
High vs. Low
Every 50nM increase
in 25(OH)D3
<20ng/mL

OR

0.45

55% decrease

[68]
[69]

OR
OR

0.60
0.57

40% decrease
43% decrease

[70]
[71]

RR

1.80 (men)
0.22
(women)

[57]

D intake
High vs. Low serum
25(OH)D3
High vs. Low serum
25(OH)D3
>100 nM of
25(OH)D3
High vs. Low
D intake
D intake
High vs. Low serum
25(OH)D3

OR
OR

0.77
0.52

18% increase in
men
78% decrease in
women
23% decrease
48% decrease

ORpooled

0.59

41% decrease

[74]

OR

0.77

23% decrease

[75]

OR
OR
OR
ORpooled

0.68
0.69
0.69
0.66

32% decrease
31% decrease
31% decrease
34% decrease

[1]
[76]
[77]
[78]
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[72]
[73]

D intake
High vs. Low
25(OH)D3
D intake
23- 24 ng/ml of
25(OH)D3
D intake

RR
OR

0.53

No effect
47% decrease

[79]
[80]

OR
OR

0.82

18% decrease
No effect

[81]
[82]

OR

0.5

50% decrease

[83]

2.5.4 Vitamin D & CRC Cohort Studies

Higher vitamin D status has been found to be protective against CRC from a few
cohort studies (Table 2.5). A recent retrospective analysis looked at the association
between vitamin D status of advanced CRC patients at the time of diagnosis and subsequent
outcomes [84]. They measured serum 25(OH)D3 levels in patients with new diagnosis of
stage IV CRC and compared it with survival. They defined adequate level of vitamin D as
>30ng/mL of serum 25(OH)D3 and found a 61% reduced risk (HR=0.61; 95% CI 0.380.98). Two prospective cohort studies have specifically assessed the association between
serum 25(OH)D3 concentrations and CRC progression [85, 86]. Mezawa and colleagues
measured blood levels of 25(OH)D3 in Stage I-IV patients and found that although
25(OH)D3 levels were significantly related to overall survival, they were not associated
with disease-free survival [85]. In another study conducted among Stage IV CRC patients
undergoing chemotherapy, concentrations of 25(OH)D3 were not significantly associated
with time to progression of disease [86]. Table 2.5 lists studies of interest that are
prospective in design have a mean follow-up of ±10 years to incident CRC and survival.
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Table 2.5: Vitamin D and CRC Prospective Cohort Studies Summary
Serum 25 (OH)D3
Low vs. High
80 nM

Outcome
measure

Statistic

OR

4.6 in men
2.7 in women
0.38

OR

Effect size
Citations
460% increase
270% increase
72% decrease

[87]

[88]
Every 10nM
increase
High vs. Low

HR

0.95

95% decrease
[89]

OR

0.77

23% decrease
[90]

Every 25nM
increase

RR

0.63

37% decrease
[91]

2.6 Vitamin D & Breast Cancer Epidemiological Studies
Research on BC and vitamin D association have been inconsistent. A high
concentration of plasma 25(OH)D3 was associated with a significantly reduced risk of
premenopausal BC [92]. Reduction in risk of BC is affected by amount of vitamin D
(intake, supplementation, seasonal variation, and race) and differs by menopause status. A
serum 25(OH)D3 level of 50 ng/ml was associated with 50% reduction in incident BC,
compared to a baseline of <10 ng/ml [93]. Every 1 ng/ml increment of plasma 25(OH)D3
level decrease BC risk by 16%. However, some studies have found opposite effects of
vitamin D in BC incidence, development, progression and survival. We present the most
recent epidemiological evidence regarding vitamin D and BC in the following sections.
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2.6.1 Vitamin D and Breast Cancer Meta Analyses and Systematic Reviews

Current breast cancer meta analyses and systematic reviews considered both intake
and supplementation of vitamin D and used breast cancer prognosis, survival, recurrence
and death as possible outcomes. Four meta-analyses identified a significant inverse
relationship between the circulating concentrations of 25(OH)D3 and BC [94-97]. Two
meta-analyses on vitamin D and BC survival have recently been published, and both
reported that higher concentrations of 25(OH)D3 were related to better survival among
women clinically diagnosed with BC [97, 98]. Low vitamin D levels were associated with
a pooled hazard ratio (HRpooled) of 2.13 (95 % CI 1.64–2.78) and 1.76 (95 % CIs 1.35–
2.30) for recurrence and death respectively, in a recent meta-analysis[99].
Another study looked at vitamin D supplementation and BC risk [100] and found
no significant association with a reduced risk of BC development in postmenopausal
women. Due to several reported inconsistencies in the relationship between vitamin D and
BC risk and most of these meta-analyses and systematic reviews recommended further
studies i.e. clinical trials for further clarification. A summary of the most current literature
is listed below.
Table 2.6: Vitamin D and BC Meta Analyses and Systematic Review Summary
Serum 25 (OH)D3
High vs. Low
High vs. Low
>75nM
<15 to >30 ng/mL
High vs. Low
Every 5ng/mL
increase
Every 25ng/mL
increase

Outcome
measure

Statistic

Effect size

RRpooled
RR
HRpooled
OR
RR
RR

0.92
0.63
0.58
0.10
0.84
0.88

8% decrease
37% decrease
42% decrease
90% decrease
16% decrease
12% decrease

[97]
[101]
[102]
[96]
[103]
[104]

OR

0.92

8% decrease

[95]

Citations
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40 ng/mL
High vs. Low
High vs. Low
Every 10ng/mL
increase
Every 20ng/mL
increase
78 nM
52 ng/ml

RR
HRpooled
RR
ORpooled

0.80
0.63
0.55
0.99

20% decrease
37% decrease
45% decrease
1% decrease

[105]
[106]
[107]
[108]

RR

0.73

27% decrease

[109]

OR
ORpooled

0.50
0.50

50% decrease
50% decrease

[110]
[93]

2.6.2 Vitamin D and BC Clinical Trials

Randomized clinical trials for BC and vitamin D association have also presented
mixed results to date, and the inconsistencies persisted though pre- and post-menopausal
sub-group analyses. One study considering the Women’s Health Initiative (WHI) clinical
trial of calcium and vitamin D (CaD) supplements (average intervention period of 7.0
years), found that a relationship between CaD and BC risk was only suggestive [111].
Subjects were vitamin D sufficient for all endpoint analyses. A deficiency of vitamin D, on
the other hand, in BC patients, was found to be unresponsive to standard low-dose D
supplementation [112].
A more recent study focused on a small group of early BC (EBC) patients treated
with adjuvant or neoadjuvant chemotherapy and effects of a tailored, high-dose, oral
vitamin D supplementation in a randomized phase III trial [113]. Their objective was to
restore a normal serum 25(OH)D3 level in this population which would reflect on the
suggested beneficial role of vitamin D. At the end of the trial, 44% of these patients
achieved vitamin D normalization.
Another population-based, double-blind, randomized placebo-controlled trial
looked at supplemental calcium and vitamin D and associated risk of common cancers and
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found that improving calcium and vitamin D nutritional status substantially reduces allcancer risk in postmenopausal women only [64].

2.6.3 Vitamin D and BC Case-Control Studies

Case-control studies examining vitamin D and BC association have produced
mixed results despite controlling for potential confounders. A Mendelian randomization
study analyzing the effects of circulating concentrations of vitamin D and subsequent
cancer risks found that there was a 11% decrease in BC risk with every 25ng/mL increase
in circulating 25(OH)D3 [56]. BC is a heterogeneous disease and it is possible that vitamin
D only affects certain BC subtypes. e.g. based on tumor type, histological grade or hormone
receptors. One study looked at this particular aspect and found the lowest risk of aggressive
BC in patients from the second tertile compared to the lowest tertile where they used serum
25(OH)D3 ≥75 nM to indicate vitamin D sufficiency [114].
BC is prevalent throughout the world, in varying degrees, due to the substantial
differences in the overall population, landscape, exposure to sun, diet, race, age
distribution, and cultural influences). Considering the rising incidence of BC and high
prevalence of vitamin D deficiency in Iran, a recent case-control study assessing BC risk
and vitamin D status, found three times lower the risk of BC incidence in the highest
quartile of serum 25(OH)3 group (OR = 0.269; 95% CI, 0.122-0.593), as well as highest
intake of vitamin D (OR=0.39; 95% CI, 0.196-0.784)[115]. This association was
significant only in the premenopausal women (OR = 0.25; 95% CI, 0.094-0.687) when
stratified by menopause status.
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Another study from India, with similar objectives, found that low serum 25(OH)D3
levels were associated with a high risk of BC (OR=2.5; 95% CI, 0.9-7.4) [116]. Although
seasonal variation in vitamin D association studies are important, exclusive research on
this topic is rather limited. Majority of the case-control studies regarding BC and vitamin
D link have been nested within large prospective cohorts and a few of them are highlighted
below.
One recent nested case-control study in the Nurses' Health Study cohort found that,
although not related to overall BC risk, serum 25(OH)D3 significantly inversed BC risk in
summer (RR = 0.66; 95% CI, 0.46-0.94) only [117]. A nested case–control study within
the Multiethnic Cohort Study of five race/ethnic groups (white, African-American, Native
Hawaiian, Japanese, and Latino) found BC risk was inversely associated with serum
25(OH)D among white (OR=0.43; 95% CI,0.23-0.80) but not in other race/ethnic groups
[118]. However, another nested case-control study within a large prospective cohort with
10 years of follow-up, studying the same association failed to establish a connection
between serum 25(OH)D levels and BC risk, although women with relatively high levels
in summer months were at reduced risk [119].
A Korean study on serum 25(OH)D3 and BC risk [120] showed significant
association with serum 25(OH)D3 highest quartile (OR=1.27; 95 %CI, 1.15-1.39) and
remained significant when stratified by menopausal status: pre-menopause (OR=1.26; 95
% CI ,1.09-1.45) and post-menopause (OR=1.25; 95 % CI, 1.10-1.41).
There have been several other studies regarding BC risk and serum 25(OH)D3 and
they’re summarized in Table 2.7.
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Table 2.7: Vitamin D and BC Case-Control Studies Summary
Serum 25 (OH)D3
<19.8 to >27 ng/mL
18.1 to 29.5 ng/mL
<12.0 to >24.0 ng/mL
<20 to >40 ng/mL
<24.0 to >33.7 ng/mL
<14.7 to >29.2 ng/mL
<12 to >30 ng/mL
9.44 to 32.8 ng/mL
<18.3 to >33.7 ng/mL
<22 to >41.7 ng/mL
<20 to >60 ng/mL

Outcome
measure

Statistic

RR
RR
RR
RR
RR
RR
RR
RR
RR
RR
RR

0.80
0.84
0.45
0.56
0.52
1.09
0.31
0.93
1.13
0.73
0.20

Effect size
Citations
20% decrease
16% decrease
55% decrease
44% decrease
48% decrease
10% increase
69% decrease
7% decrease
11% increase
27% decrease
80% decrease

[121]
[122]
[92]
[123]
[124]
[125]
[126]
[127]
[128]
[129]
[130]

2.6.4 Vitamin D and BC Cohort Studies

A recent study used a 25(OH)D3 prediction model to assess the relationship
between vitamin D and incident BC risk was conducted by Palmer and colleagues [131].
Participants were part of the Black Women’s Health Study who have been followed by
biennial mail questionnaires since 1995. The 25(OH)D3 prediction model is based on
measured 25(OH)D3 in plasma specimens obtained from 2856 participants (between 2013
and 2015) by using questionnaire-based variables from the same time frame. They found
that, when compared to the highest quartile, women in the lowest quartile of predicted
25(OH)D3 were estimated to have a 23 % increased risk of BC. The Pathways Study is a
prospective cohort that looked at serum 25(OH)D3 association with BC prognosis[132] and
found that 25(OH)D3 was significantly associated with BC-specific survival (HR=0.37;
95% CI, 0.15-0.93) in premenopausal women and supports the idea that vitamin lowers the
risk of BC morbidity and mortality.
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There aren’t a lot of retrospective studies in BC association with vitamin D and
even less in Latin American women. A recent retrospective case-cohort study examined
serum 25(OH)D3 levels in Chilean BC patients before endocrine therapy and its association
to clinical parameters at the time of diagnosis [133]. Using serum 25(OH)D3 ≥ 30 ng/ml
(75 nM) as sufficient vitamin D status [33], they found no significant association between
weight, BMI, tumor stage, tumor ER expression and changes in serum 25(OH)D3 levels.
This observation may be due to a small number of subjects studied, although the results
were like studies of season–dependence of 25(OH)D3 levels.
A recent European study that analyzed the effects of serum 25(OH)D3 on BC risk
in three ongoing, large, prospective cohort studies from the CHNACES consortium
presented a comprehensive finding on the association of serum 25(OH)D3 and site-specific
cancer incidence [134]. They found a 27% reduction in BC incidence (high vs. low)
although this difference was not significant. Their cutoff for vitamin D sufficiency was a
serum 25(OH)D3 levels >50nM and <30 nM as deficient.

2.7 Sulforaphane and Colorectal Cancer
Sulforaphane (SFN) is an isothiocyanate (ITC) that can be formed from its
precursor molecules present in cruciferous vegetables, such as broccoli, cabbage, broccoli
sprouts etc. SFN was first identified as a potent inducer of phase II detoxification enzymes,
and growing evidence indicates that SFN might have some chemoprotective
properties[17]. Some dietary compounds have been known to de-repress epigenetically
silenced genes in various cancer cells that could have important implications in cancer
prevention and therapy.
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One epigenetic mechanism that affects this process of de-repression is histone
deacetylation inhibition. HDACs affect histone acetylation status by removing acetyl
groups from the nuclear histone proteins which can cause epigenetic silencing of important
genes in cancer cells. Inhibition of this process will have an opposite effect, reducing the
net removal of histone acetyl groups (histone deacetylase or HDAC enzymes) and
potentially de-repressing silenced genes. This could result in cell cycle arrest and/or
apoptosis reducing carcinogenesis. SFN is one phytochemical that demonstrates HDAC
inhibitor action [135].
For example, one study investigated the antiproliferative and pro-apoptotic effects
of SFN on the SW620 colon cancer cell line and found that SFN at concentrations of 10–
50 μM reduces cell viability and inhibits cell proliferation in a time- and dose-dependent
manner. DNA damage was also inhibited after 24 h and 48 h in the same cell line [37].
Another study on LS-174 and Caco-2 cells (both human colon cancer cell lines) found that
a combination of SFN and mixed isothiocyanates (ITCs) reduced colon carcinogenesis by
both stimulating apoptosis and enhancing intracellular defenses against genotoxic agents
[136]. A more recent study analyzed 5 different colon cancer cell lines- HCT116, HT-29,
KM12, SNU-1040, and DLD-1 and found that SFN (5µM and 25µM) inhibited growth via
G2/M phase cell cycle arrest and increased apoptosis while exhibiting negligible toxicity
in normal (nonmalignant) cells [5]. Another study isolated different hydrolysates of
broccoli and found that the crude extract (80% alcohol extract) of broccoli florets had high
cytotoxic activity against different human cancer cell lines, particularly, colon cancer (IC50
3.88 µg/mL)[137].
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In a study examining the anti-proliferative effect of SFN on an array of human
colon cancer cell lines- DLD-1, HCT116 and LoVo, SFN exhibited anti-proliferative
effects demonstrated by colony formation assays. Colony formation was reduced by SFN
in a dose-dependent manner, especially at 20 µM [138]. In HT-29 colon cancer cells, one
study found a significant reduction in cell proliferation (≥20 µM) [139] while another found
that SFN induced cell cycle arrest in a dose-dependent manner, followed by cell death [34].
SFN also showed dose-dependent cytotoxicity and proapoptotic activity in HCT-116 cells
in another study[41].
A phase I placebo controlled, double-blind, randomized clinical trial to assess
toxicities of either glucosinolate (300 μmol/day) or isothiocyanate (75 μmol/day) showed
no toxicities or abnormal events occurred with any of the test extracts [140]. In another
study comparing natural SFN vs. SFN supplements, with subjects consuming >300 μmol
of glucosinolates every day for 7 days, consumption of SFN precursor (glucoraphanin) had
no adverse effects, indicating that a high dose of glucosinolates was well tolerated in the
subjects [141].

2.8 Sulforaphane and Breast Cancer
SFN is a chemoprotective agent used in cell culture, animal cancer models
(carcinogen-induced and genetic) as well as in xenograft models of cancer. In humans, a
key factor in determining the efficacy of SFN as a chemoprevention agent is gaining an
understanding of the metabolism, distribution and bioavailability of SFN and the factors
that alter these parameters [39]. The importance of epigenetics in the initiation and
progression of breast cancer has become more appreciated and has led many investigators
to incorporate epigenetics-based treatments in breast cancer drug development [142].
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One study investigating bulk histone acetylation and DNA methylation
modifications in a large cohort of breast tumors found that the occurrence of certain histone
marks correlates with tumor morphology and biological subtype. In other words, tumors
with adverse traditional prognostic or phenotypic characteristics were found to have
reduced levels of detectable histone acetylation marks and vice versa [143].
Effects of histone deacetylase inhibitor compounds have been studied both in vivo
and in vitro. Most of these studies used various extracts from cruciferous vegetables and in
different combinations. One study analyzed potential estrogen receptor (ER) ligands acting
as agonists or antagonists, when bound to extracts from cabbage, fermented cabbage, and
acidified Brussels Sprouts. These extracts were evaluated for their estrogenic and
antiestrogenic activities in estrogen-dependent human breast cancer (MCF-7) cells using
as endpoints proliferation and induction of estrogen-responsive pS2 gene expression. At
low concentrations (5-25 ng/mL) all the extracts reduced 1 nM estradiol-induced MCF-7
cell proliferation [144]. Another study found that SFN treatment (30μM) along with
autophagy inhibition in MCF-7 and MDA-MB-231 breast cancer cells might be a
promising strategy for breast cancer control [145]. Sulforaphane (1-5 μmol/L) decreased
aldehyde dehydrogenase–positive cell population by 65% to 80% and reduced the size and
number of primary mammospheres by 8- to 125-fold and 45% to 75%, respectively in a
recent breast cancer stem cell study [146]. A combination of HDAC inhibitors with
demethylating agents was suggested as a promising strategy for the effective treatment of
hormonal refractory BC, mainly in triple negative BC cells (TNBC) [147]. Another study
also found that SFN significantly inhibits cell proliferation in multiple TNBC cell lines
through inducing G2/M phase arrest and apoptosis [148].
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A single oral dose of 150 μmol SFN in rats resulted in mammary tissue levels of
SFN which presented with metabolites at concentrations known to alter gene expression in
vitro[149]. In a follow-up study, similar results were found in human breast tissue when
eight healthy women undergoing reduction mammoplasty were given a single dose of a
broccoli sprout preparation containing 200 μmol of SFN [149].
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CHAPTER 3

PURPOSE OF THE STUDY
Colorectal cancer is the second most invasive and third most common cancer in
both men and women in the US. Prevention of colorectal cancer is an ongoing challenge,
part of which is attributable to the constantly changing environmental factors that influence
the development of colorectal cancer like- diet, exercise, smoking, alcohol intake, obesity
etc. [1]. The most significant risk factors for breast cancer are gender (being a woman) and
age (growing older) while other factors include- radiation to chest before the age of 30,
genetics, race, overweight/obesity, alcohol intake, smoking and lack of exercise. Research
shows that women with high levels of the vitamin in their blood are more likely to survive
breast cancer than patients with low levels [2].
Both higher vitamin D status [3] and cruciferous vegetable intake [4] have been
linked to reduced risk of cancers. However, little is known about how these two factors
may work synergistically with each other to augment the anti-proliferative activity of
vitamin D. It has also been found that, enzymes involved in autocrine metabolism of
vitamin D in breast tissue may provide important targets for both the prevention and
treatment of breast cancer [5]. However, not much is known about the role of vitamin D in
normal breast cell development and specific cell cycle events such as proliferation. This is
a problem because the therapeutic window for the active vitamin D metabolite is quite
small, and has an increased risk of developing toxicity from hypercalcemia and
hypercalciuria at therapeutically effective, anti-proliferative doses of vitamin D. A
selective downregulation of the vitamin D receptor (VDR) in colon and breast cancer cells,
or alterations in the relative activity of the cellular enzymes involved in 1,25(OH)2D3
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activation (CYP27B1) and inactivation (CYP24A1) can significantly alter the availability
of intracellular concentrations of 1,25(OH)2D3. It can also alter the sensitivity of the cell to
the active D metabolite by manipulating VDR activity. We hypothesized that 1,25(OH)2D3
treatment will decrease the rate of cell proliferation in colon and breast cancer cells by
modulating D responsive genes. We also hypothesized that treatment of colon and breast
cancer cells with SFN or TSA will further support vitamin D action. We anticipate the
study findings will shed new light on potential anti-cancer mechanisms related to vitamin
D anti-proliferative effects via increased inhibition of HDAC activity through dietary
bioactive components, like SFN.
We will discuss the specific aims and hypotheses of our three papers in the
following order: epidemiological evidence from a systematic review and meta-analysis on
vitamin D and breast cancer followed by in vitro primary studies on human breast cancer
(MCF-7 cells) and colorectal cancer (Caco-2 cells) respectively.

3.1 Paper 1: A Systematic Review and Meta-Analysis of Vitamin D and Breast Cancer
Vitamin D is well known for its role in bone health primarily. However, recent
epidemiologic studies have linked vitamin D deficiency with adverse cardiovascular and
cancer-related outcomes [6]. Although vitamin D can be found in a limited number of
foods, the major source of vitamin D is the endogenous production. Plasma concentrations
of 25(OH)D3 have been used as a stable indicator of vitamin D status in humans [7].
Epidemiologic evidence for an association between plasma 25(OH)D3 and BC incidence
and/or prevalence is inconsistent [8].
Moreover, there aren’t enough clinical trials with vitamin D mostly due to lack of
adequate power. Although, certain longitudinal studies have assessed the relationship
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between plasma 25(OH)D3 concentrations and inverse CRC risk, [9-13], there are not
enough studies associated with prostate or BC incidence [11, 14-16]. Vitamin D
supplementation studies with or without calcium [17-20] reported inconclusive or
nonsignificant results for cancer [21]. The mixed results suggest that the relationship of
vitamin D status and BC risk is still incompletely understood [22] and drove our systematic
review and meta-analysis.
The primary objective of the systematic review and meta-analysis is to gather
evidence over the past ~18 years linking vitamin D status and intakes (food and
supplements) with the occurrence of breast cancer.
This study aims at reaching the objective by pooling data from the existing
literature, interpreting and evaluating the results in both pre- and post-menopausal women.
We also discussed potential biological mechanisms behind those putative associations.
The final selected 18 studies were first reviewed in a systematic way, stratifying by
study design and type of exposure with measures of association compared across studies.
We used the PRISMA guidelines in summarizing the article search. The study-specific RRs
for each exposure of interest were examined in pooled models, after testing for
heterogeneity using the I2 test. As such, a summary or pooled RR was provided using forest
plots and estimated using inverse variance weighting [23]. Random effects models that
further incorporated between-study variability were conducted using DerSimonian and
Laird’s methodology.
A pre-defined quality score (QS) was used to assess the quality of each included
study and the key findings of studies for each exposure of interest were presented using a
harvest plot. Finally, Begg’s funnel plots were used to examine publication bias; each OR
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point estimate was plotted against corresponding standard errors (SE) for each study on a
logarithmic scale [24, 25] combining all exposures (e.g. serum and dietary vitamin D
exposures).

3.2 Paper 2: Histone Deacetylase activity and Vitamin D-Dependent Gene
Expressions in Relation to Sulforaphane in Human Breast Cancer (MCF-7) Cells
Vitamin D has been found to be protective against BC [26]. Numerous studies tried
to prove the association although the findings are not consistent. However, there are limited
studies about histone deacetylation (HDAC) inhibition patterns in BC tumors. There is a
strong lack of evidence regarding BC risk and vitamin D-HDAC inhibitor combination
therapy.
The primary objective of this study is to determine how HDAC inhibition
influences vitamin D-induced gene expression in BC. The rationale is that the chosen
epigenetic modifiers (SFN and TSA) will alter the acetylation status of histone proteins,
which will loosen the histone protein complex allowing increased transcription of vitamin
D-inducible genes.

Hypothesis a: Expression of vitamin D-dependent genes will be increased by HDAC
inhibitors

Our working hypothesis for this specific aim is that the expression of vitamin Dinducible genes will be increased by concomitant treatment of cells with histone
deacetylase (HDAC) inhibitors SFN and TSA. To test this working hypothesis, we have
measured, with and without HDAC inhibitors, the mRNA expressions of VDR (vitamin D
receptor), CYP24A1, CYP27B1 and TRPV6 by real time quantitative polymerase chain
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reaction (RT-qPCR) in MCF-7 cells. Treatments were 100 nM vitamin D with and without
SFN (20µM) and TSA (1µM). Our expectation was that vitamin D treatment will increase
the expression of these selected genes and that concomitant treatment with SFN or TSA
will further augment the association.

Hypothesis b. Histone protein acetylation status will be increased by SFN and TSA
treatments

To test the relative HDAC inhibition by SFN and TSA, we measured changes in
histone protein acetylation following our chosen treatments of 100 nM vitamin D with and
without SFN (20µM) and TSA (1µM). Cells were incubated for 24 hours once 70%
confluent after being seeded onto a 96-Well plate at 10,000 cells/well. HDAC I/II reagents
(HDAC I/II Assay, Promega, 2017) were added at equal volumes to each well and
incubated for 1 hour at room temperature. Relative luminescence (RLu) were recorded
using OptiMax Luminometer and results were analyzed.
We hypothesized that, SFN and TSA will increase histone deacetylase inhibition in
MCF-7 cells and co-treatment with vitamin D would enhance D effects.

Hypothesis c: Cell proliferation will be decreased by 1,25-dihydroxyvitamin D3
treatment and will be further decreased by concomitant HDAC Inhibitor action

We hypothesized that treatment of MCF-7 cells with the HDAC inhibitors will alter
the acetylation status of histone proteins, thereby increase cellular vitamin D
responsiveness.
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We conducted colony formation (colonogenic) and migration assay to
physiologically demonstrate an increase in the anti-proliferative effects of vitamin D
combined with HDAC inhibitors SFN and TSA. Clonogenic assays demonstrate the
effectiveness of a treatment by visually examining the number of colonies formed.
Migration assay tests the ability of cells to migrate a scratch wound after treatment.
Efficacy of the treatments are inversely proportional to the distance migrated i.e. if the
distance migrated after the treatment is more than initial scratch, the test compound is less
effective in preventing migration and vice versa. We also performed a cell viability assay
that measured ATP which is directly proportional to the number of live cells in the system
post-incubation (24Hrs).
Our expectation was that vitamin D will decrease cell proliferation, which would
be further decreased by epigenetic modifiers affecting histone acetylation status.

3.3 Paper 3: Association Between Histone Deacetylase activity and Vitamin DDependent Gene Expressions in Relation to Sulforaphane in Human Colorectal
Cancer Cells
Vitamin D, despite its known functions in bone metabolism, has been in the
spotlight for its anti-carcinogenic properties for the past two decades. One study found that
colon cancer mortality in the USA was highest in places with the least amount of sunlight
[27], suggesting a protective role of Vitamin D. The development of many cancers (i.e.
prostate, lungs, colon, etc.) have been associated with a reduced expression of the vitamin
D receptor (VDR). Low VDR expression in cancer cells decreases cellular sensitivity to
vitamin D, reducing its uptake resulting in decreased anti-proliferative action in these cells
[28, 29]. Epigenomic alterations in CRC is behind the existing knowledge on gene
mutations [30] and cell-specific mechanisms are yet to be explored. To the best of our
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knowledge, this study is the first to demonstrate vitamin D- dependent key gene
expressions in relation to histone modification in human colorectal cancer using both
proliferating and differentiated Caco-2 cells as the experimental model.
The primary objective of this study is to determine to what extent treatment with
HDAC inhibitors influence vitamin D-induced transcriptional activity in Caco-2 cells.
We hypothesized that treatment of cells with vitamin D would increase the
sensitivity of Caco-2 cells which, in turn, will increase the action of HDAC inhibitors. We
also hypothesized that, an increase in HDAC inhibition preceded by adequate vitamin D
uptake will decrease progression of colorectal cancer in vitro.

Hypothesis a: Expression of vitamin D-dependent genes will be increased by HDAC
inhibitors

Our working hypothesis for this specific aim is that the expression of vitamin Dinducible genes will be increased by concomitant treatment of cells with histone
deacetylase (HDAC) inhibitors SFN and TSA. To test this working hypothesis, we have
measured, with and without HDAC inhibitors, the mRNA expressions of VDR (vitamin D
receptor), CYP24A1, CYP27B1 and TRPV6 by real time quantitative polymerase chain
reaction (RT-qPCR) in Caco-2 cells. Treatments were 100 nM vitamin D with and without
SFN (20µM) and TSA (1µM). Our expectation was that vitamin D treatment will increase
the expression of these selected genes and that concomitant treatment with SFN or TSA
will further augment the association.
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Hypothesis b. Histone protein acetylation status will be increased by SFN and TSA
treatments

To test the relative HDAC inhibition by SFN and TSA, we measured changes in
histone protein acetylation following our chosen treatments of 100 nM vitamin D with and
without SFN (20µM) and TSA (1µM). Cells were incubated for 24 hours once 70%
confluent after being seeded onto a 96-Well plate at 10,000 cells/well. HDAC I/II reagents
(HDAC I/II Assay, Promega, 2017) were added at equal volumes to each well and
incubated for 1 hour at room temperature. Relative luminescence (RLu) were recorded
using OptiMax Luminometer and results were analyzed.
We hypothesized that, SFN and TSA will increase histone deacetylase inhibition in
Caco-2 cells and co-treatment with vitamin D would enhance D effects.

Hypothesis c: Cell proliferation will be decreased by 1,25-dihydroxyvitamin D3
treatment and will be further decreased by concomitant HDAC Inhibitor action

We hypothesized that treatment of Caco-2 cells with the HDAC inhibitors will alter
the acetylation status of histone proteins, thereby increase cellular vitamin D
responsiveness.
We conducted migration assay to physiologically demonstrate an increase in the
anti-proliferative effects of vitamin D combined with HDAC inhibitors SFN and TSA.
Migration assay tests the ability of cells to migrate a scratch wound after treatment.
Efficacy of the treatments are inversely proportional to the distance migrated i.e. if the
distance migrated after the treatment is more than initial scratch, the test compound is less
effective in preventing migration and vice versa. We also performed a cell viability assay
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that measured ATP which is directly proportional to the number of live cells in the system
post-incubation (24Hrs).
Our expectation was that vitamin D will decrease cell proliferation, which would
be further decreased by epigenetic modifiers affecting histone acetylation status.
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4.1 Abstract
Background: In this systematic review and meta-analysis, we pooled and evaluated
evidence linking serum vitamin D (both in serum and diet) with breast cancer (BC)
occurrence.
Methods: Searching PubMed and Cochrane databases (January 1st 2000 through August
31st , 2017), only observational studies were included. Publication bias and consistency upon
replication were assessed, while harmonizing risk ratios (RR, 95% CI) of BC, per fixed
increment of 5 exposures [10 ng/mL of 25(OH)D; 100 IU/d for total/dietary vitamin D
intakes; vitamin D deficiency; supplement use). RRs were pooled using random effect
models.
Results: Pooled findings from 18 studies suggested a net direct association between
25(OH)D deficiency and BC, with RRpooled=1.73, 95% CI: 1.28-2.34, p<0.001). Total
vitamin D intake was also inversely related to BC (RRpooled=0.98, 95% CI: 0.96-1.00,
P=0.029, per 100 IU/d). No evidence of publication bias was found and consistency upon
replication was shown for all 5 exposures of interest.
Conclusions: Our study indicated that serum vitamin D deficiency and total vitamin D
intake were associated with BC occurrence.
Impact: Thus, pending future randomized controlled trials, vitamin D may be protective
against BC occurrence.

Key words: Vitamin D, breast cancer, meta-analysis
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4.2 Abbreviations
1,25(OH)2D=1,25 di-hydroxyvitamin D
25(OH)D=25-hydroxyvitamin D
BC=Breast cancer
CI=Confidence Interval
CVD=Cardiovascular Disease
HR=Hazard Ratio
IU=International Units
OR=Odds ratio
RR=Risk Ratio
SD=Standard Deviation
SE=Standard Error
QS=Quality score

4.3 Introduction
Breast cancer is the most common malignancy among women in the US that has
substantial medical and economic costs associated with it [1]. In 2017, an estimated
252,710 new cases of invasive BC will be diagnosed among women (BC report 2017-18)
and approximately 40,610 women and 460 men are expected to die from BC in 2017.
Although there has been an overall increase in BC death rates between 1975 and 1989, a
steady decline attributed to advanced healthcare and screening has been observed from
2006 to 2015. However, this decline has not been the same among different racial and
ethnic groups. The relative survival rates based on the most recent data as published on the
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American Cancer Society report are: 91% at 5 years after diagnosis, 86% after 10 years
and 80% after 15 years BC report 2017-18. According to a recent retrospective study that
looked at the stage-dependent average per capita cost of BC treatment, costs were higher
in patients whose cancer were more advanced at diagnoses. For example, there is
approximately a $10,000 difference in surgical costs during the first 12 months of
diagnoses between a stage 0 and IV cancer screening. [1]
Vitamin D is known to play a major role in bone health and calcium homeostasis.
In recent years, epidemiologic studies have linked vitamin D deficiency with several
adverse outcomes, including cardiovascular and cancer-related morbidity and mortality.[2]
Vitamin D is limited to certain foods (fatty fish, cod liver oil, egg yolk, some mushrooms,
meat etc.) or supplements. The major contribution to vitamin D status is the endogenous
production of vitamin D in the skin. Plasma concentrations of 25-hydroxyvitamin D
[25(OH)D] has a half-life of 1-2 months and can reflect vitamin D production, absorption,
and storage.[3] Epidemiologic evidence for an association between plasma 25hydroxyvitamin D [25(OH)D] and breast cancer (BC) incidence and/or prevalence is
inconsistent.[4]
Vitamin D deficiency is present throughout the world.[5] Increased awareness of the
association of vitamin D deficiency with various health outcomes in recent years has
contributed to an increase in vitamin D supplement use as well as the prescription of high
dose vitamin D in treating vitamin D deficiency. [6]
The results from numerous epidemiological studies that studied circulating vitamin D
concentrations and risk of various cancers have proven to be inconsistent. Moreover, there
is a lack of definitive clinical trials with vitamin D supplementation and risk of cancer
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mostly due to lack of adequate power. A recent Mendelian randomization study showed
that a multi-single nucleotide polymorphism score for circulating 25(OH)D concentration
was not directly associated with risk of several cancers including BC [7]. However, a cross
sectional study in Brazilian postmenopausal women showed that low serum 25 (OH)2
vitamin D level is a risk factor for ER negative tumors, with positive axilla and a higher
rate of cell proliferation. [8]
Several longitudinal studies have assessed the relationship between plasma 25hydroxyvitamin D [25(OH)D] concentrations and cancer risk. The results have been
summarized in several meta-analyses, which concluded that 25(OH)D concentrations are
inversely associated with colorectal cancer incidence [9-13] but are not associated with
prostate or BC incidence [11, 14-16]. Interventional studies that assessed the influence of
vitamin D supplementation with or without calcium and cancer [17-20] reported
inconclusive or nonsignificant results. [21] The mixed results from observational and
interventional studies suggest that the relationship of vitamin D status and cancer risk is
still incompletely understood.[22]
This systematic review and meta-analysis attempts to pool, interpret and evaluate
research evidence over the past ~18 years linking vitamin D status and intakes (food and
supplements) with the occurrence of BC among both pre- and post-menopausal women.
Finally, this study discusses potential biological mechanisms behind those putative
associations.
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4.4 Methods
4.4.1 Search strategy

We conducted a systematic review of the literature on BC using primarily PubMed
and Cochrane library as a secondary search. We focused on serum and dietary vitamin D
as specific exposures. We searched systematically by combining the keywords "vitamin
D" and "BC." Synonymous keywords were not included in the search to avoid
heterogeneity in defining the concepts. We restricted the literature search to human studies
published in English between January 1st, 2000 and August 31st, 2017. Figure 4.1 shows
the search result, inclusion and exclusion criteria and the final number of studies. We
considered original research published between 2000 and 2017 because the association of
vitamin D with BC was studied rarely before 2000. We assessed the papers by reviewing
titles and abstracts yielded by an initial search using relevant keywords combinations in
abstracts (i.e. vitamin D and BC). We conducted a systematic review of the literature on
BC focusing on specific exposures, namely serum and dietary vitamin D, (See Appendix
C for search details). Among those that were selected for review, we retrieved further key
information such as study design, contextual setting, sample size, main outcome and key
findings. We used EndNote (X8.1) to create a reference database and we summarized
extracted summary data in an Excel spreadsheet.
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Identification

Additional records identified
through Cochrane Database:
(n =82)

Records identified through PubMed
searching
(n = 5,246)

Included

Eligibility

Screening

Records after duplicates removed
(n = 3,451)

Records screened
(n = 2,574)

Records excluded
(n = 877)

Full-text articles assessed
for eligibility
(n = 1,682)

Full-text articles excluded,
with reasons*
(n = 877)

Studies included in
qualitative synthesis
(n = 18)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 18)

Fig. 4.1: Study Selection.*N=496 excluded based on study subject (non-human); N=
1,769 excluded based on full text availability; N=26 non-English language (excluded);
N=191 studies with male participants (excluded); N=164 participants younger than 19
years(excluded); N=787 studies with irrelevant parameters (excluded).
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and MetaAnalyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097
For more information, visit www.prisma-statement.org.
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4.4.2 Study Identification and Selection

Two independent reviewers (Sharmin Hossain and May Beydoun) determined
whether studies were selected for review and meta-analysis. We initiated study inclusion
and exclusion by examining titles and abstracts. We retained only studies with direct
relevance to our research question. We obtained full text for the selected papers, which we
then screened for potential inclusion in the systematic review and meta-analysis. The
studies that were included assessed any type of association between vitamin D status and
BC incidence or prevalence. Included studies presented findings as risk ratios (RR), hazard
ratios (HR) or odds ratios (OR). They used a binary outcome for BC and categorical
assessment of vitamin D status (usually binary). Primary reasons for excluding studies were
“No relevant data available,” “Study is a randomized controlled trial,” “Study subjects are
not adult women,” “Outcome is not incident or prevalent BC,” or “Exposure is not serum
25(OH)D or dietary intake of vitamin D”. The meta-analysis was carried out on all
observational study designs including cross-sectional, prospective and retrospective cohort
studies.

4.4.3 Data extraction

Detailed study-level characteristics were summarized in APPENDIX B (e.g. age,
gender, country), study design (e.g. case-control, cross-sectional, cohort), sample size (e.g.
number of cases and controls, or total sample size), type of exposures measured, type of
population and quality score (described later). Selected studies were sorted by year of
publication and first author’s last time. Type of exposure was identified as serum 25(OH)D
(per 10ng/mL), serum 25(OH)D (deficient vs. not), dietary vitamin D (per 100 IU/d),
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supplemental vitamin D (yes vs. no), and total vitamin D intake (per 100 IU/d). Further
data extraction for use in the meta-analysis was conducted using a series Excel sheets (1
per study) in which the final effect size and its 95% CI were estimated.

4.4.4 Qualitative review and meta-analysis

The final selected 18 studies were first reviewed in a systematic way, stratifying
by study design and type of exposure. The original measures of association are presented
and compared across studies. Using the same 18 studies, we conducted a meta-analysis to
assess the strength of the association of BC outcomes with vitamin D exposures among
pre- and post-menopausal women combined. This analysis was thus restricted to casecontrol, cross-sectional, and prospective cohort studies with available data that had
comparable measurements for each risk/protective factor, thus allowing the estimation of
a pooled measure of association across those data and studies, namely a risk ratio (RR)
with its 95% CI. Modifications to the reported RR were made when measured on different
scales of exposure [e.g. per 1 SD vs. quartiles vs. tertile vs. per 1-unit (e.g. 10 ng/mL)
increase]. All RRs were converted into a single measure of association that closely
represents the effect of a fixed incremental linear increase in the exposure on the risk of
BC. After converting the RR with their 95% CI to LogeRR with its SE, both parameters
(i.e. the point estimate and its SE) were divided by a conversion factor. In fact, in a normal
distribution, the means of the highest and lowest tertile lie 2.18 SD apart; therefore, the log
RRs were divided by 2.18 to obtain log RR per SD. Similarly, extreme quintiles effects
were divided by 2.8, while extreme quartile effects were divided by 2.54. This approach
was adopted elsewhere.[23] The value of SD was estimated using descriptive data from
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cases and controls (or total population in the case of cross-sectional or cohort studies) or
by approximating the differences between extreme quantiles and then dividing them by the
conversion factors above.[24] From this, RR per 10 ng/mL for serum 25(OH)D, or per 100
IU dietary or total vitamin D was estimated by dividing the LogeRRZ with its Standard
Error (SE)z by the estimated SD value (either reported in the study or estimated from
extreme quantiles) and multiplying it by 10 and 100, respectively. The Log-transformed
RR is then exponentiated to obtain the point estimate of RR per 10 ng/mL increase in
25(OH)D or 100 IU/d of dietary/total vitamin D intake. To obtain the 95% CI, the LogeRR
point estimate is used along with its SE to obtain the lower and upper confidence limits on
the Loge scale. These values are then exponentiated to obtain RR’s 95% CI. A similar
approach was adopted when vitamin D exposure in a specific study was reported into nonquantile categories (i.e. exposure groups with varying sample sizes). However, in this case,
each contrast with a referent category is transformed into per 10 ng/mL or100 IU/d and
then pooled into a common measure of association using random effects models within that
study. Moreover, in the latter instance, median exposure value in each category is estimated
and subtracted from the referent to obtain average increment in vitamin D exposure
corresponding to each contrast. This is then used to ensure the measure of association
corresponded to 10 ng/mL or 100 IU/d increase, for 25(OH)D and dietary/total vitamin D,
respectively. Varying units and conversion factors in the measurement of serum 25(OH)D
were also considered in these calculations. In studies with stratified analyses (e.g. by age
group), incremental RR were estimated per strata and then pooled into one estimate with
associated 95% CI, using random effects models within the study.
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The study-specific RRs for each exposure of interest were then examined in pooled
models, after testing for heterogeneity using the I2 test. As such, a summary or pooled RR
was provided using forest plots and estimated using inverse variance weighting.[25]
Random effects models that further incorporated between-study variability were conducted
using DerSimonian and Laird’s methodology.[25]

4.4.5 Harvest and funnel plots

A pre-defined quality score (QS) was used to assess the quality of each included
study. This QS is a modified version of previously used scoring systems[26] and was
applied in a previous meta-analysis.[23] In our meta-analysis, the QS scale included 4
items, namely study design, study size, outcome assessment, and adjustment for potential
confounders, each of which can be scored from 0 to 2 in ascending order of quality. Thus,
the total QS score could range from 0 to 8. Since only one outcome was studied (i.e. BC),
only one QS was linked to each study. Three independent assessments of QS items/study
were made by three co-authors (May Beydoun, Hind Beydoun and Xiaoli Chen) and the
average QS was determined. A consensus was then achieved by the 3 co-authors after
initial rating. To represent graphically the key findings of studies for each exposure of
interest, a harvest plot was used. This plot shows the exposure-outcome associations of
interest in each study, whether they were significant and in which direction (-1= “inverse
association”, 0= “null association”, 1= “positive association”) for each exposure against
QS which is presented on the y-axis. At least 3 studies were needed to create a harvest plot
per hypothesized exposure-outcome association.
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Finally, in order to examine publication bias, we used Begg’s funnel plots
(APPENDIX E); each OR point estimate was plotted against their corresponding standard
errors (SE) for each study on a logarithmic scale,[27,28] combining all exposures (e.g.
serum and dietary vitamin D exposures). This type of bias was also formally tested using
the Begg-adjusted rank correlation tests[29] and the Egger’s regression asymmetry
test.[30] All analyses were conducted with STATA 15.0 (StataCorp, College Station, TX)
.[31] Type I error was set at 0.05 for all measures of association.

4.5 Results
4.5.1 Study Selection, Characteristics and Quality Score

Out of 3,451 un-duplicated titles and abstracts between 2000 and 2017, 18
published original epidemiologic studies were considered for review and/or meta-analysis.
Those selected studies were published between 2005 and 2014 (Mean±SD: 2010±3), with
11 being US studies, 1 Canadian, 4 European and 2 from Asia (APPENDIX D). Moreover,
most studies had a case-control or nested case-control design (n=16), with only 2 being
prospective cohort studies. Eight studies comprised adult women of varying age ranges,
while 4 included only pre-menopausal women and 6 were restricted to post-menopausal
women. Overall, mean age was 54.2 with a SD of 10.3y. The cumulative sample of studies
included in our meta-analysis consisted of 125,291 subjects, with a Mean±SD:
6,690±17,245 subjects per study. Finally, mean QS with its SD was 4.56±1.69 (range:2-8),
indicating a relatively above average quality set of studies, given that the maximum score
is 8.
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4.5.2 Qualitative Review of Studies

Of 16 case-control studies included in this paper, 9 studies (56.3%) showed that a
reduced risk of BC was associated with high levels of 25(OH)D [19, 21, 24, 29, 32, 33] or
the use of vitamin D or multivitamin supplements [34-39]. The other 7 case-control studies
(43.7%), however, showed no associations of BC risk with 25(OH)D levels or vitamin D
intake [30, 32, 33, 40-43].
Of two prospective cohort studies included in this current study, both showed that
dietary calcium could reduce the risk of BC among postmenopausal women [44,45]. For
example, in the Cancer Prevention Study II Nutrition Cohort (QS=8), McCullough et al
(2005) studied dairy, calcium, and vitamin D intake and BC risk among 68,567
postmenopausal women aged 50-74 years in the US (QS=8). [46-49] Their results
supported the hypothesis that dietary calcium may modestly reduce the risk of
postmenopausal BC. In the Iowa Women's Health Study of 34,321 postmenopausal women
aged 55-69 years with 18 years of follow-up (QS=8), [42] reported that vitamin D intake
appeared to be associated with a small decrease in BC risk among postmenopausal women
in the US.

4.5.3 Meta-Analysis: Findings for Serum Vitamin D

In total, measures of the association from 12 case-control studies on serum 25(OH)
D in relation to BC were pooled, with a total number of 8,156 cases matched with 11,336
controls. Our pooled findings indicated that there was no detectable association between
serum 25(OH)D concentration and BC occurrence (RR=0.99, 95% CI: 0.98-1.00, P=0.12,
per 10 ng/mL), while based on 3 case-control studies (1,021 cases matched with 1,021
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controls), serum 25(OH)D deficiency was shown to have a direct relationship with the risk
of BC (RR=1.73, 95% CI: 1.28-2.34, P<0.001) (Fig 4.2).

Figure 4.2: Study Summary. Heterogeneity chi-squared = 58.61 (d.f. = 11) p =
0.0001. I-squared (variation in ES attributable to heterogeneity) = 81.2%. Test of ES=1:
z= 1.30 p = 0.195
4.5.4 Meta-analysis: Findings for Dietary Vitamin D (foods and supplements)

In total, measures of association from 4 studies on total dietary vitamin D (foods
and supplements) relation to BC occurrence were pooled. We demonstrate a clear net
inverse association between total vitamin D intake and BC, with a pooled RR=0.98, 95%
CI: 0.96-1.00, P=0.029, per 100 IU/d. This small inverse association was observed for
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dietary vitamin D and supplemental vitamin D usage (yes vs. no), though did not attain
statistical significance.

4.5.5 Bias Assessment: Funnel and Harvest Plots
Begg’s funnel plot indicated that most of the 22 data-points fell within the
expected confidence limits when plotting Loge(RR) against its SE. Begg’s test indicated
no publication bias, with z=0.99 and associated p-value of 0.32, and Egger’s test indicated
there was no asymmetry whereby Loge(RR) was not associated with its SE in terms of
slope. In addition, there was no bias in terms of the directionality of Log e(RR) that were
published in the literature.
Examining each individual exposure, harvest plots are presented in APPENDIX
F, plotting qualitative findings (-1=”inverse association”, 0=”null association” and
1=”positive association”) against study-level QS.[50,51] Based on the clustering of
findings, 6 of 11 studies that examined 25(OH)D in relation to BC, reported a null overall
finding. Noteworthy is that those studies had a slightly higher QS compared with those that
reported an inverse association, though the difference was not statistically significant (QS
4.4 vs. 4.0). In contrast, all studies with 25(OH)D deficiency, total/dietary vitamin D and
supplemental vitamin D reported a finding that follows the hypothesized direction of
association. The latter finding suggests consistency upon replication whereby an overall
pooled finding trending towards the hypothesized direction was consistent with the overall
finding of each individual study included in the meta-analysis.
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4.6 Discussion
This study is to our knowledge, the most up to date among very few metaanalyses conducted to synthesize the literature on vitamin D exposure and BC occurrence.
Pooled findings indicated that there was a net direct association between 25(OH)D
deficiency and BC occurrence, with a pooled RR=1.73, 95% CI: 1.28-2.34, p<0.001). An
inverse association was also observed for total vitamin D intake from foods and
supplements (RR=0.98, 95% CI: 0.96-1.00, P=0.029, per 100 IU/d) and BC. No net
association was detected between BC and serum 25(OH)D (per 10 ng/mL) or between BC
and dietary/supplemental vitamin D. There was no evidence of publication bias. Harvest
plots suggested consistency upon replication was found for all 5 exposures of interest.
In recent years, there has been considerable interest in whether vitamin D inhibits
BC development.[42] The anticarcinogenic potential of vitamin D comes from the active,
hormonal form of vitamin D, 1,25-dihydroxyvitamin D [1,25(OH)2D], which is the
product of a second hydroxylation of 25-hydroxyvitamin D [25(OH)D] in the kidneys.
Experimental studies indicate that 1,25(OH)2D can also be synthesized from 25(OH)D in
other tissues, possibly including breast tissue. [52, 53]The vitamin D receptor is activated
by 1,25-dihydroxyvitamin D [1,25(OH)D], and is found in nearly all tissues and organs in
the human body. It is responsible for the transcription of numerous genes related to cellcycle control and apoptosis. Therefore, it is of considerable interest in relation to many
cancers, including BC. [54] While the circulatory levels of the biologically active
metabolite 1,25-dihydroxyvitamin D [1,25(OH)2D] is tightly regulated, the precursor 25hydroxyvitamin D [25(OH)D] serves as an indicator of vitamin D status from other sources
i.e. vitamin D from cutaneous synthesis and diet. Since circulating 25(OH) is related to
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1,25-dihydroxyvitamin D [1,25(OH)2D] in breast tissue and circulating 1,25dihydroxyvitamin D [1,25(OH)2D] is homeostatically controlled, circulating 25hydroxyvitamin D [25(OH)D] is thought to be potentially relevant to breast
carcinogenesis.[42]
This study has many strengths. First, this systematic review of the literature is, to
our knowledge, one of the few to have examined a wide range of vitamin D exposures and
their relationships to with BC occurrence through meta-analysis. Second, we used a
validated quality scoring system as a tool to examine heterogeneity of study results based
on quality of data. However, our study results should to be interpreted with caution
considering several limitations. First, our literature search was restricted to the PubMed
and Cochrane databases, and did not include other electronic databases such as Embase or
Web of Science. Second, we used specific key terms to perform the literature search but
did not search for cross-references or unpublished studies (abstracts, conference papers,
theses and dissertations). Third, while exposures included dietary and supplemental
vitamin D in addition to serum 25(OH)D, some meta-analyses were low-powered given
the limited number of data-points available. Fourth, evidence was mostly generated from
observational studies, namely, cross-sectional, retrospective cohort and prospective cohort
studies, which precludes our ability to confirm causality. Thus, a separate meta-analysis of
randomized controlled trials is needed, once enough trials are made available for such
analysis. Fifth, the associations reported in this study may be confounded by other micro –
and macro-nutrients, as well as lifestyle factors that have been shown to affect the risk of
BC. Finally, publication bias cannot be ruled out as an explanation for these study results.
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Our review and meta-analysis indicated that serum vitamin D deficiency, as well as
total vitamin D intake, were associated with BC occurrence in the general population,
suggesting a putative protective effect of vitamin D pending future randomized controlled
trials.
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5.1 Abstract
It is relatively unknown how dietary bioactive compound, sulforaphane, in
partnership with vitamin D, regulate vitamin D-dependent gene expression in breast
cancer. It has been suggested that the combination of various bioactive components
with vitamins is crucial for their potential anticancer activities. METHODS: This study
employed a combinatorial chemo preventive strategy to investigate the impact of
dietary histone deacetylase inhibitor i.e. sulforaphane on chromatin remodeling in
breast cancer. To understand the epigenetics-mediated changes in gene expression,
MCF-7 cells were exposed for 24 hours to vitamin D (100nM) either alone or in
combination with L-sulforaphane and TSA (20μM and 1μM respectively) at 70%
confluency. Changes to VDR, CYP24A1, CYP27B1 and TRPV6 gene expressions
were quantified using real-time PCR-based assays. Histone deacetylase inhibitor
activity was assessed using HDAC I/II assay that measured global changes in
acetylation status. Cell viability was measured using ATP and MT assays. Clonogenic
and migration assays were performed to analyze the ability of single cells to grow into
colonies and % closure (migration ability) upon treatments respectively. Results were
expressed as ΔCT± standard error of means (SEM) from One-way ANOVA analyses
for mRNA expressions and mean± SEM for all other assays. RESULTS: In MCF-7
cells, treatment with 1,25 (OH)2 D3 tended to decrease VDR (13±0.4) and CYP27B1
(12±0.96) while significantly increasing TRPV6 (p=0.02, 14±0.1) and CYP24B1
(p<0.0001, 0.38±0.12) expression. D alone and D+TSA group had the opposite effects
on HDAC inhibition from SFN alone, D+SFN and TSA alone. The clonogenic assay
showed a significant decrease in colony formation with no colonies for D+TSA
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(p<0.03) and TSA alone group (p<0.03). Cell viability tended to decrease with D alone
and in combination with TSA. CONCLUSION: These data suggest that the effects of
vitamin D and sulforaphane are selective and gene-specific in MCF-7 cells.
Key words: HAT, histone acetyltransferase; HDAC, histone deacetylase; SFN,
sulforaphane; TSA, Trichostatin A; VDRE, vitamin-D response elements.

5.2 Introduction
Breast cancer is the most common cancer among women worldwide and the
incidence has continued to rise over time. [1] Nutrition influences cancer etiology in about
35% of cancer cases. [2] General preventive dietary advice often includes reducing intake
of alcohol, red meat, and saturated fat while increasing the intake of fiber, vitamin D and
phytoestrogens from various food sources. [3] Breast cancer is a heterogeneous disease and
vitamin D might only affect certain breast cancer subtypes. However, a protective effect of
vitamin D against breast cancer has been suggested in several studies, which has been
related to sunlight, dietary intake, vitamin D supplement and ethnic background. [4]
Potentially important factors associated with increased breast cancer are listed below:
Table 5.1: Factors Influencing BC Risk [5]
Factors

Modifiable

Modifiable Factors
Weight gain after the age of 18 and/or being
overweight or obese (for postmenopausal breast
cancer)
Use of menopausal hormone therapy (combined
estrogen and progestin)
Physical inactivity
Alcohol consumption
Heavy smoking
Shift work at night (i.e., that disrupts sleep patterns)
Age
Personal of Family History
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Non-modifiable

Reproductive

Inherited Mutations in BRCA1, BRCA2 of other
susceptibility genes
Atypical Hyperplasia
High dose radiation to the chest at a younger age
(e.g., for cancer treatment)
High Breast Tissue density
High BMD (bone mineral density)
Long Menstrual History
Inability to have children
Use of Oral contraceptives
Having first child after age 30
High natural levels of sex hormones

Many in vitro and pre-clinical studies have examined the use of 1,25dihydroxyvitamin D3 to treat breast cancer. Four meta-analyses identified a significant
inverse relationship between the circulating concentrations of 25-hydroxyvitamin D3 and
breast cancer [6-8]. By contrast, a large randomized clinical trial, Women’s Health
Initiative (WHI), showed that administering 400 IU vitamin D and 1000 mg of calcium
versus placebo to women did not reduce the risk of breast cancer. The finding from WHI
does not support the use of vitamin D as a prophylactic agent for breast cancer. However,
better survival among woman diagnosed with breast cancer has been reported to be related
to vitamin D intake leading to higher concentrations of 25-hydroxyvitamin D3 [8, 9]. A
high concentration of plasma 25(OH)D3 is associated with a significantly reduced risk of
premenopausal breast cancer [10]. A serum 25-hydroxyvitamin D (25(OH)D3) level of 50
ng/ml was associated with 50% lower incidence of breast cancer, compared to a baseline
of < 10 ng/ml [11].
It has been hypothesized that 1,25-dihydroxyvitamin D3 can reduce the risk of
breast cancer. Several studies have examined the effects of 1,25-dihydroxyvitamin D3 on
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mammary carcinogenesis in various cell lines and animal models and found a protective
role of 1,25-dihydroxyvitamin D3 in breast cancer development.
In breast cancer, investigations carried out on histone modifications are relatively
newer than DNA methylation studies. Post-translational histone modifications have a
critical role in breast tumorigenesis and aggressiveness of prognosis. Since different breast
cancer subtypes represent distinct gene expression profiles, it is important to clarify the
effect of histone modification on gene expression levels in breast tumors. However, there
are limited studies on histone modification patterns in breast cancer tumors, though the
numbers of investigations are increasing. There are several bioactive compounds present
naturally in food that are known to modify genetic and epigenetic profiles in various
cancers. Sulforaphane is one such compound that can be extracted from its precursor
molecules present in cruciferous vegetables e.g. broccoli, Brussel sprouts etc. It is known
to be a potent natural source of histone deacetylase (HDAC) inhibitor activity. [12] We
used Trichostatin A (TSA) as our positive control. TSA is a fungal metabolite with wellestablished, strong histone deacetylase inhibitor activity.
The objective of this study is to determine how histone modification using
sulforaphane or Trichostatin A (TSA), influences vitamin D-induced gene transcription in
breast cancer. There are not enough studies that examined this specific association and in
MCF-7 cells as a model of breast cancer. The rationale is that the chosen epigenetic
modifiers will alter the acetylation status of histone proteins, which will loosen the DNAhistone protein complex and allow increased transcriptional activity at the vitamin D
response element (VDRE) found in the promoter region of vitamin D-inducible genes.
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5.3 Methods
5.3.1 Cell Culture

Cells were treated on day 7 from the date of seeding into 6-well plates. The
experiment included six different treatment groups namely- DMSO control (0.1%), 1,25
(OH)2D3 (100nM), SFN (20 µM), TSA (1µM), 1,25 (OH)2D3 + SFN and 1,25 (OH)2D3 +
TSA (APPENDIX G). After treatment, the cells were incubated for 24 hours before
harvesting. MCF-7 cells were obtained from Arcaro lab. 1, 25 (OH)2D3 was purchased from
Enzo Life Sciences, Plymouth Meeting, PA. Trichostatin A and SFN were purchased from
Sigma-Aldrich, St. Louis, MO. Real-time PCR materials, including all primers and master
mix were purchased from Applied Biosystems, Foster City, CA. Cell culture dishes were
bought from Costar, Cambridge, MA. All other cell culture materials and materials for
RNA isolation and cDNA synthesis were purchased from Life Technologies, Grand Island,
NY.

5.3.2 RNA Isolation and Reverse Transcription

At the completion of the treatment period, cells were washed with saline, then
treated with 1 mL Trizol per well of a 6-well plate, and cells were scraped to be harvested
for subsequent RNA extraction. Cells were frozen at -80°C until RNA was ready to be
isolated in collection tubes. To isolate the RNA, 200 µL chloroform was added to each
homogenate for phase separation. Isopropanol (500 µL) was then used to precipitate the
RNA. Washing three times with 1 mL of 75% ethanol was followed by the addition of 40
µL of Diethyl pyrocarbonate (DEPC) water. The samples were then incubated for 10
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minutes at 56°C to ensure maximum RNA solubility. RNA samples were then quantified
using a Nanodrop machine (λ260/280). cDNA was prepared using the SuperScript III First
Strand Synthesis System for RT-PCR (Life Technologies, Grand Island, NY). Details of
the protocol are listed in APPENDIX H.

5.3.3 Real Time PCR

For all experiments, mRNA expressions of GAPDH, VDR, CYP24A1, CYP27B1,
and TRPV6, were measured by ViiA™ 7 Real-Time PCR System (Applied Biosystems,
Foster City, CA). Reactions consisted of 10 µL of SYBR GREEN Gene Expression Master
Mix (Applied Biosystems, Foster City, CA) with forward and reverse primers (10nM each)
and 10 µL of DNAse/RNAse Free Water with 100 ng of cDNA. Duplicates were set up for
each sample. The levels of VDR, CYP24A1, CYP27B1, and TRPV6 were measured by
the comparative ΔΔCT method (ThermoFisher Scientific, 2016). For each sample, the
relative abundance of GAPDH and the target genes were obtained. The difference between
those two abundances (target gene- GAPDH) is the ΔCT for that sample which were the
values used for statistical analysis. The mean ΔCT values were then normalized against the
mean ΔCT values of the control sample, Dimethyl Sulfoxide (DMSO), resulting in a ΔΔCT
value. 2 was raised to the – ΔΔCT to produce a relative quotient (RQ) for each sample,
with the RQ of the control being one. RQ values were used to create the mRNA expression
curves for each gene. Primer sequences are available on APPENDIX A.
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5.3.4 Histone Deacetylase (HDAC) Assay
We used a luminescent HDAC-Glo™ I/II Assay (Promega, 2017). The assay uses
an acetylated, live-cell-permeant, luminogenic peptide substrate that can be deacetylated
by HDAC activities. Deacetylation of the peptide substrate is measured using a coupled
enzymatic system in which a protease in the Developer Reagent cleaves the peptide from
aminoluciferin, which is quantified in a reaction using Ultra-Glo™ Recombinant
Luciferase. The HDAC-mediated luminescent signal is persistent and proportional to
deacetylase activity.
Cells were harvested 24 h after treatment with SFN (20 µM) and TSA exposure (1
µM), and cell lysates were analyzed for HDAC activity, as reported [13].

5.3.5 ATP Assay

We used the CellTiter-Glo® 2.0 Assay (Promega, 2017). This assay provides a
homogeneous method to determine the number of viable cells in culture by quantitating
the amount of ATP present, which indicates the presence of metabolically active cells.
Luminescence readout is directly proportional to the number of viable cells in culture. Cells
were harvested 24 h after co-treatment with SFN (20 µM) and TSA (1 µM), and cell lysates
were analyzed for ATP activity.

5.3.6 MT Assay
We used the RealTime-Glo™ MT Cell Viability Assay (Promega, 2017), and
measured cell viability in MCF-7 cells continually in the same sample well up to 48 hours.
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This gave us more information about the mode of action of our treatments about time
dependence. The nonlytic nature and rapid response of the assay made it possible to
monitor cell viability over time in the same well. The assay measures the reducing potential
of viable cells, and is ATP-independent, providing an orthogonal method for viability or
cytotoxicity determination.
Luminescence readout is proportional to the number of viable cells in culture. Cells
were harvested 24 h after co-treatment with SFN (20 µM) and TSA (1 µM), and cell lysates
were analyzed for ATP activity.

5.3.7 Caspase 3/7 Assay

We used the Caspase-Glo® 3/7 Assay (Promega, 2017) to measure apoptosis in
MCF-7 cells. The assay provides a pro luminescent caspase-3/7 DEVD-aminoluciferin
substrate and a proprietary thermostable luciferase in a reagent optimized for caspase-3/7
activity, luciferase activity and cell lysis. Adding the single Caspase-Glo® 3/7 Reagent in
an "add-mix-measure" format results in cell lysis, followed by caspase cleavage of the
substrate. This liberates free aminoluciferin, which is consumed by the luciferase,
generating a "glow-type" luminescent signal that is proportional to caspase-3/7 activity in
the system. Cells were harvested 24 h after co-treatment with SFN (20 µM) and TSA (1
µM), and cell lysates were analyzed for caspase 3/7 activity.

5.3.8 Clonogenic Assay
We used the “plating before treatment” setup for this assay[14]. MCF-7 cells were
harvested and re-plated (500/well) in a 6-well plate and allowed overnight to attach (day
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0). Cells were treated (in duplicates) the next day using DMSO as the vehicle control, D
(100nM), SFN (20µM) and TSA (1µM) as primary treatments and in combinations
(D+SFN) and (D+TSA) (day 1). The plates were then incubated for three weeks at 37˚C.
After the desired incubation period, the cells were fixed using 70% EtOH followed by
Crystal violet (0.5%) staining. Colonies were counted using a standard colony counter.
Plating efficiency (PE) and Surviving fractions (SF) were calculated as per protocol
described by Franken et al. [14]. This entire experiment was repeated two more times for
an N=3.

5.3.9 Migration Assay

A simple scratch test was used to determine the rates of closure following
treatments to assess their efficacy. MCF-7 cells were seeded in 6-well plates at a density
of 325,000 cells/well and allowed to attach overnight. Once the cells were 70% confluent,
wounds were created using the etching at the bottom of the wells as guide, using a p-200
pipet tip. The wells were then washed with 1X sterile PBS and treated as designed.
Photographs were taken on day 0 at four reference points (4 quadrants) and marked as the
“0Hr”. Each wound was then followed over the course of 24 hours to determine the rate of
closure in response to the treatments. Photographs were taken again and marked as “24Hr”.
This entire experiment was repeated for an N=3. Percent closure is calculated as below:
% closure= (0Hr avg. wound size- 24Hr avg. wound size)/ 0Hr avg. wound size
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5.3.10 Statistical Analyses

Results from real-time PCR were analyzed using one-way ANOVA with a p-value
of <0.05 used as the cut-off for statistical significance. The analysis was setup as a
randomized block design with each experiment as a block. Dunnett’s Multiple Comparison
Tests was also used to find which means of the treatment groups differed significantly from
the control (DMSO) and used a P-value of <0.05 as a cut-off for statistical significance.
All statistical analyses and figures were generated using GraphPad Prism (v 7.04). Tukey’s
post-test was conducted to determine significant multiple comparison differences.

5.4 Results
5.4.1 D-responsive gene expression

We hypothesized that the expression of vitamin D-inducible genes will be increased
by concomitant treatment of MCF-7 cells with HDAC inhibitors (SFN and TSA). We
measured, with and without the HDAC inhibitors, the mRNA expressions of genes known
to be involved in vitamin D action: namely, VDR (vitamin D receptor), CYP24A1 (24
hydroxylase), CYP27B1 (1α hydroxylase) and TRPV6 (transient receptor potential,
vanilloid family, member 6 calcium-specific channel protein) by real time quantitative
polymerase chain reaction (RT-PCR); results are expressed as ΔCT±SEM and the graphs
represent the RQ values (2^-ΔΔCT). Although, VDR expression (N=4) in MCF-7 cells was
not statistically significant from the one-way ANOVA test, Browne- Forsythe test showed
a significant association (p=0.0009). When compared to the control, D alone group (0.47±0.11), D+SFN group (-0.28±0.32), and D+TSA group (-0.20±0.29) tended to
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decrease its expression while SFN alone (0.003±0.23) and TSA alone (0.05±0.41) showed
minimal increase. There was no statistical difference observed from the Wilcoxon Signed
Rank test.
TRPV6 (N=3) expression, was overall significant (p=0.04) from the One-way
ANOVA test. D alone (3.56±2.5), D+TSA (1.21±0.69) and SFN alone (4.34±2.3) groups
tended to increase TRPV6 expression. TSA alone (19.14±9.4, p=0.04) showed a moderate
increase after D+SFN group (47.88±35.00, p=0.02) and were statistically significant. There
was no statistical difference observed from the Wilcoxon Signed Rank test.
CYP24A1 expression (N=2) was statistically significant (p<0.0001) from both the
One- way ANOVA and the Brown-Forsythe test (p<0.0001). As expected, D alone group
(36.16±8.66) demonstrated statistically significant response. SFN alone (2.69±0.90,
p<0.0001), D+SFN group (2.00±2.8, p=0.0009) and TSA alone (0.29±0.34, p=0.0002)
showed smaller change in CYP24A1. When combined with D, TSA showed the second
highest response in CYP24A1 (13.24±2.31,p<0.0001) and was statistically significant.
No treatment showed statistical significance in CYP27B1 (N=3) expression.
Results summary compared to control: D alone (-0.16±0.41), SFN alone (-0.16±0.34),
D+SFN (-0.67±0.06) and D+TSA (-0.67±0.06) decreased CYP27B1 expression while TSA
alone (0.66±0.60) tended to increase its expression. There was no statistical difference
observed from the Wilcoxon Signed Rank test. The results for RT-PCR experiments are
presented in Fig 5.1.
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Fig 5.1: mRNA Expressions of Vitamin D Responsive Genes in MCF-7 Cells. (a)
Cyp24a1 showed the highest response in D only group; (b) TRPV6 showed the highest
response in D+SFN group. Treatments had no effect on (c) Vitamin D receptor (VDR) and
(d) Cyp27b1 when compared to control. The data were analyzed by One-way ANOVA with
*p <0.05, **p<0.01, ***p<0.001 and **p<0.0001 as significant.
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5.4.2 Histone Acetylation Status

Both epigenetic modifiers used in our experiments are known to have welldemonstrated HDAC inhibitor properties. However, SFN has a more diverse biochemical
effect, including triggering increased expression of many cytoprotective proteins in the cell
than TSA (positive control). To test the relative HDAC inhibition by SFN and TSA, we
measured nuclear HDAC I/II enzyme activity and changes in histone protein acetylation to
measure the extent of alteration in histone acetylation status. MCF-7 cells were seeded at
10,000 cells/well in a 96-well, opaque walled plate. Cells were treated at 70% confluency
with the desired treatments and incubated for 24 hours before the assay was conducted.
Our expectation was that the selected dosages of SFN (20 μM) and TSA (1 μM), are
sufficient to provide significant changes in histone acetylation in MCF-7 cells. The HDAC
assay results are presented in Fig 5.2.
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Fig 5.2: HDAC Activity in MCF-7 cells. No significant difference was observed among
the treatments. Each data point represents mean± SEM (N=3).
The overall HDAC activity (N=3) was insignificant from One-way ANOVA
analysis and the treatments showed minimal to no HDAC inhibitor activity. TSA alone
group (-107.31±43.3) and SFN alone (-45.67±29.46) demonstrated the expected response
to HDAC inhibition, albeit insignificant. D alone group (194±194) showed no inhibition
and so did D+TSA group (260±185.6). D+SFN group (-45.67±66.11) showed similar
effects as SFN alone group.

91

5.4.3 ATP-dependent Cell Viability Assay

To determine cell viability, we measured cellular ATP activity. MCF-7 cells were
seeded at 10,000 cells/well in a 96-well, opaque walled plate. Cells were treated at 70%
confluency with the desired treatments and incubated for 24 hours before the assay was
conducted. Our expectation was that the selected dosages of SFN (20 μM) and TSA (1 μM)
with vitamin D (100 nM), are sufficient to decrease viability in MCF-7 cells. The results
are presented as percent (%) control in Fig 5.3.

Fig 5.3: ATP-dependent Cell Viability in MCF-7 cells. No effect of treatments was
observed on ATP-dependent viability. Values are representative of three independent
experiments (N=3) and are expressed as percent (%) control.
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5.4.4 ATP-independent Cell Viability Assay

To determine cell viability in an ATP-independent manner, we measured
cellular MT Cell Viability Substrate activity. MCF-7 cells were seeded at 10,000 cells/well
in a 96-well, opaque walled plate. Cells were treated at 70% confluency with the desired
treatments and incubated for 24 hours before the assay was conducted. Our expectation
was that the selected dosages of SFN (20 μM) and TSA (1 μM) with vitamin D (100 nM)
would be sufficient to decrease viability in MCF-7 cells. Two- way ANOVA test was
performed to test for time X treatment interaction.

Compared to control, all treatments were significant different at all time points
(p<0.0001) with an overall significant interaction(p<0.0001). Tukey’s post test showed
significant difference in D+SFN (p<0.0001) and D+TSA (p<0.0001) at 0 and 48 hours,
with an increase in cytotoxicity by SFN and TSA at 48 hours. There was no significant
difference among the treatments at 6, 12 and 24 hours. The results are presented as relative
luminescence in Fig 5.4.
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Fig 5.4: ATP-independent Cell Viability in MCF-7 cells. Maximum decrease in cell
viability was observed at 48H. Each data point represents 4 replicates and results are
expressed as (Mean±SEM).

5.4.5 Apoptosis in MCF-7 cells

We used Caspase-Glo® 3/7 lytic assay and measured the degree of caspase cleavage
of the substrate. The cleavage liberates free aminoluciferin, which is consumed by the
luciferase enzyme, generating signals proportional to caspase-3/7 activity (used as a proxy
measure of apoptosis). In other words, the higher the activity of the enzyme, the higher the
luminescent signal. MCF-7 cells were seeded at 10,000 cells/well in a 96-well, opaque
walled plate. Cells were treated at 70% confluency with the desired treatments and
incubated for 24 hours before the assay was conducted. Our expectation was that the
selected dosages of SFN (20 μM) and TSA (1 μM) with vitamin D (100 nM) would be
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sufficient to induce apoptosis in MCF-7 cells. The results are presented as relative
luminescence in Fig 5.5.
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Fig 5.5: Apoptosis in MCF-7 cells. All treatments demonstrated significant decrease in
caspase 3/7 activity in MCF-7 cells. Values are representative of four independent
experiments (N=3) and represented as percent (%) control (Mean±SEM). Tukey’s post test
showed no significant difference between D+SFN when compared to D alone.

5.4.6 Clonogenic Assay

Clonogenic assays, first tested in 1956 and later modified to fit several mammalian
cell types, including stem cells, essentially test every cell in a population for its ability to
undergo “unlimited” cell division [14]. This assay is especially suitable to determine cell
reproductive death post-treatment with ionizing radiation as well as other choice of
cytotoxic compounds. The general principle is, only a fraction of the cells will retain the
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capacity to produce colonies. We treated MCF-7 cells as per protocol (described in the
methods section) for three weeks with desired treatments. We then counted the cell
colonies (Fig 5.6) formed and the calculated the surviving fraction (SF). There seems to be
a trend of decreased colony formation when compared to control after three weeks (N=3).
Summary of treatment vs control: DMSO (0.15±0.07), D alone (0.02±0.005), SFN alone
(0.024±0.005), D+SFN group (0.024±0.0005), D+TSA (p=0.03, 0.0015±0.0015) and TSA
(p=0.03). Data is represented in the form of a surviving fraction (SF) curve in Fig.5.7.
DMSO

D

SFN

D+SFN

D+TSA

TSA

Fig 5.6: Clonogenic Assay in MCF-7 Cells. Untreated controls (DMSO) with 60 and 56
clones, respectively, formed after seeding 1000 cells per well. D treatment group had 30
and 26 clones per well, respectively, while SFN group had 11 and 30. D+SFN group had
33 and 22 clones respectively, while neither D+TSA or TSA showed any colony formation.

96

(A)
(B)

Fig 5.7: (A) Surviving Fraction Curve from Clonogenic Assay in MCF-7 Cells. (A)
D+TSA group (p< 0.03) and TSA group (p<0.03) significantly reduced colony formation
in MCF-7 cells. (B) Sample control (DMSO) cell picture on day 0.

5.4.7 Migration Assay

MCF-7 cells were plated and treated as per protocol described above. We then
calculated the % closure for each treatment compared to the control per the formula shown
in the methods section. Compared to control (N=3) the combination groups D+SFN
(0.87±0.09) and D+TSA (0.86±0.07), showed no difference in migration (Fig 5.8). D alone
(0.89±0.09) and TSA alone (0.90±0.10) groups showed moderate reduction in migration
while SFN alone (0.80±0.07) demonstrated the opposite effect in MCF-7 cells.
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Fig 5.8: Percent (%) Closure in MCF-7 cells. No significant difference was observed in
MCF-7 cells when compared to control.

5.5 Discussion
Breast cancer is the most frequently diagnosed cancer in women [15]. Breast cancer
ranks second as a cause of cancer death in women. Overall, breast cancer death rates
declined by 36% from 1989 to 2012 due to improvements in early detection and treatment,
translating to the avoidance of approximately 249,000 breast cancer deaths [5].
A large proportion of breast cancer cells contain the VDR protein. However, the
level of expression is variable within individual cells and, therefore, the biological response
to 1,25-dihydroxyvitamin D3 varies for an individual patient’s cells as well as between
patients. One of the key factors regarding the activity of 1,25-dihydroxyvitamin D3 is its
availability in the breast cancer environment. This is maintained by the balance between
synthesis and catabolism of vitamin D. Many epidemiological studies have reported
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positive associations between gene polymorphisms and risk of breast cancer; these include
vitamin D related genes such as polymorphisms in VDR, vitamin D-binding protein, as
well as the CYP24A1 gene [3]. In the present study, our chosen treatments had no effect
on VDR expression in MCF-7 cells.
Intracellular calcium plays a critical role in many fundamental cellular processes
such as proliferation, apoptosis, and secretion. Therefore, calcium levels are tightly
controlled in cells and any disruptions in intracellular calcium homeostasis play a critical
role in tumor progression in all cancer types. Studies have been conducted to analyze how
intracellular calcium homeostasis and the associated calcium signaling pathways are
altered in breast cancer cells compared with normal mammary gland cells. Calcium
channels are either upregulated or downregulated depending on the types of cancer. One
such example is the altered expression of TRPV6 in prostate, pancreatic, thyroid, colon,
ovary, and breast cancer [16]. TRPV6 mRNA was first shown to be regulated by
1,25(OH)2D3 [17] in Caco-2 cells, a human intestinal cell line. The epithelial calcium
channel TRPV6 is upregulated in breast carcinoma compared with normal mammary gland
tissue [18] and TRPV6 overexpression is strongly associated with the invasive status. It
regulates both breast cancer cell migration and invasion [19]. Although studies have shown
TRPV6 to be increased in breast carcinoma [20], one study found TRPV6 mRNA to be
expressed at very low levels in MCF-7 cells[18]. Although we did not find any significant
association of vitamin D with TRPV6 expression, D+SFN significantly increased its
expression, which is along the line of what we hypothesized.
The primary effect of exposure of breast cancer cells to 1,25-dihydroxyvitamin D3
is cell cycle arrest due to changes in the functional status of the proteins that regulate cell
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cycle [21]. 1,25(OH)2D can also induce morphological changes associated with apoptosis
in breast cancer cells [22]. 1,25-dihydroxyvitamin D3 can inhibit the invasion and
metastasis of cancer cell 1,25(OH)2D and has potent anti-angiogenic properties that can
inhibit tumor cell invasion [23]. Effect of 1,25-dihydroxyvitamin D3 on cell proliferation
can also be mediated in an indirect way, via interference to the function of estrogen
receptors (ER) [24]. 1,25-dihydroxyvitamin D3 and its analogues reduce the expression of
ERα, which in turn reduces the level of mitogenic signals to breast cancer cells from
estrogens.
CYP27B1 is present in some breast cancer cells and may lead to the autocrine
synthesis of 1,25-dihydroxyvitamin D3 from 25(OH)D3. It has been shown that breast
adipocytes also express CYP27B1 and could bio-activate 25(OH)D3 to 1,25dihydroxyvitamin D3 and in a paracrine fashion deliver 1,25-dihydroxyvitamin D3 to the
breast epithelium. The expression of CYP27B1 can be considered a central mechanism in
the association between active vitamin D and its antitumor effects [25]. In a recent study,
a targeted ablation of CYP27B1 was accompanied by significant acceleration in initiation
of spontaneous mammary tumorigenesis where cell proliferation, angiogenesis, cell cycle
progression, and survival markers were up-regulated in tumors, and apoptosis was downregulated [26]. In the present study, we found that CYP27B1 expression was not affected
by the treatment groups.
The availability of 1,25-dihydroxyvitamin D3 is also determined by its degradation,
along with its activation. This process is initiated by the 24-hydroxylation of 1,25dihydroxyvitamin D3 by the enzyme, CYP24A1. In normal tissues, this enzyme is induced
in response to 1,25-dihydroxyvitamin D3 exposure, providing a regulatory mechanism that

100

maintains the concentration of 1,25-dihydroxyvitamin D3 at a non-toxic level. Genome
hybridization studies have revealed that in certain human breast cancers the CYP24A1
gene is amplified and this may cause a reduction in the level of 25(OH)D3 and 1,25dihydroxyvitamin D3 level and could allow cells to proliferate unduly [27]. We found that
CYP24A1 expression was significantly decreased when added SFN to vitamin D, which is
the opposite of what we hypothesized. However, in advanced cancers, this role might prove
to be very beneficial.
Phytochemicals have been studied extensively for the treatment of various diseases
and disorders [28]. They exhibit a wide range of safety and target multiple pathways and
targets in breast cancer cells [29]. Current evidence suggests that naturally occurring
phytochemicals can target breast cancer stem cells (CSCs) [1, 30]. Hence, phytochemicals
are proposed to be useful in the treatment of cancer. Consumption of cruciferous vegetables
such as broccoli, correlates with decreased risk of cancer induction. This protective effect
has been shown to be in part due to the presence of an isothiocyanate (ITC)- glucoraphanin
[31, 32]. The four important ITCs formed from glucosinolates by the activity of myrosinase
are benzyl-ITC, allyl-ITC, phenylethyl-ITC (PEITC) and methylsulphinylbutyl-ITC
(sulforaphane). PEITC [33] and sulforaphane [34] are two well-studied ITCs for their
anticancer activities. Sulforaphane has been found to inhibit proliferation, angiogenesis,
and metastasis as well as induce cell cycle arrest and apoptosis in breast cancer cells. It
reactivated expression of ER-α in MDA-MB-231 cells, whereas, in combination with
tamoxifen, reduced proliferation in MDA-MB-231 cells. Sulforaphane treatment caused
cell cycle arrest and decreased cyclin A, cyclin B1 and CDC2 expression in breast cancer
(MDA-MB-231) cells [35]. Finally, sulforaphane decreased the production of IL-1β, IL-6,
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TNF-α, interferon-γ, IL-4, platelet-derived growth factor and VEGF in MDA-MB-231
cells [36]. Although more cited for its antioxidative and anti-inflammatory defense
mechanisms, the induction of proliferation arrest and apoptotic cell death primarily
contribute to its anticancer functions. [37-39] However, the precise molecular mechanisms
of sulforaphane-elicited anticancer effect are not thoroughly elucidated. [40]
Modified histones have gained importance as biomarkers of breast cancer
prognosis. The investigations carried out on mechanisms of histone modifications are also
promising for the development of efficient HDAC inhibitor therapies.
It is not clear from the results as to how the HDAC inhibitors work when combined
with vitamin D. We did observe some predicted response to D in genes such as CYP24A1,
and TRPV6. However, SFN and TSA had opposing effects in most cases. Clonogenic assay
findings confirmed that D+SFN group was more effective than D alone group even though
we did not reach statistical significance. Overall, we demonstrated significant association
between vitamin D and the HDAC inhibitors as we hypothesized but merits further
exploration due to the opposing effects of SFN and TSA.
Insights into the biology of breast cancers have been gained from the identification
of genes commonly mutated in these cells signaling pathways and have led to paradigms
that have informed the study of epigenetic alterations in cancer. These insights are also
currently being used to develop new diagnostic and prognostic assays and potential
therapies for breast cancer.
In summary, we state that the components of the vitamin D pathway can potentially
be used both as treatment and preventive strategies for breast cancer. In cancers with low
VDR expression, it may be possible that future treatments could target the genomic and
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epigenomic level alterations to increase VDR expression by modulating expression of
transcription factors or utilizing HDAC inhibitors, respectively.
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CHAPTER 6

EFFECT OF HISTONE DEACETYLASE INHIBITORS ON AND VITAMIN DDEPENDENT
GENE EXPRESSIONS IN CACO-2 HUMAN COLORECTAL CANCER CELLS
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6.1 Abstract
It is relatively unknown how dietary bioactive compound, sulforaphane, in
partnership with vitamin D, regulate gene expression linked to colorectal cancer. It has
been suggested that the combination of various bioactive components with vitamins is
crucial for their potential anticancer activities. METHODS: This study employed a
combinatorial chemo preventive strategy to investigate the impact of dietary histone
deacetylase inhibitor i.e. sulforaphane on chromatin remodeling in human colorectal
carcinoma. To understand the epigenetics-mediated changes in gene expression in
response to sulforaphane and vitamin D, Caco-2 cells were exposed for 24 hours to
vitamin D (100nM) either alone or in combination with L-sulforaphane and TSA
(20μM and 1μM respectively) at 70% confluency (proliferating) and after 13 days post
confluency (fully differentiated) and Changes to VDR, CYP24A1, CYP27B1 and
TRPV6 gene expressions were quantified using real-time PCR-based assays. Histone
deacetylase inhibitor activity was assessed using HDAC I/II assay that measured global
changes in acetylation status. RESULTS: In proliferating Caco-2 cells, D+SFN
(p<0.04) increased VDR expression and decreased CYP27B1 (p<0.01) more than D
alone (p=0.38 and p=0.07 respectively). However, in differentiated Caco-2 cells, none
of the genes had significant changes from D alone group. D+SFN (p=0.99)
demonstrated an opposing effect from D alone and decreased VDR expression.
Although statistically significant, D+SFN (p=0.01) effects on HDAC inhibitor activity
was lower than TSA alone (p<0.0004) or SFN alone group (p<0.0014).
CONCLUSION: These data suggest that colon cancer cells respond to dietary
components differently under different culture conditions. The effect of vitamin D and
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sulforaphane is selective and gene-specific in the complex multistep process of
colorectal carcinogenesis in vitro.

Key words: HAT, histone acetyltransferase; HDAC, histone deacetylase; SFN,
sulforaphane; TSA, Trichostatin A; VDRE, vitamin-D response elements.

6.2 Introduction
Colorectal cancer is one of the most invasive and the third most common cancer in
both men and women in the United States. Among men and women combined, colorectal
malignancies are the second most common cause of cancer mortality in the United States,
with approximately 50,000 deaths each year [1]. Although, a serum vitamin D level of 20
ng/mL to 50 ng/mL is considered adequate for healthy people, it is more reasonable to say
serum 25(OH)D3 levels of 30 ng/mL is physiologically beneficial in preventing chronic
diseases like cancer. Per a study using data from NHANES 2000–2004, up to 78% of
Americans have a serum levels less than 30ng/ml of 25(OH)D3 [2].
Vitamin D has been known to play an important role in bone and mineral
homeostasis. However, it has been studied for its anti-neoplastic roles ever since it was
discovered that colon cancer mortality rates were the highest in places with the least
amount of sunlight in the US [3], suggesting a protective role of Vitamin D. The active,
hormonal form of vitamin D, 1α,25-dihydroxyvitamin D [1α, 25(OH)2D] mediates its
actions through activation of the Vitamin D Receptor (VDR), a ligand-dependent
transcription factor.[4] The development of many cancers is often associated with a
reduced expression of the vitamin D receptor protein resulting in decreased cellular
sensitivity to 1α,25-dihydroxyvitamin D [1α, 25(OH)2D] and a possible loss of the anti109

proliferative action provided by vitamin D [5, 6]. Our understanding of epigenomic
alterations in colorectal cancer, is less advanced than that of our understanding of gene
mutations, but substantial progress has recently been made in this area [7]. However, the
exact mechanisms are yet to be explored.
Epigenetic effects, including changes in histone acetylation status, influence
chromatin remodeling and gene expression in cancer cells. To date, no other study has
looked at these specific vitamin D- dependent gene expressions in relation to histone
modification in colorectal cancer cells. We have used Caco-2 cells as our model as opposed
to HCT116 or other frequently used colon cancer cell lines. This is because Caco-2 cells
are more commonly used as fully differentiated cells that mimic intestinal mucosal cells
and therefore, are a preferred choice in studies involving intestinal uptake e.g. drug
interventions. This study will also address the unique question as to how Caco-2 cells
behave as colorectal cancer cells for the first time.
Many bioactive compounds have been shown to alter genetic and epigenetic
profiles in various cancers. Of these compounds, sulforaphane (SFN), found in cruciferous
vegetables such as kale, cabbage, broccoli sprouts etc., has been present as one of the most
potent, natural (histone deacetylase) HDAC inhibitors to date.[8] Trichostatin A (TSA) is
a fungal metabolite with well-known histone deacetylase inhibitor activity as well and
often used as positive controls in experiments with natural HDAC inhibitors such as
sulforaphane.
The objective of this study is to determine to what extent treatment with the histone
deacetylation inhibitors (HDACs) sulforaphane or Trichostatin A (TSA), influences
vitamin D-induced transcriptional activity. The rationale for this study is that treatment of
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cells with these epigenetic modifiers will alter the acetylation status of histone proteins.
This, in turn, will loosen the association of DNA with the histone protein complex of the
allowing increased access of the vitamin D receptor - RXR heterodimer to the vitamin D
response element (VDRE) found in the promoter of vitamin D-inducible genes.

6.3 Methods
6.3.1 Cell Culture

Cells were treated on day 7 (proliferating) 14 from the date of seeding into 6-well
plates (differentiated). The experiment included six different treatment groups namelyDMSO control (0.1%), 1,25 (OH)2D3 (100nM), SFN (20 µM), TSA (1µM), 1,25 (OH)2D3
+ SFN and 1,25 (OH)2D3 + TSA (APPENDIX G).. After treatment, the cells were
incubated for 24 hours before harvesting. Caco-2 cells were obtained from the American
Type Culture Collection (HTB-37; American Type Culture Collection, Rockville, MD). 1,
25 (OH)2D3 was purchased from Enzo Life Sciences, Plymouth Meeting, PA. Trichostatin
A and SFN were purchased from Sigma-Aldrich, St. Louis, MO. Real-time PCR materials,
including all primers and master mix were purchased from Applied Biosystems, Foster
City, CA. Cell culture dishes were bought from Costar, Cambridge, MA. All other cell
culture materials and materials for RNA isolation and cDNA synthesis were purchased
from Life Technologies, Grand Island, NY.

6.3.2 RNA Isolation and Reverse Transcription

At the completion of the treatment period, cells were washed with saline, then
treated with 1 mL Trizol per well of a 6-well plate, and cells were scraped to be harvested
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for subsequent RNA extraction. Cells were frozen at -80°C until RNA was ready to be
isolated in collection tubes. To isolate the RNA, 200 µL chloroform was added to each
homogenate for phase separation. Isopropanol (500 µL) was then used to precipitate the
RNA. Washing three times with 1 mL of 75% ethanol was followed by the addition of 40
µL of Diethyl pyrocarbonate (DEPC) water. The samples were then incubated for 10
minutes at 56°C to ensure maximum RNA solubility. RNA samples were then quantified
using a Nanodrop machine (λ260/280). cDNA was prepared using the SuperScript III First
Strand Synthesis System for RT-PCR (Life Technologies, Grand Island, NY). Details of
the protocol are listed in APPENDIX H.

6.3.3 Real Time PCR

For all experiments, mRNA expressions of GAPDH, VDR, CYP24A1, CYP27B1,
and TRPV6, were measured by ViiA™ 7 Real-Time PCR System (Applied Biosystems,
Foster City, CA). Reactions consisted of 10 µL of SYBR GREEN Gene Expression Master
Mix (Applied Biosystems, Foster City, CA) with forward and reverse primers (10 nM each)
and 10 µL of DNAse/RNAse Free Water with 100 ng of cDNA. Duplicates were set up for
each sample. The levels of VDR, CYP24A1, CYP27B1, and TRPV6 were measured by
the comparative ΔΔCT method (ThermoFisher Scientific, 2016). For each sample, the
relative abundance of GAPDH and the target genes were obtained. The difference between
those two abundances (target gene- GAPDH) is the ΔCT for that sample which were the
values used for statistical analysis. The mean ΔCT values were then normalized against the
mean ΔCT values of the control sample, Dimethyl Sulfoxide (DMSO), resulting in a ΔΔCT
value. 2 was raised to the – ΔΔCT to produce a relative quotient (RQ) for each sample,
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with the RQ of the control being one. RQ values were used to create the mRNA expression
curves for each gene. Primer sequences are available on APPENDIX A.

6.3.4 Histone Deacetylase (HDAC) Assay
We used the HDAC-Glo™ I/II Assay (luminescent) (Promega, 2017). The assay
uses an acetylated, live-cell-permeant, luminogenic peptide substrate that can be
deacetylated by HDAC activities. Deacetylation of the peptide substrate is measured using
a coupled enzymatic system in which a protease in the Developer Reagent cleaves the
peptide from aminoluciferin, which is quantified in a reaction using Ultra-Glo™
Recombinant Luciferase. The HDAC-mediated luminescent signal is persistent and
proportional to deacetylase activity.
Cells were harvested 24 h after treatment with SFN (20 µM) and TSA exposure (1
µM), and cell lysates were analyzed for HDAC activity, as reported [10].

6.3.5 ATP Assay

We used the CellTiter-Glo® 2.0 Assay (Promega, 2017). This assay provides a
homogeneous method to determine the number of viable cells in culture by quantitating
the amount of ATP present. Luminescence readout is directly proportional to the number
of viable cells in culture. Cells were harvested 24 h after co-treatment with SFN (20 µM)
and TSA (1 µM), and cell lysates were analyzed for ATP activity as per protocol.
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6.3.6 MT Assay
We used the RealTime-Glo™ MT Cell Viability Assay (Promega, 2017), and
measured cell viability continually in the same sample well up to 48 hours. This gave us
more information about the mode of action of our treatments about time dependence. The
nonlytic nature and rapid response of the assay made it possible to monitor cell viability
over time in the same well. The assay measures the reducing potential of viable cells, and
is ATP-independent, providing an orthogonal method for viability or cytotoxicity
determination.
Luminescence readout is proportional to the number of viable cells in culture. Cells
were harvested 24 h after co-treatment with SFN (20 µM) and TSA (1 µM), and cell lysates
were analyzed for ATP activity.

6.3.7 Caspase 3/7 Assay

We used the Caspase-Glo® 3/7 Assay (Promega, 2017) to measure apoptosis in
proliferating Caco-2 cells. The assay provides a pro luminescent caspase-3/7 DEVDaminoluciferin substrate and a proprietary thermostable luciferase in a reagent optimized
for caspase-3/7 activity, luciferase activity and cell lysis. Adding the single Caspase-Glo®
3/7 Reagent in an "add-mix-measure" format results in cell lysis, followed by caspase
cleavage of the substrate. This liberates free aminoluciferin, which is consumed by the
luciferase, generating a "glow-type" luminescent signal that is proportional to caspase-3/7
activity.
Cells were harvested 24 h after co-treatment with SFN (20 µM) and TSA (1 µM),
and cell lysates were analyzed for caspase 3/7 activity.
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6.3.8 Migration Assay

A simple scratch test is used to determine the rates of closure following treatments
to assess their efficacy. Caco-2 cells were seeded in 6-well plates at a density of 300,000
cells/well and allowed to attach overnight. Once the cells were 70% confluent, wounds
were created using the etching at the bottom of the wells as guide, using a p-200 pipette
tip. The wells were then washed with 1X sterile PBS and treated as designed. Photographs
were taken on day 0 at four reference points (4 quadrants) and marked as the “0Hr”. Each
wound was then followed over the course of 24 hours to determine the rate of closure in
response to the treatments. Photographs were taken again and marked as “24Hr”. This
entire experiment was repeated for an N=3. Percent closure was calculated as below:
% closure= (0Hr avg. wound size- 24Hr avg. wound size)/ 0Hr avg. wound size

6.3.9 Statistical Analysis

Results from real-time PCR were analyzed using one-way ANOVA with a p-value
of <0.05 used as the cut-off for statistical significance. The analysis was setup as a
randomized block design with each experiment as a block. Dunnett’s Multiple Comparison
Tests was also used to find which means of the treatment groups differed significantly from
the control (DMSO) and used a P-value of <0.05 as a cut-off for statistical significance.
All statistical analyses and figures were generated using GraphPad Prism (v 7.04). Tukey’s
post-test was conducted to determine significant multiple comparison differences. For all
assays ,the results are expressed as Mean±SEM.
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6.4 Results
6.4.1 Vitamin D-responsive gene expression

We hypothesized that the expression of vitamin D-inducible genes would be
increased by concomitant treatment of cells with SFN and TSA. We measured, with and
without the HDAC inhibitors, the mRNA expression of genes known to be involved in
vitamin D action and cell metabolism: namely, VDR (vitamin D receptor), CYP24A1 (24
hydroxylase), CYP27B1 (1α hydroxylase) and TRPV6 (transient receptor potential,
vanilloid family, member 6 calcium-specific channel protein) by real time quantitative
polymerase chain reaction (RT-PCR); results are expressed as RQ values (2^-ΔΔCT)±SEM.

(a) Undifferentiated Caco-2 Cells
In proliferating Caco-2 cells, VDR expression was overall significant (p=0.03)
from one-way ANOVA and Browne-Forsythe test (p<0.0001). From Dunnett’s multiple
comparison test, VDR was significantly increased by D+SFN (3.44±0.39, p=0.01) and
D+TSA (3.10±0.85,p=0.01) when compared to control. Tukey’s multiple comparison
maintained the significance when compared to vitamin D , D+SFN (p=0.02) and D+TSA
(p=0.03).
CYP24A1 mRNA levels (N=4) were significantly affected by our experiment
(p=0.01) from the one-way ANOVA and Browne-Forsythe test (p=0.02) analyses. There
was about 372 fold increase by vitamin D alone (372.2±94.1, p=0.03). Vitamin D + SFN
treatment did not increase CYP24A1 mRNA expression more than vitamin D alone;
however, concomitant treatment of vitamin D + TSA resulted in a marked increase in
CYP24A1 gene expression. ~3,500 fold (3555±695, p=0.003) in proliferating Caco-2
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cells. Tukey’s multiple comparison test did not show any additional significant association
among vitamin D and the combination groups D+SFN or D+TSA. CYP27B1 mRNA
expression (N=6) was not affected by vitamin D or the combination treatment with
epigenetic modifiers SFN and TSA.
TRPV6 mRNA expression (N=6) was increased by 44% by vitamin D alone
(0.44±0.80, p=0.01). Combination treatment with vitamin D and TSA increased TRPV6
gene expression by 93% (0.93±1.01, p=0.0006), and this increase was significantly
different than vitamin D alone (p=0.04) from Tukey’s posttest. Although SFN had no
significant effect on TRPV6 both alone and in combination with vitamin D, TSA alone
was significantly different from control (0.13±0.39, p=0.003). Relative mRNA
expression, compared to the DMSO control treatment, for proliferating Caco-2 cells are
presented in Fig 6.1.
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Fig 6.1: mRNA Expressions of Vitamin D Responsive Genes in Proliferating Caco-2
Cells. (a) Vitamin D receptor (VDR) expression was increased more than D alone in
D+TSA group; (b) TRPV6 showed the highest response in D+TSA group, (c) CYP24A1
showed similar response as TRPV6 in D+TSA group; and (d) there was no effect on
CYP27B1 expression across the treatment groups. Results are from N>3 experiments for
all genes and *p<0.05, and **p<0.01 represent significance.
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(b) Differentiated Caco-2 Cells
In fully differentiated Caco-2 cells, CYP24A1 expression was increased ~650 fold
by vitamin D treatment (643.2±122.2, p<0.0001) alone, but combination treatment with
epigenetic modifiers and vitamin D blunted the increase. Albeit the decrease relative to D
alone, D+SFN (142.2±29.53, p<0.0001) and D+TSA (191.3±29.38, p<0.0001)
significantly increased CYP24A1 expression, ~140 fold and ~190 fold respectively, when
compared to control. This association was intact when compared to D alone, i.e the
combination treatments were significantly different from D alone, D+SFN (p=0.001) and
D+TSA (p=0.009). The HDAC inhibitors SFN and TSA response on CYP24A1 were also
significantly different from D alone, SFN (p<0.0001) and TSA (p<0.0001) from Tukey’s
post test.
TRPV6 expression in fully differentiated Caco-2 cells was significantly increased
in D+TSA group (2.8±0.78, p=0.01) only. SFN had no effect on TRPV6 expression both
alone and in combination with vitamin D.
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We found that neither vitamin D treatment nor vitamin D combination treatment
with epigenetic modifiers influenced VDR and CYP27B1 mRNA expression (Figure 6.2).

Fig 6.2: mRNA expressions of vitamin D responsive genes in fully differentiated Caco2 cells. (a) CYP24A1 showed the highest response in D only group and was significantly
different from D+SFN and D+TSA groups, (b) TRPV6 was significantly increased in
D+TSA group, (c) VDR and (d) CYP27B1 expressions were not affected by the treatments.
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Results are from N>3 experiments for all genes and *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001 represent significance.

(c) Animal Tissue Sample Analyses
We also analyzed small intestinal scrapings from APC 1638 mice (5 male+5
female). The animals were fed on a diet containing 450 mg of SFN/kg. We then analyzed
the cDNA samples (prepared as per protocol in APPENDIX H) for VDR, CYP24A1,
CYP27B1 and TRPV6. We found that TRPV6 expression was significantly increased
(30±8.8, p<0.0001) in sulforaphane group when compared to no sulforaphane (control)
group (Fig. 6.3).
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Fig 6.3: TRPV6 Expression in Animal Tissue Samples. Sulforaphane increased TRPV6
expression in small intestinal scrapings from TNF𝝰- K/O mice. GAPDH was used as
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internal loading control. Results are expressed as Mean±SEM of 10 animal samples
(N=10).

6.4.2 Histone acetylation status

To test the relative HDAC inhibitor activity of SFN and TSA, we measured nuclear
global HDAC I/II activity. Caco-2 cells were seeded at 10,000 cells/well in a 96-well,
opaque walled plate. Cells were treated at 70% confluency with the desired treatments and
incubated for 24 hours before the assay was conducted. The cells were in their proliferating
stage while we carried out the HDAC assay. Our expectation was that the selected dosages
of SFN (20 μM) and TSA (1 μM), would cause significant changes in histone deacetylation
activity in Caco-2 cells.
All treatments significantly increased HDAC inhibitor activity (n=6) when
compared to control. Vitamin D had 30 fold decrease in HDAC activity (-30.17±7.07,
p=0.03) which was similar to D+SFN alone (-32.75±9.63) and D+TSA group (-30.42±4.2).
SFN alone had a bigger effect on HDAC inhibition (-42.92±9.5) with the highest effect
seen in TSA alone group as expected (-47.5±8.9).
The results of HDAC assay (normalized to control- DMSO) are presented in Fig
6.4.
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Fig 6.4: HDAC Activity in Proliferating Caco-2 Cells. All treatments significantly
decreased HDAC activity in the system. Each data point represents Mean± SEM (N=10).
The data were analyzed by One-way ANOVA and *p <0.05, **p<0.01, and ***p<0.001 is
significant. Tukey’s post test showed no significant difference among vitamin D and the
combination treatments of D+SFN and D+TSA.
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6.4.3 ATP-dependent Cell Viability Assay

To determine cell viability, we measured cellular ATP activity. Caco-2 cells were
seeded at 10,000 cells/well in a 96-well, opaque walled plate. Cells were treated at 70%
confluency with the desired treatments and incubated for 24 hours before the assay was
conducted. Our expectation was that the selected dosages of SFN (20 μM) and TSA (1 μM)
with vitamin D (100 nM) would be sufficient to decrease ATP-dependent viability in
proliferating Caco-2 cells. There was no effect of vitamin D and the HDAC inhibitors on
cell viability in an ATP-dependent manner, although Bartlett’s test (p<0.0001) and
Browne-Forsythe Test (p=0.03) results came back as significant. Tukey’s posttest also
showed no effect on ATP-dependent cell viability in vitamin D and the combination
treatments. The results are presented as percent (%) control in Fig 6.5.

Fig 6.5: ATP-dependent Cell Viability in Proliferating Caco-2 Cells. There was no
significant difference among the treatment groups on cell viability. Values are
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representative of three independent experiments (N=3). (Mean±SEM) represented as %
control. No significant difference was observed across the treatments.

6.4.4 ATP-independent Cell Viability Assay

To determine cell viability in an ATP-independent manner, we measured cellular
MT Cell Viability Substrate activity. Caco-2 cells were seeded at 10,000 cells/well in a 96well, opaque walled plate. Cells were treated at 70% confluency with the desired treatments
and incubated for 24 hours before the assay was conducted. Our expectation was that the
selected dosages of SFN (20 μM) and TSA (1 μM) with vitamin D (100 nM) would be
sufficient to decrease viability in proliferating Caco-2 cells. Two- way ANOVA test was
performed to test for time X treatment interaction.

Compared to control, all treatments were significant different at all time points
(p<0.0001) with an overall significant interaction(p<0.0001). Tukey’s post test showed
significant difference in D+SFN (p<0.0001) and D+TSA (p<0.0001) at 12 hours, D+TSA
only (p=0.02) at 24 hours, again D+SFN (p<0.0001) and D+TSA (p<0.0001) at 48 hours
with observed increase in cytotoxicity by SFN and TSA. The results are presented as
relative luminescence in Fig 6.6.
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6.4.5 Apoptosis in Proliferating Caco-2 Cells

We used Caspase-Glo® 3/7 lytic assay and measured the degree of caspase
cleavage of the substrate. The cleavage liberates free aminoluciferin, which is consumed
by the luciferase enzyme, generating the luminescent signal that is proportional to caspase3/7 activity (used as a proxy measure of apoptosis). In other words, the higher the activity,
the higher the luminescent signal. Caco-2 cells were seeded at 10,000 cells/well in a 96well, opaque walled plate. Cells were treated at 70% confluency with the desired treatments
and incubated for 24 hours before the assay was conducted. Our expectation was that the
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selected dosages of SFN (20 μM) and TSA (1 μM) with vitamin D (100 nM) would be
sufficient to induce apoptosis in proliferating Caco-2 cells. The results are presented as
relative luminescence in Fig 6.7.

Fig 6.7: Apoptosis in Proliferating Caco-2 Cells. All treatments had significant increase
in caspase 3/7 activity. Values are representative of four independent experiments (N=4)
and represented as Mean±SEM. Tukey’s post test showed no significant difference between
D+SFN and D+TSA when compared to D alone.

6.4.6 Migration Assay

Caco-2 cells were plated and treated as per protocol described previously. The
representative pictures per treatment (one of four wounds created) are shown in Fig 6.8.
We then calculated the % closure (Fig. 6.9) for each treatment compared to the control per
the formula shown in the methods section. Compared to control (N=3), D alone group
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(1.18±0.15) showed protective effect in Caco-2 cell migration. The combination groups
D+SFN (0.70±0.06) and D+TSA (0.87±0.02), as well as the individual HDAC inhibitors,
SFN (0.79±0.08) and TSA (0.88±0.10) alone showed no significant difference in
migration.

Fig 6.8: Migration assay in Proliferating Caco-2 Cells. The combination treatments had
no change in migration, D alone showed a tendency to prevent migration while the rest of
the treatment groups were unable to reflect this change.
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Fig 6.9: Percent (%) Closure in Proliferating Caco-2 Cells. No significant difference
was observed when compared to control in migration but was overall significant (p=0.03).
D+SFN reduced migration significantly when compared to D (p=0.02) from Tukey’s
posttest.

6.5 Discussion

Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality in the
US. Factors involved in the pathogenesis of colorectal cancer appear to be complex and
heterogeneous and include dietary and lifestyle factors as well as inherited and somatic
mutations [9]. It is believed that although the underlying form of genomic or epigenomic
instability determines the types of mutations that occur in colon cancer, the selective
pressures that lead to the clonal evolution of the tumors are largely the same across all
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colorectal cancers. This can explain why certain genes are more frequently mutated in
colon cancers than in other cancers (e.g. breast cancer, prostate cancer) and vice versa.
Epigenetic mechanisms that modify chromatin structure are divided into the
following: DNA methylation, histone modifications, nucleosome remodeling and noncoding RNAs. The complex interaction of these mechanisms regulate the way genes are
expressed in different cell types, developmental stages and disease states, including cancer.
[10]
Histone modification is controlled by a balance in activity between histone
acetyltransferase (HAT) and histone deacetylase (HDAC) activities. The former adds an
acetyl group to histones resulting in uncoiling or “opening” of the chromatin structure,
facilitating gene transcription. The HDACs remove acetyl groups from the histones,
leading to increased binding of DNA to histone proteins, and the coiling or “closing” of
chromatin, which inhibits transcription [11]. The HDACs are known to be critical in the
regulation of expression of genes important for cell survival, proliferation, differentiation,
and apoptosis [12]. HDACs also act as members of a protein complex responsible for
recruitment of transcription factors to the promoter region of genes, including those of
tumor suppressors, and regulation of acetylation status of specific cell cycle regulatory
proteins [13]. High HDAC expression and histone hypoacetylation have been observed in
cancer with associated transcriptional repression of genes, providing a rationale for the
investigation of HDAC inhibitors in cancer therapeutics [14].
Sulforaphane is an isothiocyanate derived from cruciferous vegetables and is
particularly enriched in broccoli and broccoli sprouts. Sulforaphane has been received great
attention due to its promising chemo preventive and therapeutic effects established in a
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variety of human cancer cell lines and in preclinical cancer models, including colon
cancer.[15] Although more cited for its antioxidative and anti-inflammatory defense
mechanisms, the induction of proliferation arrest and apoptotic death primarily contribute
to the anticancer mechanisms against post-initiated/transformed cells. [15, 16, 17]
However, the precise molecular mechanisms of sulforaphane-elicited anticancer effect are
not thoroughly elucidated.[18]
Vitamin D receptor (VDR) is a transcription factor that binds to specific vitamin D
response elements (VDREs) within the promoter regions of its primary target genes [19].
Most VDR target genes contain multiple VDREs. In the absence of a ligand, VDR acts via
co-repressor proteins i.e. histone deacetylases (HDACs) [20]. HDACs can also inactivate
non-histone proteins, e.g. p53 by deacetylation. Therefore, HDACs have multiple
influences in cellular processes. [21] Studies in animals (xenografted tumors, chemicallyinduced carcinogenesis, genetic models for CRC) and cultured cells show that
1,25(OH)2D3 exerts a variety of antitumor effects on colon carcinoma cells, including
inhibition of proliferation, increase in differentiation, sensitization to apoptosis, and
inhibition of angiogenesis and metastasis [22] Moreover, two studies have shown that
APCmin mice lacking the VDR gene develop bigger intestinal tumors [23] Zheng et al.,
2012). In addition, 1,25(OH)2D3 inhibits the pro-tumoral properties of CRC-associated
fibroblasts and, accordingly, high VDR expression in these fibroblasts is associated with a
favorable clinical outcome for metastatic CRC patients [208]. Mechanistically, these
effects are based on regulation by 1,25(OH)2D3 of crucial genes controlling the cell cycle
CDKN1A/ p21CIP1, CDKN1B/p27KIP1,c-MYC, and others), apoptosis (BAX, and
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others), invasion (metalloproteases, and others), the epithelial-to-mesenchymal transition
(CDH1/E-cadherin, and others) and angiogenesis [24].
A series of studies have shown that the expression of VDR and CY27B1 in colon
epithelial cells increases at early steps of tumorigenesis (adenomas and well differentiated
carcinomas) as compared to that in normal cells but it strongly declines in advanced, poorly
differentiated tumors [25,26]. Thus, although rarely mutated, VDR and Cyp27b1 are
downregulated in a relatively high proportion of advanced colorectal tumors. [27].
24-Hydroxylase, encoded by the CYP24A1 gene, is the key enzyme that catabolizes
1,25(OH)2D3 to the less active calcitroic acid. It has been reported that CYP24A1 is
overexpressed in several human tumor types and that changes in CYP24A1 expression are
associated with cancer development and progression. A recent study showed that
CYP24A1 expression is closely associated with CRC progression, and might be a novel
prognostic biomarker for colorectal cancer. [28]
TRPV6 mRNA was first shown to be regulated by 1,25(OH)2D3 [29] in Caco-2
cells. The dependence of TRPV6 mRNA expression on the VDR-mediated genomic
actions of 1,25(OH)2D3is supported by increased intestinal TRPV6 mRNA expression
after injection of mice with 1,25(OH)2D3[30,31]. It regulates TRPV6 expression by a
process that requires new mRNA and protein synthesis and the point of regulation lies most
likely at the transcriptional level [32]
It is clear from the results that TSA enhanced vitamin D activity in more than one
genes related to Vitamin D. The responses differed within the same gene based on the
condition of Caco-2 cells (differentiated vs. proliferating) as they were gene-specific. SFN,
really had the opposite effect of TSA in fully differentiated cells. However, in proliferating
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cells, it showed a greater impact in combination with vitamin D in two of the four genes.
Overall, we saw a mixed association between vitamin D and SFN from what we
hypothesized and therefore merits further exploration.
It has been proposed that gene mutations and epigenetic alterations contribute to
colon cancer formation through the activation of oncogenic pathways and the inactivation
of tumor suppressor genes, which regulate hallmark behaviors of cancers (Fearon et al.,
2011). Insights into the biology of colorectal cancers have been gained from the
identification of genes commonly mutated in these cells signaling pathways in colon cancer
and have led to paradigms that have informed the study of epigenetic alterations in cancer.
These insights are also currently being used to develop new diagnostic and prognostic
assays and potential therapies for colorectal cancer.
In summary, we state that the components of the vitamin D pathway can potentially
be used both as treatment and preventive strategies for colorectal cancer. In colorectal
cancers with low VDR expression, it may be possible that future treatments could target
the genomic and epigenomic level alterations present to increase VDR expression by
modulating expression of transcription factors or utilizing HDAC inhibitors, respectively.
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CHAPTER 7
DISCUSSION
Epigenetics refers primarily to alterations in gene expression at the promoter
regions of genes. Unlike genetic mutations, epigenetic alterations do not change the actual
genetic sequence and, therefore, are part of a new avenue in cancer research [1].

7.1 Epigenetic Alterations in Cancer
The epigenetic landscape is largely a reflection of factors that determine the state
of the chromatin, which determines whether the DNA is accessible to proteins that control
gene transcription or not. A relaxed or “open” chromatin state allows for gene transcription,
whereas a condensed or “closed” chromatin state prevents gene transcription [2]. The
epigenetic mechanisms currently believed to play a role in cancer include:
1) DNA methylation of cytosine bases in CG rich sequences, called CpG Islands;
2) Post-translational modifications of histones, which regulate the packaging
structure of the DNA (called chromatin);
3) microRNAs and noncoding RNAs; and
4) nucleosome positioning

7.1.1 DNA Methylation

Gene silencing may occur due to methylation of DNA in the promoter region of
genes [3]. DNA methyltransferase enzymes (DNMTs) add a methyl group (-CH3) to the
DNA structure causing hypermethylation and possibly a reduced expression of tumor
suppressor genes. DNA methylation refers to the enzymatic addition of a methyl group to
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the 5-position of cytosine by DNA methyltransferases (DNMT) to produce 5methylcytosine, a normal base in DNA [4]. Most CpGs (a dinucleotide sequence) are
methylated in normal mammalian cells with unmethylated CpGs being typically present
only in regions of DNA called CpG Islands. CpG islands are regions in the genome where
the percentage of the CpG dinucleotides is higher than expected- greater than 200–500
bases in length with greater than 50% GC content [5]. CpG islands, although protected
from methylation under normal circumstances, can become aberrantly methylated in
cancer. Methylation of CpG islands within the promoter region is correlated with
transcriptional silencing although it appears that decreased gene expression is only
characteristic of a subset of methylated genes in CRC [6, 7].
Unmethylated CpG islands within the promoter region of genes are correlated with
an open chromatin structure (euchromatin) whereas methylated CpG islands are correlated
with a condensed, closed chromatin structure (heterochromatin) and transcriptional
silencing [8]. For example, normal colonic epithelium generally has unmethylated CpG
islands in the promoter regions of genes, whereas aberrant hypermethylation of promoter
associated CpG islands is a hallmark of neoplasms.
The concept of “CpG island shores” [9] (areas of less dense CpG dinucleotides)
have been linked to hypermethylation in cancer [10]. The methylation of these CpG island
shores are generally tissue specific and has recently been shown to be altered in colorectal
cancer [10, 11]. This driving role of aberrant methylation of CpG island shores in the
development of cancer is still controversial and remains to be supported with additional
studies.
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It is important to recognize that DNA methylation is a normal mechanism in the
mammalian genome by which cells regulate gene expression. Most of the CpG sites in the
human genome, which are located outside of promoter regions, are heavily methylated.
The methylation state of a gene is regulated by a family of DNA methyltransferases
(DNMTs). When the DNMTs are not functioning properly, either due to structural
abnormalities caused by epigenetic changes or functional inabilities, formation of
malignant cells and/or progression leads to the development of a specific cancer e.g.
colorectal, breast, prostate cancer etc.

7.1.1.1 DNMT Inhibitors
DNMT inhibitors, also referred to as demethylating agents, have been under
preclinical and clinical investigation for over 30 years [12]. After formation of an
irreversible complex with DNMT, the enzymes degrade [13] and prevent methylation of
daughter DNA in CpG islands during DNA replication. At low concentrations (30-300nM),
these

inhibitors

(e.g.

5-Aza-2'-deoxycytidine

or

AZA)

exhibit

potent

DNA

hypomethylation properties, whereas high concentrations (≈3–10 μM) are cytotoxic [14].
Other DNMT inhibitors in an earlier phase of development include 5-aza-2′-deoxycytidine
(DAC) analogues such as SGI-110 and zebularine.
Although DNA methylation is one of the two key epigenetic mechanisms in cancer,
we focused on histone modification for our research, which will be discussed now.
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7.1.2 Histone Modification

DNA is packaged into chromatin and coils around structural histone proteins in
cells. The histones are responsible for maintaining the shape and structure of chromatin.
Many post translational alterations can occur at specific amino acids (e.g. lysine) in the
exposed tail of histone proteins, which result in a conformational change in the chromatin
structure and in the transcription of important genes necessary to suppress carcinogenesis,
such as tumor suppressor genes. These chromatin alterations include acetylation,
methylation or phosphorylation [15].
Histone acetylation is controlled by a balance in activity between histone
acetyltransferase (HAT)-adds the “acetyl” group (open state) and histone deacetylase
(HDAC)- removes the “acetyl” group (closed state). The HDACs are known to be critical
in the regulation of expression of genes important for cell survival, proliferation,
differentiation, and apoptosis [3]. HDACs also act as members of a protein complex that
recruit transcription factors to the promoter region of genes, e.g. tumor suppressor genes,
and regulation of acetylation status of specific cell cycle regulatory proteins [16].

7.1.2.1 HDAC Inhibitors
High HDAC expression and histone hypoacetylation have been observed in cancer
with associated transcriptional repression of genes, providing a rationale for the
investigation of HDAC inhibitors in cancer therapeutics [17].
Aberrant HDAC activity has been documented in a variety of tumor types and led
to the development of HDAC inhibitors as anticancer therapeutics [18]. Modest clinical
benefits were previously reported with relatively weak HDAC inhibitors such as valproic
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acid and phenylbutyrate in advanced solid tumors or hematologic malignancies [19]. More
potent HDAC inhibitors include both class-specific (I and II) inhibitors (entinostat and
romidepsin) and pan HDAC inhibitors (vorinostat, belinostat and panobinostat). Clinical
studies in solid tumors are ongoing with HDAC inhibitors, alone or in combination with
other agents.

7.2 Epigenetics and CRC
Epigenetic alterations, like gene mutations, contribute to the pathogenesis and
molecular heterogeneity of various cancers. This is highlighted by the identification of a
CpG island methylator subtype of colorectal cancer (CRC) that has a distinct epigenome
with a high frequency of methylated genes [20]. Our understanding of epigenomic
alterations in colorectal cancer, however, is less advanced than that of our understanding
of gene mutations, but substantial progress has recently been made in this area [2]. In the
following sub-sections, we will discuss the role of epigenetics in CRC, including the
contribution of epigenetics to the molecular heterogeneity of colorectal cancer, and the
clinical applications of these epigenetic alterations as biomarkers for early detection,
diagnosis, and management of patients with CRC.

7.2.1 Epigenetic pathophysiology of CRC

The classic view of cancer is that it arises because of the accumulation of mutations
in key tumor-suppressor genes or oncogenes, which deregulate homeostatic functions and
cause the transformation of normal cells into cancer cells. Sequencing of colon cancer
genomes has revealed that there is only a small number of functionally important gene
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mutations out of the hundreds of mutations found in the average colon cancer genome. A
recent analysis of approximately 13,000 genes revealed mutations in the coding sequence
of approximately 67 genes in the average colon cancer genome, of which a subset of 12
genes were proposed to be the genes most likely to be involved with cancer formation in
individual cancers [21]. The current cancer genome sequencing efforts demonstrate that
most cancer genomes carry hundreds of mutations, providing a major challenge to
determine which of these mutations play a pathogenic role in the formation of the cancer
(“driver mutations”) and which are merely a consequence of this process (“passenger
mutations”).
Furthermore, CRC can be sub-grouped based on the type of genomic instability that
they display. Different patterns of mutant genes demonstrate the underlying genomic
instability in cancer and influences the susceptibility to and selection for specific mutations.
It is believed that although the underlying form of genomic or epigenomic
instability determines the types of mutations that occur in CRC, the selective pressures that
lead to the clonal evolution of the tumors are largely the same across all CRCs. This
concept can explain why certain genes are more frequently mutated in colon cancers than
in other cancer types (e.g. breast cancer, prostate cancer) and vice versa.
It has been proposed that gene mutations and epigenetic alterations contribute to
colon cancer formation through the activation of oncogenic pathways and the inactivation
of tumor suppressor genes, which regulate hallmark behaviors of cancers [22].

7.3 Epigenetics and BC
Breast cancer is generally induced by the accumulation of altered gene regulations
which cause abnormal cell growth and expansion. In addition to genetic mutations,
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epigenetics also play an important role in breast cancer tumorigenesis. Studies have
focused on initiating molecular mechanisms in cancer development; identification of new
biomarkers to predict breast cancer aggressiveness and the potential of epigenetic therapy
[23].

7.3.1 Epigenetic pathophysiology of BC

7.3.1.1 DNA Methylation
Aberrant methylation plays an important role in BC development. DNA
hypomethylation has been generally demonstrated on a genome-wide scale in cancer
studies while hypermethylated DNA regions of certain genes, especially normally
unmethylated CpG islands, were frequently reported. A growing number of studies have
focused on hypermethylated genes in breast cancer which have crucial roles in cell-cycle
regulation, apoptosis, tissue invasion and metastasis, angiogenesis and hormone signaling
[24, 25]. Aberrant methylation profiles of these genes are associated with BC stage and
prognosis, therefore methylation status of key cell cycle regulating genes have been
proposed as reliable markers for BC [26].
Global DNA hypomethylation is prevalent in breast tumors. Up to 50% of the cases
represent reduced 5-methylcytosine content when compared with matched-control normal
tissues [23]. Whole genome distribution of aberrant DNA methylation in eight breast
cancer cell lines and normal human mammary epithelial cells was analyzed by [27]. It was
shown that hypomethylation was distributed throughout the whole genome and
simultaneous

hypermethylation

occurred

at

CpG-rich

regions.

In

addition,

hypomethylation was three- to five-times more frequent than hypermethylation. Studies
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have shown that promoter hypermethylation of tumor suppressor genes has mostly resulted
in downregulation of gene expression.

7.3.1.2 Histone Modification
In breast cancer, investigations carried out on histone modifications are relatively
newer than DNA methylation studies. Post-translational histone modifications have a
critical role in breast tumorigenesis and aggressiveness of prognosis. In addition, they are
potential therapeutic targets. Since different breast cancer subtypes represent distinct gene
expression profiles, it is important to clarify the effect of histone marks on gene expression
levels in breast tumors. However, there are limited studies about histone modification
patterns in breast cancer tumors, though the numbers of investigations are increasing in
this field.
In a study of global histone modifications in breast cancer tumors, histone
modification levels were significantly higher in steroid receptor [27]. The study concluded
that reduced detection levels of these histone marks would be correlated with poor
prognostic characteristics. Another study investigated the arginine and lysine methylation
of BRCA1 in breast cancer cell lines and breast tumor tissue samples [28] and found that
BRCA1 is methylated at arginine and lysine residues both in cell lines and tumor samples.
However, lysine methylation was only detected in triple negative MDA-MB-231 cells,
while arginine methylation was detected in both MDA-MB-231 and MCF-7 cells. MCF-7
cells are estrogen, progesterone receptor positive, HER2 receptor negative and show wildtype p53. Per these results, they proposed that methylation may affect the ability of BRCA1
binding to specific promoters or affects protein-protein interactions that alter the
recruitment of BRCA1 to these promoters.
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Another study demonstrated lysine histone modification patterns in breast cancer
cell line MCF-7 and normal mammary epithelial cell line MCF-10A and found no
significant difference [29]. In another study, histone modification profiles in MCF-7 cells
demonstrated that the promoters were the most abundant regulatory elements [30].
Modified histones have gained importance as biomarkers of breast cancer prognosis. The
investigations carried out on mechanisms of histone modifications are also promising for
the development of efficient HDAC inhibitor therapies.

7.4 Epigenetics of Vitamin D
Insufficient intake or metabolism of vitamin D appears to play a key role in the
development of a multitude of diseases affecting the central nervous system, the skeleton
and various organs where metabolic disturbances may contribute to the generation of
malignancies [31]. In the following section, we will discuss the effects of different
epigenetic components of vitamin D metabolism.

7.4.1 Regulation of Vitamin D Receptor (VDR)

Although several rapid and non-genomic actions of active vitamin D have been
described [32], most of the effects of vitamin D are mediated by the vitamin D receptor
(VDR). VDR is the only protein that binds 1,25(OH)2D3 effectively at sub-nanomolar
concentration [33]. This finding somewhat simplifies the understanding of vitamin D
signaling, since the physiological effects of the hormone largely overlap with the actions
of the transcription factor VDR, a ligand-activated transcription factor.
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Unbound 1,25(OH)2D3 freely enter a cell and bind to a VDR present in the
cytoplasm or the nucleus [34]. VDR is classified as a class II nuclear receptor, which forms
a heterodimer with retinoid X receptor (RXR). This heterodimer binds to the vitamin D
response elements (VDREs), which are in the promoter region of key genes [35]. Many
vitamin D target genes, e.g. p21, p27 and e-cadherin, have been found to regulate cell cycle
arrest and cell differentiation [36, 37]. Therefore, it has been proposed that 1,25(OH)2D3
or its pharmaceutical analogs can possibly be used as a therapeutic for cancer by mediating
VDR activity.
VDR is one of approximately 1900 transcription factors, which are encoded by the
human genome [38]. In addition, VDR is a member of the superfamily of nuclear receptors,
most of which are specifically activated by lipophilic molecules [39]. The transcription
factor VDR is the only high-affinity target for 1,25(OH)2D3 within the cell nucleus [33].
Its lipophilic properties allow 1,25(OH)2D3 to pass through all biological membranes, i.e.,
gene regulation by vitamin D does not involve additional plasma membrane-associated
signal transduction steps. Moreover, VDR is rather ubiquitously expressed, i.e., most
human tissues and cell types are responsive to 1,25(OH)2D3 [40].
Proliferation of the non-malignant breast epithelial cell line, MCF-12A, was
sensitively and completely inhibited by 1,25(OH)2D3 (70 nM) [41] while MDA-MB-231
cells demonstrated a resistance towards 1,25(OH)2D3 (> 100 nM) which correlated
significantly with reduced Vitamin D receptor (VDR).

7.4.1.1 Mechanism of Action
Vitamin D exerts its activity in association with its receptor (VDR) and another
nuclear receptor, the retinoid X receptor (RXR), in combination with histone
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acetyltransferase (HAT). The chromatin of a previously inactive gene can become relaxed
upon binding of transcription factors to DNA recognition sequences. This process is
counteracted by recruitment of factors having HDAC activity. Accessory transcription
factors (ATFs) may be localized proximal or distal of VDR, with distances of up to several
hundreds of base pairs, which can be overcome by loop domains of the transcriptional
complex [31].

7.4.2 Regulation of CYP27B1
CYP27B1 possesses 1α-hydroxylase activity, which is critical for the last step in
vitamin D activation. This enzyme is found in the inner mitochondrial membrane and
converts 25(OH)D3 to its active form 1,25(OH)2 D3. It is mainly expressed in the proximal
tubule of the kidneys, but it is also expressed in many other vitamin D target tissues, albeit
at lower activity levels [42]. The CYP27B1 gene has been reported to harbor a CpG island
in its promoter [43]. However, recent DNA sequence updates have shifted the CpG island
from the CYP27B1 promoter region into the gene coding sequence.

7.4.2.1 Mechanism of Action
The promoter region of CYP27B1 contains a negative vitamin D response element
or nVDRE [44]. This region is responsible for 1,25(OH)2D3-dependent trans repression.
This repression seems to be achieved through recruitment of both HDACs and DNMTs by
VDR/RXR to the promoter region of CYP27B1 [45]. In cancer, expression of CYP27B1
is often downregulated. This may be explained by increased methylation of the CpG island
located within CYP27B1. Methylation of CYP27B1 in various diseases cause reduced
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local activation of 1,25(OH)2D3 thus reducing local levels of active vitamin D and
restricting its functions [46].
In the breast cancer cells MDA-MB231, CYP27B1 hypermethylation led to gene
silencing, while in prostate cancer cell lines, combination of the DNMT1 inhibitor and the
HDAC inhibitor TSA resulted in increased activity of CYP27B1 [47].

7.4.3 Regulation of CYP24A1

The 1,25(OH)2D3 24-hydroxylase is an inner mitochondrial membrane enzyme,
which catalyzes and inactivates both 25(OH)D3 and 1,25(OH)2D3 [48-50]. Its primary site
of expression are the kidneys, playing a crucial role in regulating systemic vitamin D
metabolite levels. However, CYP24A1 is also found in many other vitamin D target tissues
i.e. skin, gut etc. The promoter of CYP24A1 is spanned by a CpG island which can be
regulated by DNA methylation [46] and has several response elements including two
VDREs.

7.4.3.1 Mechanism of Action
In healthy kidney, skeletal muscle, whole blood, brain, skin fibroblasts, and sperm
the CYP24A1 promoter is not methylated [51], although the expression levels are highly
variable. Although, methylation of CYP24A1 was low (5%) peripheral blood lymphocytes
[52], it was highly methylated in full term human placenta (56%). In colon cancer cell lines,
administration of anti-tumor drug, 5-aza-2-deoxycytidine (DAC), induced CYP24A1
expression in a cell line-specific manner, independent of the methylation level of the
promoter. In these cells, induction of CYP24A1 expression by DAC seemed to be
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independent of CYP24A1 promoter methylation [53]. Moreover, the methylation level of
the CYP24A1 promoter was comparably low both in colon adenocarcinomas and the
adjacent mucosa, although the expression of CYP24A1 was significantly higher in the
tumors [54]. Taken together, the regulation of CYP24A1 by DNA methylation appears to
be tissue-dependent, both in health and disease.
One study investigated the mRNA expression levels of the CYP24A1 gene in
malignant and normal breast tissues [55] and found that the mRNA expression of
CYP24A1 was significantly upregulated in the tumor tissues (P<0.01). This major
difference revealed that the normal breast tissues transcriptionally expressed CYP24A1
slightly. These results are suggestive of dysregulation of the vitamin D signaling and
metabolic pathways during tumorigenesis in breast cancer.

7.4.4 Regulation of TRPV6

TRPV6 is a member of the vanilloid subfamily of transient receptor potential (TRP)
proteins and functions as an epithelial calcium channel in organs, such as the intestine,
kidney, and placenta [56]. TRPV6 mRNA expression is strongly regulated by
1,25(OH)2D3 in the intestine and in Caco-2 (human colon) cells. 1,25(OH)2D3 regulates
TRPV6 expression by a process that requires new mRNA and protein synthesis and the
point of regulation lies likely at the transcriptional level. In Caco-2 cells, 1,25(OH)2D3 is
the primary hormonal regulator of intestinal calcium absorption by a process involving an
increase in transcellular calcium transport [57]. However, the molecular mechanism has
not been fully described. TRPV6 mRNA was first shown to be regulated by 1,25(OH)2D3
[58] in Caco-2 cells. The dependence of TRPV6 mRNA expression on the VDR-mediated
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genomic actions of 1,25(OH)2D3 is supported by increased intestinal TRPV6 mRNA
expression after injection of mice with 1,25(OH)2D3 and that TRPV6 expression was
lower in vitamin D receptor knockout mice as compared to wild type mice [56]. Few studies
have investigated TRP genes in human breast cancer and have demonstrated that TRPC6
and TRPV6 expression increased in both breast cancer tissues and cell lines, with both
TRPC6 and TRPV6 regulating cell proliferation [59]. In a study examining the effect of
tamoxifen on TRPV6 function and intracellular calcium homeostasis in MCF-7 breast
cancer cells, tamoxifen decreased the transport rates of calcium [60].

7.4.4.1 Mechanism of Action
The TRPV6 gene codes for an epithelial calcium channel protein known to play an
important role in intestinal calcium absorption. Upregulation of TRPV6 mRNA expression
in the colon may be an important mechanism of vitamin D-mediated calcium absorption.
TRPV6 gene expression in Caco-2 cells was enhanced in presence of Vitamin D Receptor
Elements (VDREs) in the promoter region [56].
Migration and invasion are important features of malignant cells and their
therapeutic inhibition might be critical to avoid metastasis of solid tumors. One study
attempted to characterize the abilities of TRPV6 expressing cells, by studying their
migration potential and the effect of channel [61]. They found that, TRPV6 was strongly
expressed in breast adenocarcinoma tissue and TRPV6 mRNA expression was upregulated between 2fold and 15-fold compared with the average in normal breast tissue.
Whereas TRPV6 is expressed in the cancer tissue, its role as a calcium channel in breast
carcinogenesis is poorly understood. An in vitro model showed that TRPV6 can be
regulated by estrogen, progesterone, tamoxifen, and 1,25(OH)2D3 and has a large
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influence on breast cancer cell proliferation [59]. TRPV6 may be a novel target for the
development of calcium channel inhibitors to treat breast adenocarcinoma expressing
TRPV6.

7.5 Epigenetics of Sulforaphane
Cruciferous

vegetables

(crucifers),

include

species

predominantly from

Brassicaceae family and the more common members are cultivars of Brassica oleracea
genus including broccoli, cabbage, cauliflower, Brussel sprouts, and kale; as well as
Raphanus genus, i.e. various types of radish. The health benefits of these vegetables are
partly due to the nature of the phytochemicals they contain and the glucosinolates [62], the
enzymatic hydrolysis products that can modify genes [63]. Nutraceuticals can target
survival, proliferation, invasion, angiogenesis, and metastasis, thereby influencing various
steps of tumor cell development [64].
Sulforaphane is a bioactive food component or nutraceutical, with potential health
benefits that are mainly exerted through epigenetic modification of genes. The principal
role of sulforaphane in these epigenetic modifications is believed to be primarily due to its
histone deacetylase (HDAC) inhibitor activity.

7.5.1 Phase II Detoxification and SFN

Potentially harmful, foreign compounds (e.g. carcinogens) [65, 66] often involve
Phase I and II components, which eventually permits their excretion from the cells. A
compound which activates Phase I and Phase II enzymes is called a bifunctional inducer;
and, if it activates only Phase II enzymes, it is a monofunctional inducer [67]. Upon
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treatment in the cells with oxidants including H2O2, oxidative stress and conformational
changes occur. Therefore, for an optimal cellular detoxification environment, Phase II
reactions should be at a rate that prevents intermediate products of Phase I from
accumulating. Aliphatic sulforaphane acts as a monofunctional inducer, whereas the indole
isothiocyanates (ITCs) from mature broccoli are bifunctional inducers derived from
another glucosinolate, glucobrassicin [68].

7.5.2 Histone Deacetylase Inhibition

In a recent study to test whether SFN inhibits HDAC activity in vivo, an average
daily dose of 7.5 μmol per animal for 21 days, suppressed the growth of human PC-3
prostate cancer cells by 40% in male nude mice [69]. There was a significant decrease in
HDAC activity in the xenografts, as well as in the prostates and mononuclear blood cells
(MBC), of mice treated with SFN, compared to controls. In human subjects, a single dose
of 68 g BroccoSprouts inhibited HDAC activity significantly in peripheral blood
mononuclear cells (PBMC) 3 and 6 hrs. following consumption from the same study.
In human embryonic kidney 293 cells, SFN dose-dependently increased the activity
of TOPflash reporter and inhibited HDAC activity, resulting in an increase in acetylated
histones [70]. Bioactive dietary supplements such as green tea polyphenols (GTPs) and
sulforaphane (SFN) inhibit DNA methyltransferases (DNMTs) and histone deacetylases
(HDACs), respectively, which are of central importance to cancer prevention. In a recent
study of estrogen receptor ER-negative MDA-MB-231 cells, GTPs and SFN alone or in
combination lead to the reactivation of ER expression which was consistently correlated
with promoter hypomethylation and hyperacetylation [71]. General hypothesis regarding
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SFN action was that the ability of SFN to target aberrant acetylation patterns, in addition
to effects on phase II enzymes, might make it an effective chemoprevention agent.

7.6 Epigenetics of vitamin D in CRC
The components of the vitamin D pathway can potentially be used both as treatment
and preventive strategies for CRC. The active metabolite 1,25 (OH)2 D3 targets the Wnt/βcatenin signaling pathway by up regulating key tumor suppressor genes, which promotes
an epithelial phenotype, but is only useful when the VDR is present [72]. In colorectal
cancers with low VDR expression, it may be possible that future treatments could target
the genomic and epigenomic level alterations present to increase VDR expression by
modulating expression of transcription factors or utilizing HDAC inhibitors, respectively.
Colorectal cancer can be treated by targeting transcription factors that downregulate the vitamin D receptor, which is essential for vitamin D to mediate its effects in
promoting an epithelial phenotype. Furthermore, potential preventative measures to protect
individuals from colon cancer include- increasing serum levels of 25(OH)D3 by either sun
exposure, diet or supplements.

7.6.1 Mechanistic links between vitamin D and CRC

High levels of serum 25(OH)D3 are related to lower incidence rates in many
cancers, particularly colon cancer [73-75]. 25(OH)D3 is a hepatic metabolite in the vitamin
D pathway that is converted by the 1α-hydroxylase enzyme in the kidneys to form
1,25(OH)2D3. The vitamin D pathway includes both endogenous (cutaneous synthesis)

153

and exogenous sources (diet, supplements) of vitamin D, so both can cause a significant
increase in serum 25(OH)D3.
Unbound 1,25(OH)2D3 enters a cell and bind to a VDR present in the cytoplasm
or the nucleus [34]. VDRs are expressed in normal colonic cells, but it has been shown that
VDR expression levels decrease in the later stages of colon cancer; the mechanism behind
this phenomenon is not fully understood [76]. Therefore, treatment with 1,25(OH)2D3 may
not be as effective in the later stages of colon carcinogenesis due to the development of
cellular resistance to 1,25(OH)2D3. It has been suggested that both genomic and epigenetic
modifications might be involved in the reduction of VDR expression [77-82]. For instance,
Malinen and colleagues demonstrated that the down regulation of 25(OH)D3 due to
reduced expression of CYP27A1 via HDACs can be overcome with the use of HDAC
inhibitors [83]. Furthermore, it is proposed that an individual could reduce their risk of
colorectal cancer approximately 30–50% by either increasing vitamin D intake to 2000
IU/day or increasing their sun exposure to raise blood levels of 25 (OH)D3 to greater than
30 ng/ml [84].

7.7 Epigenetics of vitamin D in BC
A large proportion of breast cancer cells contain the VDR protein, however the
level of expression is variable within individual cells [85] and, therefore, the biological
response to vitamin D also varies between patients. The primary effect of exposure of
breast cancer cells to 1,25 (OH)2D3 is cell cycle arrest due to changes in the functional
status of the proteins that regulate cell cycle [86]. An effect of 1,25(OH)2D3 on cell
proliferation can also be mediated in an indirect way, via interference to the function of
estrogen receptors (ER)[87]. 1,25 (OH)2D3 and its analogues decrease the expression of
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ERα, which in turn reduces the level of mitogenic signals to breast cancer cells from
estrogens [88]. Another mechanism of the anticancer action of 1,25 (OH)2D3 against
breast cancer cells is that it down-regulates the expression of aromatase, which catalyzes a
step-in estrogen synthesis [89].
One of the key factors regarding the activity of 1,25 (OH)2D3 is its availability in
the BC environment. This is maintained by the balance between synthesis and catabolism.
CYP27B1 is present in some breast cancer cells, to control the autocrine synthesis of 1,25
(OH)2D3, but this enzyme is also active in breast cancer microenvironment. It has been
shown that breast adipocytes produce CYP27B1, bio-activate 25(OH)D3 to 1,25 (OH)2D3
and in a paracrine fashion deliver 1,25 (OH)2D3 to the breast epithelium [90]. On the other
hand, the availability of 1,25 (OH)2D3 is maintained by its degradation, maintained by the
24-hydroxylase enzyme (CYP24A1). In normal tissues, this enzyme is expressed in
response to 1,25 (OH)2D3 exposure, providing a negative feedback mechanism that
maintains a steady concentration of 1,25 (OH)2D3 in the plasma [91]. Genome
hybridization studies have revealed that in certain human breast cancers the CYP24A1
gene is amplified and this may cause a reduction in the level of 1,25 (OH)2D3 and cause
cells to proliferate unduly [87].

7.7.1 Mechanistic links between vitamin D and BC

The mechanism behind reduction in BC risk related to vitamin D intake is mainly
due to cell cycle arrest and apoptosis by 1,25(OH)2D3 [86, 92]. 1,25(OH)2D3 can also
induce morphological changes associated with apoptosis in breast cancer cells [93].
1,25(OH)2D3 can also inhibit metastasis of cancer cells and has potential anti-angiogenic
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properties that can inhibit tumor cell invasion [94]. Vitamin D can act as an antiinflammatory agent such that 1,25(OH)2D3 can down-regulate the expression of
cyclooxygenase-2, which plays a role in prostaglandin synthesis in human breast cancer
[89]. Many epidemiological studies have reported positive associations between gene
polymorphisms and risk of BC; these include vitamin D related genes such as VDR,
vitamin D-binding protein (VDBP), as well as the CYP24A1 gene [95].
Several studies have examined the effects of 1,25(OH)2D3 on mammary
carcinogenesis in cells and animal models and found a protective role of 1,25(OH)2D3 in
BC development. The relationship of vitamin D with risk of breast cancer may be subtypespecific, with evidence of stronger effects of vitamin D for more aggressive breast cancer,
especially in African women.

7.8 Epigenetic effects of SFN in CRC
Colorectal cancer (CRC) has high morbidity and mortality rates worldwide and is
a global health problem. The conventional radiotherapy and chemotherapy regimen for
CRC not only has a low cure rate but also causes side effects [96]. Many studies have
shown that adequate intake of fruits and vegetables in the diet may have a protective effect
on CRC occurrence, possibly due to the special biological protective effect of the
phytochemicals in these foods. SFN is one such compound present in cruciferous
vegetables. In colon cancer cells, sulforaphane is associated with decreased cell
proliferation, cell cycle arrest and apoptosis [97].
A few mechanisms that are known to be affected by SFN in CRC are as below:
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7.8.1 Inhibiting phase I metabolic enzymes

Cytochrome P450 is a major component of phase I metabolic enzymes and can
convert xenobiotics into more electrophilic, reactive, mutagenic or even carcinogenic
bioactive compounds. 1,25(OH)2D3 in Caco2 cells, can induce some cytochrome enzymes
which can mediate the metabolism of carcinogens, making them less carcinogenic.
Previous studies have shown that SFN competitively inhibited or covalently modified some
cytochrome enzyme isoforms and reduced their expression, thereby inhibiting DNAadduct and chemical carcinogenesis [98, 99]. In another study, SFN was found to
significantly reduce the expression of the enzyme mRNA in Caco-2 cells [100].

7.8.2 Inducing phase II metabolic enzymes

Phase II metabolism is composed mainly of binding reactions, wherein carcinogens
and their metabolite reactive oxygen species (ROS) bind to endogenous ligands such as
glutathione and glucuronic acid. Currently, many studies have confirmed that SFN induces
the expression of several phase II metabolic enzymes in CRC cells, including glutathione
reductase (GR), glutathione S-transferase (GST), aldehyde reductase (AR), NAD[P]H:
quinone oxidoreductase (NQO) and uridine 5’-diphospho (UDP)-glucuronosyltransferase
(UGT) [96]. Glutathione reductase converts the active and oxidized glutathione to stable
and reduced glutathione (GSH). Glutathione transferase catalyzes the binding of
electrophilic substrate with GSH to induce its excretion. AR and NQO catalyze the
conversion of metabolically active aldehydes and quinones to relatively stable alcohols and
hydroquinones respectively, reducing their activities and damaging effects. UGT catalyzes
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the transferring of β-glucuronic acid from UDP-glucuronic acid to active substrates,
thereby increasing their solubility and facilitating their excretion.
Treatment of Caco-2 cells with 25 μM SFN for 24 h significantly increased mRNA
and protein expression levels of UGT1A1, 1A8 and 1A10 as well as their enzymatic
activity [100]. It has also been shown that SFN and SFN-GSH significantly improved
mRNA and protein expression levels of UGT1A1, mRNA expression level of GSTA1 and
activity of bilirubin in HepG2 and HT-29 cells [101].

7.8.3 Inhibiting HDAC activity

Nrf2 pathway is likely to play a role in the inhibition of HDAC by SFN. A study
has found that carcinogen 1,2-dimethylhydrazine more likely induced CRC in wild-type
Nrf2+/+ mice than in mutant Nrf2-/+ mice and that HDAC level in wild-type mice was
significantly increased as compared to that in Nrf2-/+ mice upon treatment with 400 ppm
SFN in diet (Rajendran et al., 2015). SFN treatment had a more profound effect on reducing
tumors in wild-type mice than in Nrf2-/+ mice. Other studies have shown that SFN
inhibited the activity of HDAC by promoting its degradation in the cytoplasm (Yin et al.,
2016).

7.8.4 Cell cycle arrest

Previous studies have shown that SFN arrested cell cycle in many types of CRC
cells. For example, SFN arrested Caco-2 cells in the G1/G2 [100] and G2/M phases [102],
and arrested HCT116 cells in the G2/M phase [103]. SFN also augmented the expression
of p21, which exerted inhibitory activity on cyclin-dependent kinase (CDK) and regulated
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the levels of many cell cycle proteins. While arresting HT-29 cells in the G0/G1 phase,
SFN significantly induced the expression of p21 and reduced the expression level of some
regulatory proteins, which is vital for G1phase, such as cyclin A, cyclin D1 and c-Myc, at
high doses (>25 μM) [104].

7.8.5 Inhibiting tumor angiogenesis

Kim et al., 2015, have found that SFN significantly reduced the expression level of
vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1α (HIF-1α), both
of which are associated with angiogenesis and tumor metastasis, and inhibited tumor
metastasis in a dose-dependent manner in hypoxia-treated HCT116 cells [105]. SFN might
inhibit CRC progression and tumor angiogenesis in a similar manner.

7.8.6 Enhancing the efficacy of chemotherapy drugs

Studies have shown that both SFN and antineoplastic agent oxaliplatin could inhibit
the proliferation of Caco-2 cells in a dose-dependent manner. Pretreatment of HT-29 cells
with 2.5 μM SFN activated the cancer drug PR-104A and reduced its EC50 by 3.6-fold.
Similar results were observed with SW620 cells. However, SFN had little effect on normal
colon cells [106]. Therefore, SFN combined with traditional chemotherapy drugs might
reduce drug resistance and enhance drug efficacy. The potential chemopreventive effect of
SFN on CRC has also been confirmed by in vivo animal studies. Animal experiments have
shown that 2-6 h after oral gavage of 5-20 μmol/L SFN, the highest level of SFN was
detected in small intestine, prostate, kidney and lung (in a descending order) [107].
Therefore, SFN might provide a targeted chemopreventive effect in the prevention of CRC.
159

7.9 Epigenetics of SFN in BC
Phytochemicals have been studied extensively for the treatment of various diseases
and disorders [96]. They exhibit a wide range of safety and target multiple pathways and
targets in breast cancer cells [108]. Current evidence suggests that naturally occurring
phytochemicals can effectively target breast cancer stem cells, [109, 110] and are proposed
to be useful in the treatment of BC.
Consumption of cruciferous vegetables such as broccoli, bok choy, Brussel sprouts
etc. correlates with decreased risk of cancer induction and this protective effect has been
shown to be in part due to the presence of an isothiocyanate (ITC) glucoraphanin [62, 111].
The four important ITCs formed from glucosinolates by the activity of myrosinase are
benzyl-ITC,

allyl-ITC,

phenylethyl-ITC

(PEITC)

and

methylsulphinylbutyl-ITC

(sulforaphane). PEITC [112] and sulforaphane [113].
Sulforaphane was found to inhibit proliferation, angiogenesis, and metastasis as
well as induce cell cycle arrest and apoptosis in breast cancer cells. Sulforaphane
reactivated expression and reduced proliferation in MDA-MB-231 cells, probably via
histone modifications and DNA demethylation-facilitated activation of ER-α [71].
Sulforaphane treatment caused cell cycle arrest at S- and G2/M-phase with enhanced levels
of p21WAF1 and p27KIP1 and decreased cyclin A, cyclin B1 and CDC2 expression in
breast cancer cells [114]. It also decreased the production of IL-1β, IL-6, TNF-α,
interferon-γ, IL-4, platelet-derived growth factor and VEGF in breast cancer cells [115].
In addition, sulforaphane has a marked effect on cell cycle checkpoint controls and
cell survival and/or apoptosis in various other cancer cell lines, though the molecular
mechanisms that remain poorly understood [116-120].
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The effect of SFN on various human cell lines, animal models as well as human
subjects have been listed below:
Table 7.1: Summary of SFN effects in cancer
Subjects

SFN Dosage

Human

200 μmol

Duratio
n
1 hour

Human

102 μmol

1 hour

Cell Type

SFN Dosage

HEK293
(human
embryonic
Kidney cells)
SW620 (human
colon
cancer
cell)
Caco2, HT-29
and
SW480
(human
colorectal
cancer cells)

Outcome
Measure
SFN
metabolites
in
breast
tissue

Duratio
n
5µM SFN + 48 hours
100ng/L TSA

100 µM

72 hours

References

(left)1.45±1.1
[121]
2 and (right)
2.00±1.95
pmol/mg
tissue
NQO1 mRNA Increase
[122]
expression
mRNA
expression by
200%
Outcome
Effect
References
Measure
HDAC
Reduced
[69]
activity
HDAC activity
SFN+TSA
<60%
SFN<30%
TSA <25%
Cell
<20%
than
[123]
Proliferation control

1, 5, 10 and 24 and β-defensin-2
20
48 hours (HBD-2)
μmol
gene
expression

HepG2 cells
1.0, 2.5, 5.0 6 hours
(human hepatic and
10.0
cancer cells)
μmol

Effect

CYP1A1
mRNA
expression

At 24 hours:
1.6X increase
(by 20 μmol)
in HBD-2
At 48 hours:
2X
increase
(by 20 μmol)
in HBD-2
Increased
mRNA
expression:

1.0
2.2X
2.5
2.8X
5.0
3.8X
10.0
3.6X
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μmol=
μmol=
μmol=
μmol=

[124]

[125]

LNCap
10 μmol
C4-2 (human 20 μmol
prostate cancer 40 μmol
cells)

24 hours

Androgen
Receptor
(AR)
And Prostate
Specific
Antigen
(PSA)
protein
levels

Decrease in AR
and
PSA
protein
expression by
25%
compared to
control when
treated with
40 μmol SFN

[126]

Mice
triple Various
negative breast Concentratio
cancer (TNBC) ns of SFN
cells

72 h

SFE exhibited
antiproliferati
ve
effects
against
multiple kinds
of TNBC cells
ex and in vivo

[127]

Animals

SFN dosage

F344 rats

5 µM

Exposur
e time
2 weeks

Effects
of
SFN
treatments
on
Cell
proliferation
, cell cycle
arrest and
apoptosis
Outcome
measure
colonic
aberrant
crypt
foci
(ACF) and
multicrypt
foci

SpragueDawley
(female)

glucosinolate 5 days
Rats s (25 and 100
μmol)
and
isothiocyanat
es (25, 50,
and
100
μmol)

mammary
tumor
formation

SpragueDawley
(female)

SFN 75 and 5 days
Rats 150 μmol

Multiplicity
of tumors

162

Effect
Reduction in
the total ACF
from 153 to
109–115 (P <
0.01)
and
multicrypt foci
from 52 to 35
(more
than
four
crypts/focus;
P < 0.05).
Reduced
incidence at all
doses
of
glucosinolate
and
isothiocyanate
treatment (P =
0.0197
and
0.0190,
respectively)
Reduction in
tumor
multiplicity by
75 and 150
μmol, 0.45 and
0.26
times
respectively
((P = 0.01)

References
[128]

[68]

[99]

7.10 SFN in carcinogenesis: Overall
It is important to understand the metabolism of drugs or pharmaceutical substances
(also known as xenobiotic metabolism) or bioactive food components like SFN, to fully
elucidate its mechanism of action. The goal of xenobiotic metabolism is to transform
various non-polar metabolites generated by multiple chemical reactions, to a more polar
form that can then be more easily eliminated from the body. There are three phases of
xenobiotic metabolism: (i) Phase I reactions introduce or expose functional groups on the
drug to increase the polarity of the compound and activate them. The primary and first pass
site of this metabolism occurs during hepatic circulation. Additional Phase I metabolism
occurs in gastrointestinal epithelial, renal, skin, and lung tissues. Phase I reactions are
broadly grouped into three categories, oxidation, reduction, and hydrolysis (ii) In Phase II
reactions, these activated xenobiotic metabolites are conjugated with charged species such
as glutathione (GSH), sulfate, glycine, or glucuronic acid. The addition of large anionic
groups (such as GSH) detoxifies reactive electrophiles and produces more polar
metabolites that cannot diffuse across membranes, and may, therefore, be actively
transported. (iii) Conjugates and their metabolites are excreted from cells in Phase III of
their metabolism.
Sulforaphane (SFN) has shown to be an effective cancer chemopreventive agent in
several animal carcinogenic models as presented in the summary table above (Table 7.1)
and is thought to induce Phase II detoxification enzymes with promoter antioxidant
response elements [129-131]. Recent work has implicated multiple mechanisms of
sulforaphane action, with the majority of studies focusing on SFN as a potent Phase II
enzyme inducer and additional evidence for cell cycle arrest and apoptosis. Early research
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focused on Phase II enzyme induction by sulforaphane as well as on the inhibition of
enzymes involved in carcinogen activation, but there has been growing interest in other
mechanisms of chemoprotection by sulforaphane. Upregulation of Phase II metabolism is
likely a critical mechanism leading to cancer prevention by sulforaphane in the “initiation”
phase, helping to more rapidly eliminate genotoxins from the body.
To date, very few human clinical trials have evaluated the effects of sulforaphane
on cancer outcome; however, several pilots and Phase I human sulforaphane trials have
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CHAPTER 8
SUMMARY AND CONCLUSIONS
How the complex interactions of human exposures, metabolism, and genetics are
related to the development of colorectal and breast cancers being influenced by vitamin D
and sulforaphane is not yet known.
A more complete understanding of vitamin D and sulforaphane in human
carcinogenesis from organ site–specific biologic mechanisms, prospective serologic
analyses, genetic variation, and short-term clinical trials including metabolomic profiling
holds the key to elucidating the effect of vitamin D in colorectal and breast cancers in the
future.
Insights into the biology of these cancers have been gained from the identification
of genes commonly mutated in the cell signaling pathways and have led to paradigms that
enriched the study of epigenetic alterations in cancer. These insights are also currently
being used to develop new diagnostic and prognostic assays and potential therapies for
colorectal cancer. Possible mechanisms include, effects of vitamin D on cell proliferation
and differentiation, and apoptosis.
It is evident from the existing literature that clinical trials of vitamin D
supplementation at both the blood and tissue levels are needed to pinpoint the specific
mechanisms in both colorectal and breast cancer. Finally, examination of vitamin D in
relation to cancer survival is a relatively uncharted area that deserves much greater
attention.
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Large-scale clinical cohort studies are critical and required to confirm the
chemopreventive effects of SFN on CRC and BC.
Future studies should determine whether sulforaphane in food might play a
chemopreventive role through the molecular mechanisms discussed previously, as well as
determine its effective concentration, bioavailability and interactions with other dietary
components. Understanding the distribution, metabolism and excretion of SFN in
vivo could become a significant avenue of research.
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APPENDIX A

TABLE: GENE PRIMER SEQUENCES

Genes
VDR
TRPV6
Cyp24a1
Cyp27b1
GAPDH

Forward Seq.
5'-GAG GGA ACA GAC AGG
AGA AAT G-3'
5'-GAC CTG CGT GGG ATA
ATC AA-3'
5'-TGT GTG TGT GTC CGT
GTA TG-3'
5'-CCA TGT GGC AGA AGG
GAT AA-3'
5'-CAT GGG TGT GAA CCA
TGA GA-3'
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Reverse Seq.
5'-TAT CGT GAG TAG GCA
GGA GAG-3'
5'-CAG GAA GCG AAG TGA
GAA CA-3'
5'-CCT GCA CCA CAG ATC
CTA AAT-3'
5'-AAA CCG TAA ACC AGG
CTA GG-3'
5'-GGG TGC TAA GCA GTT
GGT-3'

APPENDIX B

TABLE: SUMMARY OF STUDIES SELECTED IN OUR META-ANALYSIS OF VITAMIN D AND BC, PUBMED 20002017
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Health
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Mean:
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Mean
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High
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reduced
risk of
BC.

Mean±
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25(OH)D Mean:
n/a
n/a
:
32.3
IA;
ng/mL*
*
Selfreported
diagnosis
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risk of
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opausal
BC. The
stronger
inverse
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receptor
-positive
tumors
deserve
further
study.
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and
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the
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the fully
adjusted
models
included
age at

Reduced
BC risk
was
associate
d with
use of
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D or
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min

Vitamin
D could
help
prevent
BC

182

live births,
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physical
activity
(P trend

25(OH)
D levels
were not
associat
ed with
subsequ
ent BC
risk

(N=1,067
)

question
naire;

186

BCs
were
confirme
d by both
local and
central
medical
record
and
patholog
y report
review
by
trained
adjudicat
ors who
were
blinded
to
randomiz
ed
allocatio
n, with
such
records
available

= .20)

6
[128]

USA

Prostate,
Lung,
Colorecta
l, and
Ovarian
(PLCO)
Cancer
Screening
Trial

187

Nested
casecontrol
study
within a
screening
trial
Cases
(N=1,005
)
And
controls
(N=1,005
)

Post
55-74
y
Mean:
~62
y**
Mean
followup
time:3.
9y

in 98.2%
of cases.
QS=0+2+2+2=6(Range:0-8)
25(OH)D 26.7
n/a
n/a
:
ng/mL
IA;
Incident
BC cases
were
ascertain
ed
through
selfreport in
an annual
health
survey,
linkage
to state
cancer
registries
, death
certificat
es,
physician
reports,
and nextof-kin
reports
(for

BMI at age
18 to 20,
age at
menarche,
age at
menopause
, HRT use,
history of
benign
breast
disease,
family
history of
BC,
combined
parity, age
at first
birth,
smoking
status,
alcohol
intake, and
total
calcium
intake.

The RR
of BC for
the
highest
quintile
of
25(OH)D
concentr
ation
versus
the
lowest
was 1.04
(95% CI,
0.751.45; Ptrend =
0.81)

No
inverse
associati
on
between
circulati
ng
25(OH)
D and
BC risk

188

7
[178]

Germ Populatio
any
n-based
casecontrol
study
from
southern
Germany
(Freiburg
and
RheinNeckarOdenwald
)

Pre
30-50
y
Mean:
~42.6
y*

deceased
participa
nts). A
total of
92% of
the
ascertain
ed BC
cases
were
confirme
d through
review of
medical
records.
QS=0+1+1+2=4(Range:0-8)
25(OH)D 51.3
n/a
n/a
:
nmol/L
IA;
Cases
were
identified
through
frequent
monitori
ng of
hospital
admissio
ns,
surgery

Stratified
by age
and
adjusted
for time of
blood
collection,
number of
births,
first-degree
family
history,
age at
menarche,
duration of

Compare
d with
the
lowest
category
(<30
nmol/L),
the ORs
(95% CI)
for the
upper
categorie
s (30–45,
45–60,
≥60

There is
a
protectiv
e effect
of
vitamin
D for
premeno
pausal
BC

Cases
(N=289)
and
controls
(N=595)

189

8
[125]

USA

Cancer
Preventio
n Study-II
(CPS-II)
Nutrition
Cohort

Nested
casecontrol
within
Prospecti
ve cohort
study

Post
47-85
y
Mean:
~69.5
y**

schedule
s and
patholog
y reports
in 38
hospitals.

breastfeeding,
BMI,
alcohol
consumpti
on.

nmol/L)
were
0.68
(0.43–
1.07),
0.59
(0.37–
0.94) and
0.45
(0.29–
0.70),
respectiv
ely (Ptrend=
0.0006)

QS=0+1+1+2=4(Range:0-8)
25(OH)D Mean:
n/a
n/a
:
49.1IA;
59.5
nmol/L
Eligible
dependi
cases
ng on
included season.
women
who
reported
a new
diagnosis
of BC on
a
biennial

Reproducti
ve risk
factors,
history of
benign
breast
disease,
family
history,
education,
alcohol
use,
postmenop
ausal
hormone

No
associati
on
between
25(OH)D
and BC
(OR =
1.09,
95% CI
0.701.68, P =
0.60) for
the top
vs

Results
do not
support
an
associati
on
between
adulthoo
d serum
25(OH)
D and
postmen
opausal
BC.

Cases
(N=516)
and
controls
(N=516)

190

CPS-II
Nutrition
Cohort
Survey
between
the date
of their
blood
draw and
30 June,
2005 (n
= 514) or
who did
not
report an
incident
BC but
for
whom
fatal BC
was
identified
through
linkage
with the
National
Death
Index (n
= 2).
QS=0+0+2+1=3(Range:0-8)

use, diet,
recreationa
l physical
activity
and zip
code (for
latitude).

bottom
quintile.

9
[124]

Den
mark

Casecontrol
study

Cases
(N=142)
and
controls
(N=420)

Total
29-87
y
Mean:
~58
y**

191

25(OH)D Cases:
n/a
n/a
:
69 ± 23
LC;
nmol/L
Control
Mammo s:
graphy,
76 ± 28
followed nmol/L
by
pathologi
c
examinat
ion.
Informati
on on
studied
subjects
from The
Danish
National
Hospital
Discharg
e
Register
and the
Danish
Cancer
Register
were also
retrieved.
QS=0+1+0+1=2(Ramge:0-8)

Controls
matched
with cases
on
menopausa
l
state, and
time of
year of
blood
sampling
(± 2 mo).

Compare
d with
the
lowest
tertile of
25(OH)D
levels,
risk of
BC was
significa
ntly
reduced
among
women
in the
highest
tertile
(RR=
0.52;
95% CI:
0.320.85)

Risk of
BC was
inversel
y
associat
ed with
25(OH)
D levels

10
[180]

Finla
nd

Finnish
Maternity
Cohort
Nested
casecontrol
study
within
cohort

192

Cases
(N=311)
and
controls
(N=311)

Pre
30-34
y
Mean:
~33
y**

25(OH)D Mean:
:
43
IA;
nmol/L
*

Missing
informati
on on
diagnosis
of BC.

n/a

n/a

Controls
matched to
cases by
parity, age,
year, and
season.

Serum
25(OH)D
level was
not
associate
d with an
increased
risk
neither at
the 1st
nor at the
2nd
pregnanc
y
samples
(OR =
1.4,
95%CI
0.6–3.4;
OR 1.4,
95%CI
0.7–2.8,
respectiv
ely), but
was
associate
d with an
increased
risk of
PABC
(OR =

Vitamin
D may
not be
related
to BC
risk

2.7;
95%CI
1.04–6.7)
11
[121]

Franc French
e
E3N
Cohort
Nested
casecontrol
within
cohort

193

Cases
(N = 636)
Controls
(N=
1,272)

Total
Cases
(56.9±
6.4)
and
control
s
(56.9±
6.4)

QS=0+1+1+2=4(Range:0-8)
25(OH)D Cases:
n/a
n/a
:
24.4±10
IA;
.9
ng/mL

Every 23 y,
question
naire was
sent out.
In each
question
naire,
participa
nts were
asked
whether
a cancer
had been
diagnose
d, and if
so,
patholog
y
reports
were

Control
s:
25.1 ±
11.0
ng/mL

BMI
, HRT use,
history of
mammogra
phy history
and of
breast
benign
disease,
family
history of
BC, parity,
smoking
status, use
of oral
contracepti
ves, age at
menarche,
and
physical
activity,
alcohol
consumpti
on, total
energy,
calcium/vit
amin D

Found a
decrease
d risk of
BC with
increasin
g
25(OH)D
3 serum
concentr
ations
(odds
ratio,
0.73;
95%
confiden
ce
interval,
0.550.96; Ptrend =
0.02)
among
women
in the
highest
tertile)

There is
a
decrease
d risk of
BC
associat
ed with
high
25(OH)
vitamin
D3
serum
concentr
ations,
especiall
y in
younger
women

requested
from the
attending
physician
s.

194
12
[181]

USA

Nurses’
Health
Study II
Nested
casecontrol
study
within
cohort.

Both
All
women
(50.9±
12.6),
premenop
ausal
(39.73
±7.83),

QS=0+1+1+2=4(Range:0-8)
25(OH)D Cases:
n/a
n/a
:
25.4±9.
IA;
5
ng/mL
BC cases
were
Control
identified s:
on
25.0±
biennial
9.6
question ng/mL

dietary
intakes,
vitamin
D/calcium
supplement
use, serum
calcium,
PTH,
estradiol,
progestero
ne,
estradiol
(pmol/L,
continuous
) and
progestero
ne
(nmol/L,
continuous
).
BMI at age
18 y and at
the time of
blood
collection,
ages at
menarche
and first
birth,
parity,

No
significa
nt
associati
on was
observed
between
plasma
25(OH)D
levels

Circulati
ng
25(OH)
D levels
were not
significa
ntly
associat
ed with
BC risk

Cases (N
= 613)
Controls
(N=
1,218)

postmenop
ausal
(58.68
±7.46)

195
13
[175]

USA

Casecontrol
study
Cases
(N = 194)
Controls
(N= 194)

Total
40-70y
Mean:
~58.3
y*

naires;
the
National
Death
Index
was
searched
for nonresponde
rs. All
BC cases
occurred
after
blood
collectio
n but
before 1
June
2007.
QS=0+0+1+2=3(Range:0-8)
25(OH)D Cases:
n/a
n/a
:
32.7±14
IA;
.4
ng/mL
Histologi
cally
Control
confirme s
d
37.4±15
primary, .9
incident, ng/mL
BC, with

family
history of
BC, and
history of
benign
breast
disease.

and BC
risk (top
vs.
bottom
quartile
multivari
ate RR =
1.20,
95% CI
(0.88 to
1.63), Pvalue,
test for
trend =
0.32)

in this
mostly
premenopa
usal
populati
on

Age, race,
date of
blood
collection,
and
laboratory
used for
vitamin D
testing.

BC cases
had
significa
ntly
lower
25(OH)D
levels
than CF
controls
(BC:
32.7

BC
patients
with a
more
aggressi
ve
molecul
ar
phenoty
pe
(basal-

no prior
cancer
history
except
nonmela
noma
skin
cancer.

14
[182]

196

USA, Nested
Swed Caseen
control
From two
cohorts:
New
York
Universit
y
Women’s
Health
Study and
the
Northern
Sweden
Mammar
y
Screening
Cohort

Total
34-65
y
Mean:
~52.6
y*

QS=0+2+2+2=6(Range:0-8)
25(OH)D Cases:
n/a
n/a
:
53.0±14
IA;
.9
nmol/L
For the
NYUWH
S,
Control
incident
s:
cases of
54.2±18
invasive .6
BC
nmol/m
were
L
identified
by
mailed
question
naires or
followup

Age at
menarche,
age at first
birth/parity
, family
history of
BC, BMI,
past HRT
use, and
alcohol
consumpti
on.

ng/mL
vs. CF:
37.4
ng/mL; P
= .02)

like) and
worse
prognost
ic
indicator
s had
lower
mean
25(OH)
D levels

No
associati
on was
observed
between
circulatin
g levels
of
25(OH)D
and
overall
BC risk
(multivar
iateadjusted
model
OR =
0.94;
95% CI:
0.76-1.16

Circulati
ng
25(OH)
D levels
were not
associat
ed with
BC risk
overall

Cases (N
= 1,585)
Controls
(N=
2,940)

197

telephon
e
interview
s every 2
to 4
years
after
1991,
suppleme
nted
by
linkages
to state
cancer
registries
in New
York,
New
Jersey,
and
Florida
and the
US
National
Death
Index.
Medical
records
were
reviewed
to

for the
highest
vs.
lowest
quintile,
P-trend =
0.30)

198

confirm
selfreported
cases.
Using a
capturerecapture
analysis,
we
estimated
that
combinin
g active
and
cancer
registrybased
followup
resulted
in a BC
ascertain
ment rate
of 95%.
For the
NSMSC,
annual
linkages
to the
Swedish
National

15
[176]

Saudi
Arabi
a

Casecontrol
study

199

Cases (N
= 120)
Controls
(N= 120)

Total
47.8±1
2.4 y

Cancer
Registry
were
used to
identify
incident
cases of
BC in the
cohort.
QS=0+0+1+2=3(Range:0-8)
25(OH)D 15.4±12 n/a
n/a
: LC
.3
ng/mL
All
women
presented
with
invasive
BC at the
clinic
or were
receiving
standard
medical
checkups at the
same
women’s
clinic
and were
shown on

Age, BMI,
history of
cancer,
parity,
family
history of
cancer,
exercise,
location of
exercise
(indoors or
outdoors),
multivitam
in use,
presence
BC in
daughters,
benign
breast
disease,
menopause

In
comparis
on with
those in
the
highest
category
of
vitamin
D status
for this
populatio
n (>20
ng/mL),
the
adjusted
ORs
(95%
CIs) for
invasive
BC were

An
inverse
associati
on exists
between
serum
25(OH)
D
concentr
ations
and BC
risk in
Saudi
Arabian
women

medical
record
review to
be
free of
cancer.

6.1 (2.4,
15.1) for
women
with a
serum
25(OH)D
concentr
ation ,10
ng/mL
and 4.0
(1.6,
10.4) for
women
with a
serum
concentr
ation of
10 -20
ng/mL
(P-trend
=
0.0001)

Daily
sunlight
exposure,
covering
body
against
sunlight,
calcium

The lack
of
vitamin
D and
calcium
suppleme
ntation
increased

200

, and
breastfeedi
ng

16
[179]

Iran

Populatio
n based
casecontrol
study
Cases

QS=0+0+1+2=3(Range:0-8)
Pre
25(OH)D Cases:
n/a
Vitami
34-36
: IA
15.2±8.
nD
y
2
supple
Mean:
ng/mL
ment,
~35y** Daily
% yes:
intake of
calcium
Control
Cases:
and
s:
0.0%

Vitamin
D may
have a
role in
BC
incidenc
e but it
needs

(N=60)
and
controls
(N=116)

vitamin
D and all
dietary
resources
of
mentione
d factors
were
collected.

201

We
selected
cases
from
patients
who
underwe
nt
surgery
from
2010 to
2012 in
Emdad
Shahid
Beheshti
Universit
y
hospital.
Cases
were

15.5±7.
5
ng/mL
Overall:
15.4
ng/mL*

supplement
s, vitamin
D
Contro supplement
ls:
s, fish and
9.7%
egg intakes
and weekly
profile of
egg
consumpti
on.

slightly
the risk
of
premeno
pausal
BC
(p=0.009
,
OR=1.11
5, CI
95%=1.0
491.187)

further
proof

202

identified
from
both selfreports
registrati
on and
confirme
d by
pathologi
cal
reports.
The
pathologi
cal
feature of
cases
was
collected
from
pathologi
cal
reports in
the
patholog
y archive
of the
mentione
d
hospital.
QS=0+1+2+2=5(Ramge:0-8)

17
[118]

USA

Nested
casecontrol
study
within the
Multiethn
ic Cohort
Study
Cases:
N=707
Controls:
N=707

Post
Mean:
~67.8
y**

203

25(OH)D Overall: n/a
:
LC
Mean
25(OH)
Incident
D:
invasive 31.4
BC cases ng/mL*
were
*
identified
by
Vitamin
linkage
D
to the
deficien
Surveilla cy (<16
nce,
ng/mL):
Epidemi 7.2%*
ology,
and End
Results
Program
registries
in the
states of
Hawaii
and
Californi
a
through
October,
2010,
including
729

n/a

Body mass
index,
parity,
family
history of
BC, use of
multivitam
in and
calcium
supplement
s, season,
sunburn
history and
engagemen
t in
strenuous
sports.

20
ng/mL
increases
of
plasma
25(OH)D
3 [OR=
0.28;
95% CI:
0.140.56] and
25(OH)D
[OR=0.4
3; 95%
CI: 0.230.80]
were
inversely
associate
d with
BC risk
among
white
women,
but not
among
women
in other
race/ethn
ic
groups.

Circulati
ng
25(OH)
D3 and
25(OH)
D were
associat
ed with
a
reduced
risk of
postmen
opausal
BC
among
whites,
but not
in other
ethnic
groups,
who
reside in
low
latitude
regions.

18
[183]

USA

eligible
postmen
opausal
women
with a
diagnosis
of
invasive
BC.
QS=0+1+1+2=4(Ramge:0-8)
25(OH)D Median n/a
n/a
:
25(OH)
IA
D

204

Nurses’
Health
Study II

Pre
45-46
y

Nested
casecontrol
within a
cohort.

Mean: BC cases
~45.1± were
4.4 y** identified
through
the
biennial
question
naires:
Cases
had no
previousl
y
reported
cancer
diagnosis
before
blood

Cases (N
= 584)
Controls
(N= 584)

Cases:6
2.6
nmol/L

Control
s:
61.4
nmol/L

Body mass
index
(BMI) at
age 18 and
at blood
collection,
age at
menarche,
parity and
age at first
birth,
history of
benign
breast
disease,
family
history of
BC, and
alcohol
consumpti
on.

No
associati
on
between
plasma
calculate
d free
25(OH)D
and risk
of BC
overall
(highest
vs.
lowest
quartile
RR=1.21
; 95 %
CI: 0.83–
1.77), Ptrend =
0.50)

There is
no
associati
on
between
circulati
ng free
25(OH)
D or
circulati
ng
VDBP
levels
with BC
risk
among
mostly
premenopa
usal
women.

collectio
n and
were
diagnose
d after
blood
collectio
n but
before
June 1,
2007.
Abbreviations: 95%CI=95% confidence interval; 25(OH)D=25-hydroxyvitamin D; BC=BC; BMI=Body Mass Index; HR=Hazard
Ratio; HRT=Hormone Replacement Therapy; IA= Immunoassay; LC= Liquid Chromatography; n/a=Not applicable; NDI=National
Death Index; OR=Odds Ratio; P-trend=P-value for the trend test; QS=Quality Score; RR=Risk Ratio;
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*Estimated based on available categorical data and ranges within each category, with sample sizes for each category.
**Estimated based on available data on mean and SD for cases and controls and sample sizes of cases and controls.

APPENDIX C
SEARCH TERMS

((((("vitamin d"[MeSH Terms] OR "vitamin d"[All Fields] OR "ergocalciferols"[MeSH
Terms] OR "ergocalciferols"[All Fields]) AND incident[All Fields]) AND ("breast
neoplasms"[MeSH Terms] OR ("breast"[All Fields] AND "neoplasms"[All Fields]) OR
"breast neoplasms"[All Fields] OR ("breast"[All Fields] AND "cancer"[All Fields]) OR
"BC"[All Fields])) AND ("25-hydroxyvitamin D"[Supplementary Concept] OR "25hydroxyvitamin D"[All Fields] OR "25 hydroxyvitamin d"[All Fields] OR
"calcifediol"[MeSH Terms] OR "calcifediol"[All Fields])) OR 25[All Fields] AND
("hydroxide ion"[Supplementary Concept] OR "hydroxide ion"[All Fields] OR "oh"[All
Fields]) AND D[All Fields]) AND ("epidemiology"[Subheading] OR "epidemiology"[All
Fields] OR "incidence"[All Fields] OR "incidence"[MeSH Terms]) AND ("free full
text"[sb] AND ("2007/01/01"[PDAT] : "2017/01/01"[PDAT]) AND "humans"[MeSH
Terms] AND English[lang] AND "female"[MeSH Terms] AND "adult"[MeSH Terms]).
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APPENDIX D
SUPPLEMENTAL METHODS

Quality score
The quality score is composed of 5 items, and each item was allocated 0, 1 or 2 points. This
allowed a total score between 0 and 8 points, 8 representing the highest quality. The
following items are included in the score:
1. Study design
0 for case-control studies
1 for cross-sectional studies
2 for longitudinal studies (retrospective or prospective) or non-randomized intervention
studies
2. Population
Observational studies
0 if n <500
1 if n 500 to 2000
2 if n >2000

3. Outcome (see table below)
0
BC
If not reported or if
diagnosis was
based on a proxy
for disease
(i.e. use of
medication that is
not specific to the
disease or
symptoms)

1
If diagnosis was
self-reported or
retrieved from
reports (e.g.
medical records)
not collected
specifically for
study or was based
on the use of
disease-specific
medication (e.g.
antidiabetic
medication)

2
If diagnosis was
made during study
using adequate test
or official
registries were
checked by a
researcher

4. Adjustments
0 if findings are not controlled** for at least age and gender
1 if findings are controlled for age and gender
2 if an intervention study is adequately randomized or if findings are additionally
controlled for other key covariates (e.g. age at menarche, parity, family history of BC
etc.)
207

** ‘Controlled for’ here refers to: adjusted for in the statistical analyses (e.g. with multiple
regression); stratified for in the analyses (e.g. pre- and post-menopausal separately); or
narrow selection criteria of study participants on this covariate (e.g. Pre-menopausal
women only).
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Metaanalyzed
study
[129]

Author/year

Assessment

BertoneJohnson/2005

[185]

McCullough/2005

[177]

Knight/2007

[184]

Robien/2007

[127]

Chlebowski/2008

[128]

Freedman/2008

[178]

Abbas/2009

[125]

McCullough/2009

[124]

Rejnmark/2009

A
B
C
A
B
C
A
B
C
A
B
C
A
B
C
A
B
C
A
B
C
A
B
C
A
B
C

Study
design

209

Population

Outcome

Adjustments QS

[180]

[121]

[181]

[175]

[182]

[176]

[179]

[118]

[183]

Agborsangaya/2010 A
B
C
Engel/2010
A
B
C
Eliassen/2011
A
B
C
Peppone/2012
A
B
C
Scarmo/2013
A
B
C
Yousef/2013
A
B
C
Bidgoli/2014
A
B
C
Kim/2014
A
B
C
Wang/2014
A
B
C
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APPENDIX E
BEGG’S FUNNEL PLOT

0

Studies
1%
5%
10%

Standard error

.2

.4

.6

.8
-2

-1

0
Effect estimate

1

2

Begg's Test
adj. Kendall's Score (P-Q) = 35
Std. Dev. of Score = 35.46
Number of Studies =
22
z = 0.99
Pr > z = 0.324
z = 0.96
(continuity corrected)
Pr > z = 0.338
(continuity corrected)
Egger's test
Std_Eff
slope
bias

Coef.

Std. Err.

t

P>t

[95% Conf. Interval]

-.0223186 .0158607 -1.41 0.175 -.0554034
.6823854 .8081164 0.84 0.408 -1.003316
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.0107662
2.368087

APPENDIX F
QUALITATIVE FINDINGS

25(OH)D, 0

25(OH)D, 1

25(OH)D DEFICIENCY, 0

25(OH)D DEFICIENCY, 1

DietaryVitD, 0

SupplVitD, -1

SupplVitD, 1

4
2

0

5

10

15

20

0

TotalVitD, 0

4

6

8

TotalVitD, -1

2

QS

6

8

2

4

6

8

25(OH)D, -1

0
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0
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15

20

StudyID
Graphs by Exposure and Finding

FIGURE: GRAPHS BY EXPOSURE AND FINDINGS
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APPENDIX G
CALCULATION OF TREATMENTS

Vitamin D (Enzo: BML-DM200-0050)
Stock Solution
Working Solution

Treatment Solution

Trichostatin A (TSA) (Sigma: T1952)
Stock Solution
Working Solution

Treatment Solution

L- Sulforaphane (SFN) (Sigma: S6317)
Stock Solution
Working Solution
Treatment Solution

50 µg in 50 µL EtOH
=2.4 mM (2.4X10-3M)
Dilute to 1:1000
2µL stock solution in 2000 µL (2mL)
EtOH
= 2.4 µM (2.4X10-6M)
Dilute to 42 µL working solution in 13mL
media
=100 nM

10 mM Concentration
Dilute to 1:1000
2 µL Stock Solution in 2mL DMSO
=10 µM
1 µM =200 µL working solution in 2mL
media

20 mM in DMSO
17.5 µL Stock Solution in 3.5 mL DMSO
=100 µM concentration
20µM= 400µL working solution in 2mL
media
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APPENDIX H
LABORATORY PROTOCOL
RNA Isolation
1. Cell Harvest
a. Remove the media
b. Use 1mL Tri-reagent (Trizol) per well (6-well plates)
c. Scratch the cells from the well with a cell scraper
d. Pipet suspension till thick and stringy, transfer to 1.5 mL Eppendorf tubes
e. Samples can be stored at -80˚c if necessary
f. If frozen, samples need to be kept at room temperature for 5 minutes before
starting the phase separation
2. Phase Separation (samples need to be kept on ice)
a. Add 150 µL chloroform reagent to the homogenate
b. Invert vigorously for 15 seconds
c. Allow the mixture to sit at room temperature for 5 minutes
d. Centrifuge at 12,000g for 15 minutes at 4˚c
3. RNA Precipitation
a. Transfer the aqueous phase into a fresh 1.5 mL Eppendorf tubes
b. Add 0.5 mL of 100% isopropanol and mix gently by inversion
c. Keep on ice for 15 minutes
d. Centrifuge at 12,000g for 20 min at 4˚c
4. RNA Washing and Solubilization
a. Remove the supernatant (be careful not to disturb the pellet)
b. Add 1 mL of 75% Ethanol (EtOH)
c. Kick samples at the bottom to dislodge the pellet
d. Centrifuge at 7,500g for 5 minutes at
e. Remove EtOH (careful not to lose the pellet at the bottom)
f. Briefly spin samples down, remove the remaining liquid
g. Air dry (keep samples open for several minutes)
h. Add 40 µL DEPC water to the samples, invert and spin down
i. Incubate 10 minutes at 56˚c to homogenize the RNA and then keep on ice
for several minutes
B. RNA Quantification
a. Turn on the NanoDrop machine
b. Blank the machine with 1 µL of DEPC water
c. Take 1 µL of sample
d. Press OK to get readings at 260/280 nm
e. Dilute samples as necessary (we need at least 2µg RNA for PCR)
214

C. cDNA Synthesis
a. The following protocol is designed to convert 5µg of total RNA into cDNA)
b. Mix and briefly centrifuge each component before use
f. Combine the following in 0.5 mL DNA/RNAse free tubes(final volume 10
µL)
• 1 µL Primer: 50 mM oligo (DT)
• 1 µL 10 mM dNTP mix
• 8 µL of 5 µg RNA and DEPC water
• Incubate for 5 minutes at 65˚c then place on ice for at least 1
minute (Protocol Library: Wood Lab)
g. Prepare the following mix (for one reaction)
• 2 µL 10X RT buffer
• 4 µL 25 mM MgCl2
• 2 µL 0.1 M DTT
• 1 µL RNaseOUT (40 U/µL)
• 1 µL SuperScript III- RT (200 U/µL)
h. Add 10 µL of cDNA Synthesis mix to each RNA/primer mixture (mix gently
and collect by brief centrifugation)
i. Incubate as follows:
• 10 minutes at 25˚c followed by
• 50 minutes at 50 ˚c
• Terminate the reaction at 85 ˚c for 5 minutes, then chill on
ice
j. cDNA synthesis reactions can be stored at -30 ˚c to -10 ˚c or used for PCR
immediately
D. Real Time qPCR
1. cDNA Quantification
a. Take 1 µL of each sample and measure the concentrations by using the
NanoDrop machine
b. Total Volume= 1 µL cDNA and DEPC water to make each sample
have 50 µg/mL cDNA
2. Preparation of MasterMix (each tube will have 20 µL of final volume)
a. 10 µL TaqMan Gene Expression Master Mix (Applied Biosystems
#4369016)
b. 1 µL TaqMan Gene Expression Assay
• Housekeeping gene (GAPDH) with VIC dye- Applied
Biosystems Hs 99999905_m1
c. 1 µL TaqMan Gene Expression Assay
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•

Target gene (VDR) with FAM dye- Applied Biosystems Hs
99999905_m1
• Target gene (TRPV6) with FAM dye - Applied Biosystems Hs
01114089_g1
• Target gene (DKK1) with FAM dye - Applied Biosystems Hs
_m1
• Target gene (CYP24a1) with FAM dye - Applied Biosystems
Hs 00167999_m1
• Target gene (CYP27b1) with FAM dye - Applied Biosystems
Hs 00168017_m1
d. 4 µL of DEPC water
e. 4 µL cDNA (200ng/ mL total cDNA
Formula for the amount pipetted into each tube:
(# of reactions) X (Volume of reagent per reaction) + (# of reactions) X (Volume of
reagent per reaction) X (.10) = Amount in the MasterMix
[Note: 10% more is added because the mixture is sticky and pipetting can be difficult]
3. Preparation of qPCR plate
a. Pipette 16 µL of prepared MasterMix into each micro centrifuge tube
(Applied Biosystems # 4346906)
b. Pipette 4 µL of cDNA samples into each reaction tube (run in duplicates)
c. Homogenize samples by spinning the tubes down
4. ViiA-7 Real-Time PCR System
a. Turn on the machine
b. Place the plate holding all reaction tubes into the plate reader
c. Click on ViiA-7 software on Desktop
• Give the new experiment a name
• Set up the reaction plate: 96 well
• Method of comparison: standard curve
• Protocol: TaqMan Standard MasterMix
d. Setting up the experiment
• Define target genes (choose different colors for each gene)
• Select VIC dye for GAPDH and FAM for all the target genes
• Mark concentrations for each treatment
• Assign Target and samples: mark the boxes with appropriate
labels and concentrations
• Select ROX dye for passive reference
e. Select Start and then click on the experiment number to start the
experiment (Note: clicking on Start alone will not initiate the
experiment)
f. The experiment will be completed in 1.45 hours for the data to be
exported to an excel file for analysis.
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